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Microtubules are composed of α- and β-tubulin subunits and are highly dynamic 
elements of the cytoskeleton that help maintain fidelity during cell division.  This aspect of 
microtubules makes them a very useful target for the treatment of tumors.  The potent 
microtubule-stabilizing agent (+)-discodermolide is a sponge-derived polyketide natural product 
and is a polyhydroxylated and polymethylated, C24:4 fatty acid lactone carbamate.  The 
microtubule-stabilizing action of discodermolide was predicted by computational chemistry.  
Biochemical, pharmacological, and antiproliferative activity studies with discodermolide showed 
it to have potent hypernucleating, microtubule-stabilizing and microtubule bundling properties.  
Synthetic analogues of discodermolide were made to establish a structure-activity relationship 
(SAR) for discodermolide.  The library consisted of analogues with modifications made on the 
lactone and carbamate/diene portions, with altered stereochemistry on C-11 and C-17, 
conformational analogues based on the solution structure of discodermolide, and macrocyclic 
analogues of discodermolide.  Biological evaluation of the analogues suggested the diene, the 
carbamate on C-19 and the stereochemistry on C-11 and C-17 to be important for the activity of 
the parent molecule, and that the lactone moiety is amenable to modifications.  Of interest were 
the conformational and macrocyclic analogues that showed promising microtubule-targeting 
 iv
activities.  Furthermore, these studies paved way for the discovery of the related natural product 
dictyostatin as a potent microtubule stabilizer.  Dictyostatin is a macrocycle with stereochemistry 
very much like discodermolide.  Intensive biochemical and pharmacological studies showed 
dictyostatin to have comparable, or superior in some respects, properties to those of 
discodermolide and paclitaxel.  Biological analyses of structural analogues of dictyostatin 
suggested that the macrolactone and the bottom half of dictyostatin have a critical role in the 
biological activity of the parent molecule.  The top portion of the molecule was amenable for 
modifications without much loss of activity; however, this half of the molecule seemed crucial 
for the microtubule binding property of the parent molecule.  These studies identified 
dictyostatin to be the most potent of the microtubule stabilizers studied.  One interesting 
analogue, C16-normethyldictyostatin, was identified to have promising activity comparable to 
the parent molecule. 
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1. INTRODUCTION 
1.1. MICROTUBULES - A drug target for cancer therapy 
Microtubules (MTs) are key elements of cytoskeleton that orchestrate many important events in 
the cell (Schiff et al. 1979).  It was a century ago that tubulin/MTs were serendipitously 
discovered when the underlying complex process of cell division, called mitosis, was under 
investigation (Dustin 1984).  A peripheral structure formed of minute parallel concentric fibrils 
[also referred to as tubules, the name ‘microtubule’ was coined by Mohri] was first observed in 
nucleated red blood cells.  At the same time, colchicine, extracted from Colchicum autumnale 
administered as tincture for the treatment of gout, was observed for the first time to cause mitotic 
arrest (Borisy and Taylor 1967a).  The same studies showed that [3H]colchicine binds to (i) a 
cellular protein, (ii) a soluble protein in the 6S fraction, (iii) the mitotic apparatus in cell-free 
extracts, and (iv) a protein subunit from MTs (Borisy and Taylor 1967a, 1967b; Shelansky and 
Taylor 1967).  Since then, rapid discoveries suggested good evidence for MTs' important 
regulatory role in many cellular processes.  In cancer biology, MTs garnered much attention only 
after the discovery of the mechanism of the anticancer activity of paclitaxel (Taxol®), a natural 
product obtained from the pacific yew tree, Taxus brevefolia (Schiff et al. 1978).   
Oncology therapeutics occupy a prominent place in drug design and discovery and 
contribute to over seventy-seven percent of global oncology revenues (Commercial insight).  
Amongst the oncology drugs available in the drug market, cytotoxics have occupied the 
cornerstone and are considered the drugs most prescribed for various kinds of cancers, ranging 
from benign to aggressive.  Cytotoxics are now the first line of choice for the treatment of 
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refractory, hormone-resistant and metastatic cancers.  One of the major classes of cytotoxics is 
the mitotic poisons, including MT stabilizers and destabilizers.  The mechanism of action and 
clinical success of paclitaxel has drawn great interest for tubulin or MTs as a target for the cure 
of cancer, a disease state where patients bearing the rapidly and abnormally growing cells are in 
a desperate need for therapeutic intervention at any of the possible phases of cell cycle, not the 
least of which is the mitotic phase.  Clinical studies have shown that cancer therapy with 
paclitaxel as the first line of choice for the treatment of metastatic cancers given either as a single 
agent or in combination with other cytotoxics like doxorubicin have met with good success 
(Rowinsky et  al. 1990; Mamounas et al. 1995; Davidson 1995; Davidson 1996).  However, the 
overall response observed in a clinical study is 32% for single agent therapy; combination 
therapy has shown an overall response rate observed of over 90% (Perez 1998; Perez 1999).  
Hence, continuous effort is ongoing in the search for potent MT-targeted chemotherapeutic 
agents to treat various types of cancers.  One of the many clinical drug candidates that comprise 
the R&D pipeline of major pharmaceutical companies is invariably a microtubule-targeting agent 
(Mani et al. 2004).  Success in using tubulin/MT as a target for the treatment of cancer has 
developed because of the sound knowledge gained over the years in understanding tubulin form, 
function and dynamics, along with advancements made in synthetic and high-throughput 
screening techniques for rapid compound development and identification.  A discussion of MTs, 
their dynamic role in cell division (importantly during mitosis), factors influencing MT 
dynamicity and properties is given in the next section.  This will be followed by a discussion on 
microtubule-targeting agents focused on microtubule stabilizers -- paclitaxel, discodermolide and 
dictyostatin.   
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1.2. Tubulin polymerization dynamics 
MTs are polymeric forms of tubulin formed by self-assembly of α-β heterodimers (Dustin 1984).  
Longitudinal (head-to-tail) association of α-β tubulin dimers forms a protofilament of a MT 
(Nogales 2001).  The primary structural element of the mitotic spindle involved in cell division is 
the MT (Wittmann et al. 2001).  Two important properties regulate spindle assembly formation 
from the MT lattice, 1) MT dynamicity and 2) mechanochemical properties of MT-associated 
proteins (called motor proteins, dyneins and kinesins).  The structure of the mitotic spindle is 
constituted of morphologically different subpopulations of MTs: kinetochore, interpolar and 
astral MTs -- the definition of all these is implicit in their nomenclature (Mastronarde et al. 
1993).  The spindle structure is highly dynamic with a turnover half-life of about 60-90 s (Saxton 
et al. 1984; Salmon et al. 1984).  A representation of microtubules, the mitotic spindle and 
mitosis is shown in Figure 1.  The rapid turnover of spindle MTs is characterized by catastrophe 
and rescue events; a catastrophe event is the rapid conversion of the polymerized state of MTs to 
the depolymerized state.  The opposite holds true for the rescue events (Verde et al. 1992).  The 
destabilization rate of MTs outweighs the stabilization process in a catastrophe event, and in a 
rescue event it is exactly the reverse.   
The primary function of the mitotic spindle is to separate sister chromatids 
(chromosomes) so that each half of the replicated chromosome is positioned at the opposite ends 
of the spindle pole (Wittmann et al. 2001).  This process involves a complex interplay of MTs, 
motor proteins, and the mechanochemical forces generated by proteins associated with 
kinetochores, chromosome arms and astral MTs.  The mitotic phase in a cell starts at the 
condensation of chromatin to form chromosomes, during which kinetochores assemble at the 
centromeric regions of the chromosomes (Figure 1).  Kinetochores form a high-affinity site on 
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B 
C 
the chromosomes to help search for and capture spindle MTs, attach spindle MTs to 
chromosomes, coordinate chromosome motility on the spindle, and regulate the transition from 
metaphase to anaphase (Zhai et al. 1995; Rieder and Salmon 1998).  The mechanisms by which  
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Representation of microtubules and mitosis 
A. Tubulin subunits polymerize to form a sheet of protofilaments that assemble to form 
microtubule polymer (Adapted from: Dustin 1984).  B. Microtubule organization in the 
cytoplasm before cell division (Adapted from: Wittmann et al. 2001). Sister chromatids are 
tethered to the microtubules and aligned along the equatorial plate before cell division. C. 
Different phases of mitosis.  Microtubules play a crucial role in each of the four phases 
(interphase, metaphase, anaphase, and telophase) of mitosis. 
(Adapted from: http://mitchison.med.harvard.edu/research/Microtubules.htm) 
 
 
A 
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the ‘search-capture-attach’ and the other events controlled by kinetochores are still not well- 
understood.  There are several factors in the cell that regulate the process of MT turnover that 
make up for the remarkable dynamicity of the spindle architecture.  Important players during this 
process have been identified amongst which are guanosine-5’-triphosphate (GTP), motor 
proteins (dynein and kinesins), microtubule-associated proteins (MAPs), divalent cations (Ca++, 
Mg++), temperature, etc., that contribute to the process of mitosis in many ways (Kirschner and 
Williams 1974; Weingarten et al. 1975; Soifer 1986; Wittmann et al. 2001; Karsenti and Vernos 
2001; Carazo-Salas et al. 2001).  Quite a few of these factors, studied for their role as mitotic 
spindle regulators albeit not thoroughly understood, have been of immense interest and under 
extensive investigation.  Most of the regulatory elements that control the spindle assembly 
process and the turnover rate are also known to be cell cycle-dependent (Karsenti and Vernos 
2001).  This feature of cell-cycle-dependent regulation explains the differing relative rates of MT 
turnover during different phases of cell cycle.  
Dynamic events during polymerization of tubulin are, to a great extent, known to be 
regulated by the presence of the nucleotide GTP, MAPs and motor proteins (Soifer 1986; Grover 
et al. 1995; Weisenberg and Deery 1976; Kirschner and Williams 1974).  Figure 2 represents the 
effect of GTP on the dynamic events of tubulin assembly.  GTP is a crucial regulatory factor in 
MT assembly process.  GTP is known to be localized in the exchangeable site on β-tubulin (i.e., 
GTP there can be hydrolyzed to GDP, and the GDP can be exchanged for GTP) and in a non-
exchangeable site on α-tubulin (where the GTP is not hydrolyzed) (Mitchison 1993).  Tubulin 
with GTP bound to β-tubulin (GTP-tubulin) is known to be competent for assembly and the 
GTP-cap maintains the stability of MTs (Desai and Mitchison 1997).  Because the nucleotide at 
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the plus (growing) end of the MT is exchangeable, this end of a MT is capped by β-tubulin.  
MTs are thus known to exhibit polarity and are in a state of dynamic equilibrium, with assembly  
 
 
minus-end  plus-end B     A 
 
Figure 2. Schematic representation of the role of GTP in microtubule assembly process 
A. GTP binds to β-subunit of tubulin, makes it competent for assembly (polymerization/rescue) 
and promotes polymerization at the plus-end of microtubules.  GTP-cap maintains the stability of 
microtubules (Adapted from: Downing and Nogales 1998).  B.  Representation of the state of 
dynamic equilibrium in microtubules, with assembly (polymerization/rescue) occurring at plus 
end and disassembly (depolymerization/ catastrophe) mainly occurring at the minus end. 
(Adapted from: Desai and Mitchison 1997)  
 
 
(polymerization/rescue) occurring at the plus end and disassembly 
(depolymerization/catastrophe) mainly occurring at the minus end (Margolis and Wilson 1978).  
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These events contribute to the MT dynamic instability and treadmilling processes observed in 
MTs.  The crystal structure of the paclitaxel-tubulin complex revealed the location of the 
nucleotides on each monomer (Downing and Nogales 1998; Downing 2000).  The interactions 
along the protofilament interface (longitudinal contacts) involve binding of Glu254 on α-tubulin 
with the corresponding residue on β-tubulin.  The primary interactions across the 
interprotofilament interface (lateral contacts) involve the M-loop from one dimer with helix H3 
on the other dimer.  GTP hydrolysis and phosphate release during the depolymerization process 
induces a conformational change that leads to the peeling or curving of protofilaments to form 
rings or sheets.  
The dynamic behavior of MTs, the catastrophe, and the rescue events are largely under 
the influence of regulatory elements/proteins, motor proteins, and MAPs apart from GTP.  
Important factors/proteins identified to promote catastrophe events include Op18/stathmin and 
XKCM1-Kin I, the latter of which belongs to the kinesin superfamily (Wittmann et al. 2001; 
Belmunt and Mitchison 1996).  The mechanism by which the two proteins induce MT 
disassembly could be one of the many possible.  These include promoting GTPase activity, 
inducing catastrophe by sequestering tubulin dimers and disrupting interactions between 
protofilaments.  Factors that help stabilize the MT polymerization process are termed MAPs 
(Wittmann et al. 2001).  There are several MAPs identified to date, important ones include tau, 
MAP2, MAP4, Dis1-family MAPs and XMAP215.  MAPs induce MT polymerization by 
protecting MT ends (decrease catastrophe rates) or by stabilizing the lateral contacts between the 
protofilaments (increase rescue rates).  Literature reports suggest that Dis1-MAPs antagonize the 
kinesin family proteins (Kin1) preventing the depolymerization of MTs (Nabeshima et al. 1999).  
Kin1 is constitutive and the activity of Dis1 proteins is regulated by phosphorylation (Desai et al. 
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1999).  There is good evidence that the levels of the factors that support spindle assembly, 
disassembly and rapid turnover of MTs during different phases of cell cycle are under the control 
of cell-cycle regulating factors.  Studies done in frog oocyte systems reveal that spindle 
dynamics seemed to be under the influence of cyclins and cdc2, the levels of which vary at 
different phases of the cell cycle.  Like Dis1 family proteins, XMAP215 during mitotic phase is 
phosphorylated by cyclin-dependent kinase 1 (cdk1), which in turn is regulated by cyclins 
(Vasquez et al. 1999).  Stathmin, a known MT destabilizer, is hyperphosphorylated during 
mitosis by cdks (Andersen et al. 1997).  While MAPs like XMAP215 are active during the 
mitotic phase, inhibitors of MTs (XKCM1) are active during interphase and metaphase 
(Tournebize et al. 2000).   
MTs exhibit polarity with the plus-end of MTs in the polymerizing state and the minus-
end in the depolymerizing state (Margolis and Wilson 1978; Margolis et al. 1978).  The 
poleward movement of MTs is under the control of the MAPs and motor proteins that play a key 
role during mitosis.  Several mechanisms have been identified for the organization and 
maintenance of bipolarity of the mitotic spindle.  Motor proteins are essential for centrosome 
separation (regulated by cortical dyneins), for sorting of randomly growing MTs around 
chromatin into an array consisting of parallel and antiparallel MTs (BimC and Eg5 motors), for 
cross-linking MTs (minus-end directed dynein, dynactin, NuMA, etc.), and for movement of 
spindle poles away from chromosomes with the involvement of plus-end directed kinesins 
(Wittmann et al. 2001).  The search-and-capture mechanism responsible for promoting the 
connection between kinetochores and spindle MTs is not the only important step in the spindle 
assembly process.  The self-organization of the mitotic spindle by motor proteins and Ran-GTP-
dependent nucleation of mitotic spindle around the chromosomes play important mechanistic 
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roles in the triggering of spindle assembly and dynamics (Carazo-Salas et al. 1999).  The 
nucleation of dynamic MTs around chromosomes in the presence of centrioles, MT abundance, 
and MT length are all under the control of Ran-GTP.  The generation of Ran-GTP around the 
chromosomes, promotion of nucleation and stabilization of centrosomal MTs is under the control 
of a factor named regulator of chromosome condensation (RCC1).   
The self-organization, search-and-capture and centrosome-dependent nucleation of the 
mitotic spindle are all crucial for maintaining fidelity during cell division.  All these steps 
involve perfect coordination of spindle assembly, MTs and motor proteins.  Perturbation of any 
of the above components would lead to abnormal mitosis or mitotic arrest.  This feature has been 
explored for cancer therapy in order to halt rapidly proliferating cells by discovering therapeutic 
interventions targeting one or more of the components of mitotic spindle.  The studies reported 
here were done with this goal in mind for MT-targeting agents. 
Tubulin or MT polymerization dynamics, regulated by so many factors, is under both 
kinetic and thermodynamic control.  MT dynamics follows the classical Oosawa-condensation 
model wherein nucleation is a prerequisite for polymer formation (Oosawa and Kasai 1962).  
Nucleation of tubulin subunit assembly can either be a spontaneous process or can be induced by 
any polymer-promoting agent.  This is followed by elongation of the nuclei to form MT polymer.  
The nucleation step in the process of tubulin/MT assembly confers a ‘lag time’ to the MT 
assembly process.  Polymer formation is a time-, temperature- and reaction component-
dependent process (Gaskin et al. 1974).  Microtubule assembly and the factors regulating the 
assembly process can be understood most readily by employment of isolated protein-based 
experiments in the presence or absence of regulatory factors.  This was one of the goals of the 
studies reported here.  The rate processes during microtubule assembly follow the law of mass 
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action.  The rate of formation of MTs (the forward reaction) is dependent on the association rate 
constant (Kon) for subunit assembly and the tubulin monomer concentration in the system.  This 
reaction mechanism, similar to any other process, follows Newton’s law: for every action there is 
an equal and an opposite reaction.  Dissociation of the assembled tubulin counteracts the 
polymer assembly process and the rate of disassembly (the backward reaction) is dependent on 
the rate constant (Koff) of dissociation of MTs to tubulin.  This process continues until 
equilibrium is reached, a stage at which the association and dissociation rates for tubulin 
polymerization process tend to be equal.  The rate of polymerization equals that of 
depolymerization under this condition and the rate of change in the growth rate of the polymer is 
zero, also referred to as the steady-state condition.  This reaction can be observed in a 
spectrophotometer (ideally at 37 oC) containing all the reaction components (tubulin and 
microtubule-inducer) as a turbidity profile represented as a change in O.D at 350 nm against 
increments of time (Gaskin et al. 1974).  This profile is ideally a sigmoidal curve that shows 
saturation at equilibrium time points at which stage steady-state conditions are reached.  Under 
this circumstance, the concentration of tubulin required to achieve steady-state is known as the 
critical concentration (Cc) of tubulin, which is a ratio of Koff over Kon.  This parameter speaks 
about the MT polymer formation or inducing ability of test agent since Cc is inversely related to 
the affinity (K) of the monomer for microtubule polymer (Correia and Lobert 2001).  Hence, the 
lower the Cc of tubulin required for MT polymer formation, the higher is the affinity of the 
monomers for polymers under a given set of reaction condition.  In the case of a MT-promoting 
agent, this would translate to the ability of the test agent to promote tubulin assembly and hence 
to the potency of the agent as a MT stabilizer.  The Cc can be quantified and related to the 
energetics of the assembly mechanism under known reaction conditions using a simple equation 
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for Gibb’s free energy: δG = -RTlnK.  The lower the Cc for assembly, the higher is the affinity 
and the lower is the free energy for polymer formation or stabilization (Kasai 1969).  The Cc is 
one of the parameters that provides information on the both the kinetic and thermodynamics 
processes underlying the tubulin assembly mechanism.   
The tubulin polymerization process is known to be influenced by temperature - the free 
energetics for MT assembly process are lower with rises in temperatures (Inoue and Sato 1967).  
An Arrhenius plot of 1/T versus lnK illustrates the temperature-dependency of a ligand-induced 
assembly process. The slopes and intercepts yield enthalpy and entropy parameters that can be 
used to explain the thermodynamics of the MT assembly mechanism.  At lower temperatures, the 
nucleating ability of tubulin subunits to form MT polymer is low in the presence of GTP.  Hence, 
at 0-20 oC GTP does not induce assembly.  Increasing the temperature to 37 oC drives the 
polymer forming reaction forward, thus suggesting that MT assembly process is energy-
dependent.  However, in the presence of an inducer like paclitaxel, or a more potent compound 
like discodermolide, the nucleation process is more spontaneous and the assembly process occurs 
at much lower temperatures (10-20 oC for paclitaxel, 0 oC for discodermolide).  The ability of a 
MT-inducing agent to nucleate assembly at lower temperatures is referred to as 
‘hypernucleation’ and this parameter reflects on the binding energetics, and hence potency, of a 
test agent to induce MT-polymer formation.  Literature reports suggest that paclitaxel-induced 
microtubule polymer formation is an enthalpy-driven, exothermic process (Edler et al. 2005). 
Binding kinetics and energetics provide good information on building protein-ligand 
models.  Parameters like Cc, binding constants (KD and K values) and inhibition constants (Ki 
values) are enough to assess a ligand-induced MT assembly mechanism both in vitro and in vivo.  
Studies done here using isolated tubulin were aimed at understanding the microtubule assembly 
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process under different sets of reaction conditions, and emphasized the qualitative and 
quantitative aspects of the MT polymerization dynamics.  Others have investigated the energetics 
of tubulin polymerization dynamics in the presence of MT stabilizers and/or destabilizers.  The 
studies done here made an attempt towards rationalizing the experimental observations for 
structure-activity and pharmacological evaluations on MT perturbing libraries on the basis of 
binding energetics.  Biochemical experiments done supported the in silico observations and the 
data generated could be of valid use in understanding structure-activity relationships for future 
drug design studies.     
1.3. Microtubule-targeting agents 
Mitotic poisons that target MTs are known to either stabilize MTs by inducing polymerization of 
tubulin or destabilize MTs by triggering depolymerization events (Hamel 1996).  Based on the 
mechanism by which they block assembly or disassembly, MT-targeting agents have been 
broadly classified as 1) MT-stabilizing (polymerizing) agents, e.g., paclitaxel, or 2) MT- 
destabilizing (depolymerizing) agents, e.g., vinca alkaloids and colchicine.  Furthermore, MT 
binding domains have been categorized based on the site of binding to tubulin or tubulin 
polymer:  the taxoid site (T), the vinca domain (V), and the colchicinoid site (C).  The studies 
done here were focused on MT-stabilizing agents and hence the discussion in the following 
pages will be limited to MT stabilizers. 
1.3.1. Paclitaxel  
Structure, discovery of the mechanism of action and location of paclitaxel binding site on 
tubulin polymer  
 In the early 1960's the National Cancer Institute organized a collection of plants from the 
U.S. for evaluation as potential sources of anticancer drugs (Horwitz 2004; Cragg and Newman 
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2004). The Pacific yew (Taxus brevifolia) was collected and the extract from this tree was 
confirmed to be active against 9KB cancer cells in culture and in animal carcinoma test systems.  
By 1971, a crystalline derivative of a compound, originally called taxol but later renamed to 
paclitaxel was examined by X-ray crystallography and the structure of this interesting agent was 
determined (Figure 3) (Wani et al. 1971).  By 1978, the efficacy of paclitaxel against tumors was 
first reported. Upon exposure to this compound, there was an increase in the mitotic index of 
P388 cells and an inhibition of human HeLa and mouse fibroblast cells (0.25 µM) in the G2 and 
M phases of the cell cycle (Schiff et al. 1979).  Tubulin polymerization experiments identified 
paclitaxel to be a promoter of MT assembly.  This compound caused a concentration-dependent 
increase in turbidity, decreased the lag time for assembly independent of tubulin concentration, 
and decreased the Cc of tubulin required for assembly.  Paclitaxel-induced MTs were found to be 
resistant to depolymerization in the presence of 4 mM CaCl2.  The MTs it causes are shorter in 
length and more in number in than those induced by GTP.  Eva Nogales and Kenneth Downing 
first resolved the 3D structure of tubulin in complex with paclitaxel by high resolution 
cryoelectron microscopy (electron crystallography) analysis of tubulin-paclitaxel assembled as a 
monolayer on zinc sheets (Nogales et al. 1995; Nogales et al. 1998).  These studies revealed that 
paclitaxel binds to the amino-terminal region of β-tubulin near the interprotofilament contacts 
and that there is one paclitaxel site per tubulin heterodimer.  This data was supported by 
biochemical experiments where photoaffinity labeled paclitaxel derivatives bound to residues in 
this region of the protein - Gly368, Thr274, Val23, His227 and Asp224 (Rao et al. 1995). 
Considering that paclitaxel is a natural product available in very limited amounts and the 
fact that it is one of the very few drugs to show high success in the clinic for the treatment of 
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various tumors of malignant phenotype, many efforts have been put forth for devising 
semisynthetic strategies and synthetic variants of paclitaxel (Miller and Ojima 2001).  However, 
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Figure 3. Structures of microtubule-stabilizing agents 
Ojima’s pharmacophore model is depicted.  Domains A, B, and C in paclitaxel, the epothilones, 
discodermolide, and the eleutherobin have identical pharmacophore groups. 
(Adapted from: Ojima et al. 1999)   
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because of undesirable effects, poor solubility and drug resistance associated with paclitaxel and 
its analogues, there is continuing hope for the discovery of paclitaxel-like MT-targeting agents 
that can have equivalent or superior anticancer properties without having any of the undesirable 
effects.  One of the well known structural analogues of paclitaxel, docetaxel (Taxotere®), 
received FDA approval and is showing great promise in the clinic (Guenard et al. 1993).  
Structurally, docetaxel differs from paclitaxel in that it has a C-3’-tbutyloxy carbonyl group 
(instead of a C-3’-benzamido group) and a free hydroxyl group at C-7 (instead of an acetate 
group).  Quite a few novel and potent chemical entities from natural products have shown 
interesting biological activities and have outpaced the taxane group of compounds.  The post-
taxane era of natural product-derived MT-stabilizing agents includes discodermolide 
(Gunasekera et al. 1990; ter Haar et al. 1996a; ter Haar et al. 1996b), the epothilones (Gerth et 
al. 1996; Bollag et al. 1995; Kowlaski et al. 1997; Altmann, K-H et al. 2000a; Altmann, K-H et 
al. 2000b), laulimalide (Quinoa et al. 1988; Corley et al. 1988; Mooberry et al. 1999), the 
eleutherobins (Lindel et al. 1997; Long et al. 1998), the sarcodictyins (D’Ambrosio et al. 1987; 
Ciomei et al. 1997), peloruside A (West et al. 2000; Hood et al. 2002) and, most recently, 
dictyostatin (Shin et al. 2002, Isbrucker et al. 2003).  The structures of some these agents are 
represented in Figure 3.  Following the discovery of these many structurally different molecules, 
all having MT-stabilizing actions, efforts were made towards establishing a common 
pharmacophore model for MT stabilizers.   
Ojima et al. (1999) derived a common pharmacophore model using NMR, X-ray 
crystallography and molecular modeling studies.  Using nonataxel as the model, the regions of 
possible overlap were identified for a set of MT stabilizers known to bind to the taxoid site on 
tubulin polymer.  Figure 3 represents the regions of common overlap for some of the 
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microtubule-stabilizing agents.  The binding interactions suggested for paclitaxel show that the 
side chains as well as the baccatin core of the molecule are involved in the interactions with the 
β-subunit of the tubulin.  Very recently, however, electron crystallography, NMR and molecular 
modeling studies done with epothilone A (epoA) bound to α,β-tubulin suggest a far different 
pharmacophore model (Nettles et al. 2004).  The major differences between the paclitaxel and 
epoA binding models, shown in Figure 4, will be briefly discussed in the following section: 
Paclitaxel binds to the β-tubulin subunit of tubulin polymer primarily through hydrophobic 
interactions with complementary residues on the M-loop, helices H7 and H10, and β-strand B9.  
The important pharmacophoric groups are the C-3’-benzamido phenyl, the C-3’-phenyl and the 
C-2-benzoyl phenyl that are involved in hydrophobic interactions with segments of helices H6 
and H7 (Snyder et al. 2001).   The complementary residues interacting with the C-2-benzoyl 
phenyl include Leu-217, Leu-219, a CH2 of Asp-226 and His-229 on and adjacent to helix H7. 
The consequence of His-229 positioned in between the C-2 and C-13 paclitaxel side chains 
affords a "T"-form for paclitaxel in the binding model.  The C-3’-phenyl group is in close contact 
with the β-sheet strands B8 and B10.  The C-3’-benzamido phenyl binds to the N-terminal amino 
acids on helix H1, critical residues being the isopropyl group of Val-23, methylene groups of 
Lys-19, Glu-22 and Asp26.  The C-4-acetate is tethered above the hydrophobic pocket 
encompassing helix H7, the M-loop and the B9-B10 loop.  The C-8-methyl is oriented towards 
Thr-276 and Gln-281 of the M-loop, the O-21 interacts with Thr-276 and the C-12 methyl lies in 
close contact with Leu-371 on the B9-B10 loop. Epothilone A conformational analyses 
suggested a different pharmacophore model as compared to the one for paclitaxel, even though 
these two molecules share a common binding site (Nettles et al. 2004).  This binding model 
supports the existing antiproliferative activity data for mutated ovarian carcinoma cell lines in  
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Figure 4. Representation of binding models for paclitaxel and epothilone A  
The upper half of the figure has structures of paclitaxel, docetaxel, epothilone A, and epothilone 
B.  The lower half of the figures represents the two different binding models for microtubule-
stabilizing agents bound at the taxoid site of tubulin polymer.  The model on the left represents 
paclitaxel binding model and the one on the right epothilone A binding model.  
(Adapted from: Nettles et al. 2004) 
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the presence of paclitaxel and epoA.  The 1A9PTX10 cell line, which has Phe270 mutated to 
Val270, is resistant to paclitaxel but is quite sensitive to epoA.  The predicted model is supported 
by biochemical data and suggests that the macrocycle of epoA is drawn more toward the M-loop 
and is away from Phe270 that lies in the hydrophobic cavity comprised of strand B9.  Hence, the 
mutation of Phe270→Val270 did not influence the biological activity of epoA. The polar 
functional groups spanning C1-C7 of epoA are involved in hydrogen bonding interactions with 
M-loop residues mainly, Thr274, Arg278 and Arg282.  Cells expressing the β-tubulin mutation 
of Ala364 on B10 loop are resistant to paclitaxel  (1A9PTX22 cells); however, this cell line 
retained sensitivity towards epoA.  This re-emphasizes the fact that the epoA macrocycle and the 
hydrophilic functional groups are away from B10 and are not involved in any interaction with 
residues of loop B10.  The thiazole ring of epoA, analogous to the C-2-benzoyl group of 
paclitaxel, tethers to His227.  These two new pharmacophore models stand as valuable 
references for drug design of taxoid site binding agents.  Noteworthy from these studies is the 
fact that these agents have a common taxoid binding site on β-subunit of tubulin polymer, but 
share minimum overlapping binding interactions within this region.  Modeling studies might 
give clues to the synergistic or additive effects of paclitaxel-mimetics on MT polymerization 
dynamics. 
1.3.2. Discodermolide  
Structure, discovery of the mechanism of action and conformational & pharmacophore 
studies 
The MT-stabilizing agent (+)-discodermolide is a sponge-derived polyketide natural 
product obtained from the Caribbean sponge Discodermia dissoluta, originally shown to possess 
immunosuppressive action and antiproliferative activity in various cell lines (Gunasekera et al. 
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1990).  The MT-stabilizing action of discodermolide (structure shown in Figure 3) was 
discovered when in silico studies for quantitative structure-activity relationship evaluations on 
tubulin polymerization perturbing agents were done with a goal to search for new potent 
antimitotic agents (ter Haar et al. 1996a).  Computational studies utilizing the algorithms CASE 
and MultiCASE revealed that the substructural moieties statistically most responsible for activity 
(biophores) identified for discodermolide were isosteric with those observed for steganacin, a 
known colchicine-site binding agent and an inhibitor of MT polymer formation.  These 
biophores were shared with paclitaxel.  Discodermolide was thus predicted to have tubulin 
binding activity and it was of interest then to observe for the effect of discodermolide on tubulin 
dynamics.  Studies in vitro using isolated bovine brain tubulin preparation show discodermolide, 
like paclitaxel, to have a potent MT-stabilizing action (ter Haar et al. 1996b).  It was also 
observed that discodermolide is superior to paclitaxel in that it hypernucleates tubulin assembly 
to form MTs and stabilizes the polymer against cold-induced disassembly much more potently 
than paclitaxel, competes with paclitaxel for binding to tubulin polymer and inhibits the growth 
of paclitaxel-resistant cancer cell lines (Kowalsky et al. 1997).  Furthermore, in vivo growth 
inhibition, cell and nuclear morphological, electrophoretic and flow cytometric analyses on 
human breast carcinoma cells show it to have potent growth inhibitory (low nM range), cell 
cycle perturbing (G2/M block) and apoptosis-inducing activities similar to or even greater than 
that observed for paclitaxel (Balachandran et al. 1998).  Moreover, considering that the clinical 
use of paclitaxel has been limited because of undesirable effects, poor solubility, and drug 
resistance, one would anticipate discodermolide to be a promising and novel chemotherapeutic 
agent against different kinds of cancers.  This compound was one of the candidates taken into 
phase II clinical trials in the Novartis R&D pipeline.  Pre-clinical and Phase I clinical trials on 
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healthy volunteers showed it to be very effective with less toxicity than paclitaxel symptoms.  
This molecule was going through Phase II clinical until recently but, unfortunately, recent 
reports from Novartis indicate termination of clinical trials with discodermolide owing to toxicity 
issues met with this compound upon dose escalation done on a group of patients recruited for a 
Phase II clinical trial (Novartis 2005).   
 Discodermolide is a polyhydroxylated, polymethylated, C24:4 fatty acid lactone 
carbamate.  Its structure consists of a linear polypropionate backbone with 13 stereogenic 
centers, three (Z)-olefenic bonds at C8-C9, C13-C14, and C21-C22, a tetrasubstituted δ-lactone 
(C1-C5), a carbamate (C19) and a terminal cis-diene (C21-C24 ).  X-Ray crystallographic 
studies suggested that the molecule adopts a corkscrew shape (Gunasekera et al. 1990; Ballone et 
al. 1999).  NMR analysis of this compound in acetonitrile showed that the molecule assumes a 
helical form and this observation is in congruence with the designated solid state conformation 
(Smith et al. 2001).  The conformation of discodermolide appears to be a curved, tilde (‘~’) 
shape in which an elongated hydrophobic core is surrounded by polar groups projecting outward.  
The center part of the molecule adopts a U-turn shape to minimize syn-pentane interactions by 
the methyl groups in the main chain and to avoid A-1,2 strain by the vinyl groups projecting 
from the methyl-bearing stereocenters (Jimenez-Barbero et al. 2002). Different conformations 
were found by NMR analysis of discodermolide dissolved in DMSO-d6, with the X-ray structure 
contributing only 1% of the total number of conformers (Monteagudo et al. 2001).  The major 
conformers included corkscrew, sickle and awl types.  Modeling studies attempted to identify a 
common pharmacophore at the taxol/β-tubulin site for paclitaxel and discodermolide have 
proposed a low energy discodermolide conformation with a protein-ligand hydrogen-bonding 
pattern similar to that observed for paclitaxel (Ojima et al. 1999).  Molecular dynamic 
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calculations and conformational analysis suggest the C-11 and C-19 fragment of discodermolide 
is in superposition with the hydrophobic surface (C2 side chain) of nonataxel.  It was also 
observed that C-20 to C-24 diene of discodermolide could be overlaid on the C3’-N-tBoc group 
of nonataxel.  The dataset here represented a collection of several thousand 
conformations/energy manifolds that are possible for discodermolide, implying/indicating 
conformational mobility and a high degree of flexibility possessed in this molecule; however, 
avoidance of A-2,3 and A-1,2 interaction strain was not taken into account.  Regardless, the 
biological activity made this molecule attractive for synthesis and SAR studies.  Understanding 
the SAR of discodermolide on a structural basis will provide important clues for building 
protein-ligand models and for discerning the optimum binding conformation for discodermolide. 
1.3.3. Dictyostatin 
Structure and mechanism of action 
Dictyostatin is a marine natural product derived from Lithisda species belonging to 
Corallistidae family.  Pettit et al. were the first to isolate and attempt structural assignment for 
this molecule (Pettit et al. 1994).  Structurally, dictyostatin resembles discodermolide and this 
molecule was hypothesized to be similar in biological activity to that of discodermolide (Shin et 
al. 2002).  A discussion on the accurate assignment of structure and the potential of dictyostatin 
as a microtubule-stabilizing agent is given in Chapter 4 (and for now I prefer holding it to 
maintain a good level of suspense).   
Investigations done towards the dissertation project were aimed at understanding the 
biochemistry, pharmacology, and structure-activity relationship aspects of novel synthetic 
microtubule-stabilizing agents.  The objectives of the dissertation studies were the following: 
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1. Pharmacological and structure-activity relationship studies of synthetic discodermolide 
analogues 
2. Biochemical, pharmacological, and structure-activity relationship evaluation of dictyostatin, a 
structural congener of discodermolide. 
3. Kinetic and thermodynamic evaluation of discodermolide, dictyostatin, and their synthetic 
analogues binding to microtubule polymer. 
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2. MATERIALS AND EXPERIMENTAL PROCEDURES 
2.1. Materials 
Discodermolide analogues, dictyostatin and dictyostatin analogues were synthesized as described 
(Shin et al. 2002; Shin et al. 2004; Shin et al. 2005; Shin et al. (unpublished); Minguez et al. 
2003; Choy et al. 2003).  Paclitaxel and [3H]paclitaxel (specific activity 16.2 Ci/mmol) were 
provided by the Drug Synthesis and Chemistry Branch, National Cancer Institute.  (+)-
Discodermolide and [5-3H]discodermolide (14.4 Ci/mmol) were generous gifts from Novartis 
Pharmaceuticals Corp., and epothilone B and [14C]epothilone B (111 mCi/mmol) from Novartis 
Pharma AG.  Docetaxel was obtained from the pharmacy at the University of Pittsburgh Cancer 
Institute.  GTP was obtained from Sigma and purified by triethylammonium bicarbonate gradient 
chromatography on DEAE-Sephacel.  DideoxyGTP (ddGTP) was obtained from US 
Biochemicals.  Purified tubulin and heat-treated MAPs were prepared as described previously 
(Hamel and Lin 1984).  Bovine brain tubulin free from unbound nucleotide was prepared as 
reported earlier (Grover and Hamel 1994).  Ca2+- and Mg2+-free RPMI-1640 culture medium 
were from GIBCO/BRL-Life Technologies.  Fetal bovine serum (FBS) was from Hyclone.  
Human carcinoma cell lines (1A9, 2008, PC3, MDA-MB-231 and T47D) were all available by 
previous acquisitions in the Day laboratory.  Parental human ovarian carcinoma 1A9 and the β-
tubulin mutant subclone 1A9PTX10 and 1A9PTX22 cell lines were generous gifts from Drs. 
Tito Fojo and Paraskevi Giannakakou at the National Cancer Institute.  Since cytotoxics are used 
in the clinic primarily to treat hormone-resistant and hormone-refractory cancers of malignant 
phenotype, cell culture experiments were done utilizing cell lines that are mostly hormone-
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resistant.  A brief description of each cell line is as follows:   1A9 is a subclone derived from 
A2780 ovarian carcinoma cell line.  1A9PTX10 is the mutant form of 1A9 ovarian carcinoma 
cell line that has Phe270 mutated on β-tubulin to Val270.  1A9PTX22 is also derived from 1A9 
parental ovarian carcinoma cell line that has Ala364 mutated to Thr.  2008 is a human ovarian 
carcinoma cell line, PC3 is an androgen-independent prostate cancer cell line, MDA-MB-231 is 
an estrogen receptor alpha-independent breast cell line, and T47D is a breast carcinoma cell line.  
Mouse anti-α-tubulin was from LabVision. Rabbit anti-phosphohistone H3 was from Upstate 
Cell Signaling, and fluorophore donkey anti-rabbit and -mouse antibodies were from Jackson 
Immunoresearch. Flutax-2 was from Invitrogen.  All other chemicals were obtained from either 
Sigma or Fisher Scientific and used as received.  
2.2. Experimental procedures 
A. Paclitaxel site inhibition assay:  The abilities of test agents to displace radiolabeled paclitaxel 
from tubulin polymer were determined with a procedure described previously (Hamel et al., 
1999).  [3H]Paclitaxel solutions were prepared in 0.75 M monosodium glutamate (MSG). Test 
agents (4 µM final concentration), prepared in 25% (v/v) DMSO-0.75 M MSG, were mixed with 
radiolabeled agents and warmed to 37 oC.  A reaction mixture (50 μL) containing 0.75 M MSG, 
4.0 μM tubulin and 40 μM ddGTP was prepared and incubated at 37 oC for 30 min to preform 
MTs. Drug mixtures with the radiolabeled tracer were added to preformed polymer and 
incubated for 30 min at 37 oC.  Bound tracer was separated from free tracer by centrifugation of 
the reaction mixtures at 14,000 rpm using a Beckman Coulter AllegraTM 64R centrifuge for 20 
min at room temperature.  Radioactive counts from the supernatant (50 μL) were determined by 
scintillation spectrometry (LS6500-Beckman Coulter multi-purpose scintillation counter). Bound 
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tracer was calculated by subtracting the amount of tracer found in the supernatant from the 
amount of total tracer added to each reaction mixture.  Percent inhibition values were determined 
with respect to controls. 
B. Saturation binding kinetics of [3H]paclitaxel on tubulin polymer:  The saturation binding 
kinetics of paclitaxel were established before evaluating the kinetics in the presence of test 
agents.  Pre-warmed [3H]paclitaxel solutions in the concentration range studied (0.025-2 µM) 
were added to and incubated at 37 oC for 30 min with 4.0 μM tubulin polymer preformed in 0.75 
M MSG containing 40 μM dideoxyGTP.  Unbound [3H]paclitaxel was determined by 
scintillation spectrometry after centrifugation as described above, and bound [3H]paclitaxel 
values were calculated.  Nonspecific binding of [3H]paclitaxel in the presence of docetaxel (12 
µM) was determined.  Specific binding of [3H]paclitaxel in nmol/mg was determined from the 
difference between total and nonspecific binding values.  Saturation binding kinetic parameters, 
KD and Bmax, were then determined using PRISM software version 4.0 (GraphPad Software, Inc., 
San Diego, CA, USA) based on the best-fit model fitting strategy. 
C. Inhibition kinetics of discodermolide and dictyostatin:  The inhibition kinetics of dictyostatin 
at the taxoid site on tubulin polymer were determined as follows.  An equal volume of the test 
agent, in the concentration range studied, was mixed with a [3H]paclitaxel solution (varied 
concentrations) and the resulting solution was warmed to 37 oC. Test agent mixtures were added 
to preformed polymer containing a mixture of 0.75 M MSG, 4.0 µM tubulin and 40 µM 
dideoxyGTP, and incubated for 30 min at 37 oC.  Radioactivity in the supernatant, obtained by 
centrifugation at 14000 rpm for 20 min, was determined by scintillation spectrometry. 
Nonspecific binding and specific binding of [3H]paclitaxel in the presence of inhibitors were 
determined as described above. The percent inhibition values were calculated.  Kinetic analyses 
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of the data were performed using PRISM software version 4.0 (GraphPad Software, Inc., San 
Diego, CA, USA) for the determination of the inhibition pattern(s) and inhibition constants (Ki 
values) for discodermolide and dictyostatin.   
D. Purity check of [3H]paclitaxel by HPLC-radiometry:  Radiochemical purity of [3H]paclitaxel 
was determined by high pressure liquid chromatography (HPLC) connected to a radiochemical 
detector.  HPLC conditions were as follows.  A phenyl column (Alltech® Alltima, 5 μ, 4.6 mm x 
250 mm) was used for separation under gradient conditions.  Mobile phases consisted of solvents 
A and B run under gradient conditions.  Solvent A composed of CH3OH/CH3CN/H2O in the ratio 
4:3:13 and solvent B composed of CH3OH/CH3CN/H2O in the ratio 4:11:5.  Gradient conditions 
included 30 min 100% A, 31-40 min 100% B, 41-45 min 100% A.  The flow rate was 1 
mLl/min.  The injection volume was 50 μL, the run time was 45 min, and the retention time was 
20 min.  The UV wavelength used for single mode detection was 227 nm and a Radiomatic 
tandem radiochemical detector was used.   
E. Cell culture experiments:  Test agent-induced growth inhibition of human carcinoma cell 
lines  (1A9, 1A9PTX10, 1A9PTX22, MDA-MB231, T47D, PC3 and 2008) were evaluated 
following the antiproliferative assay protocol as described earlier (Lazo et al. 2001). Cells were 
maintained in RPMI medium with 10% FBS. The maintenance medium of 1A9PTX10 and 
1A9PTX22 cells also contained 17 nM paclitaxel and 10 µM verapamil.  Maintenance medium 
for T47D carcinoma cell lines was DMEM.  Prior (48-72 h) to experimentation, resistant cells 
were transferred to verapamil- and paclitaxel-free RPMI containing 10% FBS.  Cells were 
seeded into 96-well plates, allowed to attach and grow for 48 h, then treated with either vehicle 
(DMSO; N=8) or a range of concentrations of test agent (each concentration in quadruplicate) for 
72 h.  Cell number was determined spectrophotometrically at 490 nm minus absorbance at 630 
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nm after exposure to 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium and N-methylphenazine methylsulfate (MTS) at both the time zero 
of the experiment as well as at the 72 h time point.  The fifty percent growth inhibitory 
concentrations (GI50) of test agents were calculated from the spectrophotometrically determined 
expansion of the control cells over the 72 h period.  
F. Tubulin polymerization assay:   Tubulin assembly was monitored turbidimetrically at 350 nm 
in temperature-controlled, multichannel Gilford 250 spectrophotometers as described previously 
(ter Haar et al. 1996b).  Reaction mixtures without test compounds consisted of tubulin (1 
mg/ml), heat-treated microtubule-associated proteins (MAPs; 0.75 mg/ml, if present), GTP (100 
µM, if present), and 0.1 M (4-morpholino)ethanesulfonate (Mes), pH 6.9. Baselines were 
established after addition of all reaction components (except the test agents) to the cuvettes held 
at 0 oC.  Test agents, predissolved in DMSO, were then added to give the indicated final 
concentrations (and a constant DMSO concentration of 4% v/v). Each reaction mixture (0.25 mL 
final volume) was then subjected to the temperature changes indicated in the text and figures.  
The positive controls were either paclitaxel (typically 10 µM) or GTP.  The negative control was 
4% v/v DMSO.  Tubulin polymerization assays done in the Beckman-Coulter DU7400 
spectrophotometers had the same protocol as described above except that the MSG, pH 6.6, was 
used in place of Mes, and the reaction mixtures contained no heat-treated MAPs nor GTP. 
G. Electron microscopy:  Samples for electron microscopic analyses were aliquots taken directly 
from cuvettes during the turbidimetry determinations.  Each aliquot was placed on a 200-mesh, 
carbon-coated formvar-treated copper grid and stained with 1% (w/v) uranyl acetate (ter Haar et 
al. 1996b).  Excess staining solution was removed by wicking with torn Whatman filter paper 
and the grid was allowed to dry while protected from dust at room temperature. Grids were 
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examined in a JEM 1210 TEM 120 kV electron microscope.  The images obtained were 
examined visually for polymer morphology.  MT lengths in the digital images were measured 
using Metamorph® version 6.1r2, Universal Imaging Corp.) image analysis software.  
H. Critical concentration experiments:  The critical tubulin concentrations for 10 µM test agent 
to induce polymerization at 37 oC were determined with a centrifugation-based procedure 
described previously (Dabydeen et al. 2004). Briefly, reaction mixtures (0.1 ml) containing 
varying concentrations of tubulin in 0.1 M Mes, pH 6.9, 4% DMSO and test agents as 
appropriate were prepared and incubated for 30 min at 37 °C.  The reaction mixtures were 
centrifuged for 15 min at 14,000 rpm at room temperature (20-22 °C).  A metered aliquot was 
removed from the supernatant and its protein concentration determined by the Lowry method. 
Data were analyzed using PRISM software version 4.0 (GraphPad Software, Inc., San Diego, 
CA, USA).   
I. Lowry assay:  The procedure was based on the Lowry protocol reported in the literature 
(Lowry et al. 1951).  A 1 L, 2x Lowry solution A was prepared by adding 40 g of Na2CO3, 8 g of 
NaOH and 0.4 g Na/K tartrate.  Lowry solution B consisted of 0.5% w/v (i.e., 5 g/L) 
CuSO4.5H2O.  Within 1 h of  beginning the assay, Lowry solution C was prepared by mixing the 
2x solution A with H2O and solution B in a 25:25:1 v/v/v ratio.  One ml of solution C was added 
to each sample (all samples, blanks and standards had the same volume, whether 25, 50 or 100 
μl).  All samples were vortexed.  Fifty μl of the Folin-phenol reagent was added to each sample 
and the samples vortexed again.  The samples were incubated for at least 1 h until the reaction 
reached equilibrium (i.e., a stable blue color).  The absorbances of samples at 650 nm were 
determined with a Beckman coulter DU640 spectrophotometer.   
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J. Pelleting assay (for determination of EC50):  The EC50  value is defined as the concentration 
of test agent required to polymerize 50% of the tubulin compared to amount of tubulin polymer 
found in the pellet of the DMSO control incubation, and was determined with a procedure 
reported earlier (Gapud et al. 2004).  The reaction condition included 0.2 M MSG, 10 μM 
tubulin, 5% v/v DMSO and varying concentrations of test agents.  The reaction mixtures were 
incubated at room temperature for 15 min, centrifuged for 10 min at 14,000 rpm, and protein 
concentration determined by the Lowry method.  On average, 5.5 ± 4.0 % of the tubulin pelleted 
in the DMSO control.  
K. Multiparameter fluorescence microscopy: High information content cell-based fluorescence 
screening was carried out under previously detailed conditions (Minguez et al. 2002).  Human 
cervical epithelial HeLa (for Henrietta Lacks, from whom they were derived in 1951) carcinoma 
cells were used for this experiment.  HeLa cells growing at log phase were trypsinized and plated 
in 40 µL at a density of 7,000-8,000 cells per well in calf skin collagen I-coated 384well plates 
(Falcon #3962; Fisher Scientific).  Cells were exposed to test agents or 0.5% DMSO within 2-8 h 
of plating.  Concentrated DMSO stock solutions of all test agents were diluted into solutions of 
HBSS medium plus 10% FBS and added to the microplate wells (10 µL per well), using an 
automated liquid handling system (Biomek® 2000; Beckman-Coulter, Inc.) to provide a serial 2-
fold dilution of each test agent.  The cells were incubated in the presence of test agents for 24 h.  
At the end of the incubation, the medium was removed and replaced with HBSS containing 4% 
formaldehyde and 10 µg/mL Hoechst 33342 (25 µL/well) to fix the cells and fluorescently label 
their chromatin, respectively.  After incubation at room temperature for 20-30 min, the solution 
was removed from each well and replaced with HBSS (100 µL/well).  Further reagent additions 
were made to the microplates using the Biomek 2000.  After removing the HBSS from each well, 
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cells were permeabilized for 5 min at room temperature with 0.5% w/w Triton X-100 in HBSS 
(10 µL/well).  This step extracts a fraction of the soluble cellular components, including soluble 
tubulin. The wells were washed with HBSS (100 µL/well), followed by addition of a primary 
antibody solution containing mouse anti-α-tubulin (at a 1:3000 dilution) and rabbit anti-
phosphohistone H3 (at a 1:500 dilution) in HBSS (10 µL/well).  After 1 h at room temperature, 
the wells were washed with HBSS as above, followed by the addition of a secondary antibody 
solution containing fluorescein-5-isothiocyanate (FITC)-labeled donkey anti-mouse (at a 1:300 
dilution) and Cy3-labeled donkey anti-rabbit (at a 1:300 dilution) antibodies diluted in HBSS (10 
µL/well). After 1 h at room temperature, the wells were washed as above, and HBSS was added 
(100 µL/well).  The plates were placed in an ArrayScanII® HCS Reader with the Target 
Activation BioApplication Software coupled to Cellomics® Store and the vHCS™ Discovery 
Toolbox (Cellomics, Inc.) to analyze images.  Briefly, the instrument was used to scan multiple 
optical fields, each with multiparameter fluorescence, within a subset of the wells of the 384-well 
microplate.  The BioApplication software produced multiple numerical feature values, such as 
subcellular object intensities, shapes, and location for each cell within an optical field.  Data 
were acquired from a minimum of 1,000 cells per well, except in cases where added test agents 
reduced the attachment of cells to the substrate.  A nuclear mask was generated from Hoechst 
33342-stained nuclei, and object identification thresholds and shape parameters were set such 
that the algorithm identified over 90% of the nuclei in each field.  Objects that touched each 
other or the edge of the image were excluded from the analysis.  Tubulin mass was defined as the 
average green (FITC) pixel intensity in an area defined by the Hoechst-defined nuclear mask. 
This cytoplasmic area around the nucleus contains cytoskeletal components and has been shown 
to be a region from which sensitive measurements of cytoplasmic characteristics can be made 
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(Giuliano and Taylor 1994).  The percentage of phospho-histone H3 positive cells was defined as 
the number of cells whose average red (Cy3) staining intensity exceeded the average Cy3 
intensity plus two standard deviations of vehicle-treated cells, divided by the total number of 
cells.  Data were analyzed using PRISM software version 4.0 (GraphPad Software, Inc., San 
Diego, CA USA).  
L. Flutax-2 binding experiments:  Glutaraldehyde-fixed microtubules and a fluorescent 
analogue of paclitaxel (Flutax-2) were used to determine the binding kinetics and 
thermodynamics of test agent-tubulin interactions using methods recently described (Andreu and 
Barasoain 2001; Diaz et al. 2003).  A fluorescent-labeled paclitaxel derivative called Oregon 
Green® 488 paclitaxel conjugate (commonly referred to as Flutax-2) was obtained from 
Invitrogen.  The fluorescent label on this probe was obtained by derivatizing the 7β-hydroxy 
group of paclitaxel with difluorocarboxyfluorescein group (Figure 34 in the Appendix).  
Flutax-2 binding experiments were done to obtain binding kinetic as well as thermodynamic 
parameters and are based on fluorescence anisotropy technique.  The set of experiments involved 
were preparation of gluraldehyde-fixed microtubules, determination of concentration and number 
of binding sites, and determination of inhibition constants by fluorescence competitor assay.  
Each one of these experiments will be discussed below.  Flutax-2 experiments with no inhibitor 
provide information on the concentration and number of binding sites, stoichiometry of binding 
sites, equilibrium binding constants and thermodynamic parameters.  
Preparation of cross-linked microtubules: Microtubules were cross-linked with 
glutaraldehyde following the experimental procedure described previously (Andreu and 
Barasoain 2001).  Bovine brain tubulin was dialyzed against a buffer consisting of 10 mM 
sodium phosphate, 1 mM EGTA, 0.1 mM GTP, and 3.5 M glycerol pH 6.8 for about 2 h after 
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which MgCl2 (6 mM) and GTP (1 mM) were added to the solution.  This is glycerol-induced 
assembly buffer (GAB, pH 6.5).  The solution consisting of tubulin (50 µM) was assembled into 
microtubules at 37 oC for 30 min.  The assembled microtubules were cross-linked with 20 mM 
glutaraldehyde at 37 oC for 10 min and the reaction quenched with 60 mM NaBH4.  The 
morphology of the cross-linked microtubules was verified by EM.  The cross-linked 
microtubules were dialyzed against the desired buffer (which was GAB-0.1 mM GDP buffer) for 
2 h in the cold and stored at 4 oC with 0.05% sodium azide.  The total tubulin concentration was 
determined by Lowry method.  
Determination of the concentration of taxoid binding sites:  The concentration of taxoid 
binding sites was determined following the procedure described earlier (Andreu and Barasoain 
2001).  Flutax-2 concentration was determined after diluting the sample in 50 mM dipotassium 
phosphate buffer pH 9.0 at an extinction coefficient of 80, 000 M-1 cm-1 at 494 nm.  The assay 
was done in a 96-well plate.  Increasing concentrations of cross-linked microtubules (0.004-12.5 
µM) were added to 25 nM Flutax-2 in the GAB-GDP buffer, pH 6.5 in the presence and absence 
of 10 µM docetaxel.  The plate was scanned using a fluorescence plate reader with polarizer 
filters installed in it.  Each well was scanned in λexc 495 and λems 520 range using fluorescein 
filter and a dichroic mirror as the beam splitter that operates at 520 nm (Figure 34 in the 
Appendix).  Fluorescence anisotropy was determined from the raw parallel and perpendicular 
fluorescence intensity data.  The concentration of bound Flutax-2 (Fb) was determined using the 
following equation:  
[F]b  = [F]o[(r-rmin)/(rmax-rmin)]   
where, ‘r’ is the observed anisotropy value, rmin is the minimum anisotropy observed for Flutax-2 
only sample containing no protein, and rmax is the maximum anisotropy obtained for Flutax-2 in 
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the presence of highest concentration of cross-linked microtubules.  The experimental rmin and 
rmax values were in the range of 0.05-0.08 and 0.25-0.28.  The concentration of free binding sites 
was determined from the difference between total concentration of microtubules and bound 
concentration of Flutax-2, the equation for which is: 
 [S] = [S]o – [F]b       
where, [S] is the concentration of free binding sites determined from total concentration of 
microtubule binding sites [S]o and bound concentration of Flutax-2 [F]b.   
The equilibrium binding constant (Kb) from the free concentration of microtubule binding sites 
versus anisotropy data was determined from the following equation.  Iterations were done using 
WINNONLIN version 3.0 from which the best-fit values for rmin and rmax were determined.   
 r  = rmin +  (rmax-rmin)Kb[S]/(1 + K [S]) 
Determination of the number of taxoid binding sites for Flutax-2:  The number of 
taxoid binding sites was determined by adding increasing concentrations of Flutax-2 to 50 nM or 
100 nM of cross-linked microtubules in the presence and absence of 10 µM docetaxel.  The 
samples were rotary shaken for 5 min and incubated at 37 oC for 20 min at different temperature 
conditions (room temperature and 37 oC).  GAB-GDP, pH 6.5 buffer was used.  The bound and 
free Flutax-2 concentrations were determined, as described above, from which the number of 
binding sites (n) were determined using appropriate equations.   
 [F]b/[S]o = [F]o (r – rmin)/[S]o (rmax – rmin) 
 [F]  = [F]o – [F]b 
 [F]b/[T]o = nKbF/(1 + Kb[F]) 
Iterations were done using WINNONLIN version 3.0 from which the best-fit values for n and Kb 
were determined. 
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Competitive fluorescence assay for microtubule-stabilizing agents:  A solution of 50 
nM Flutax-2 and 50 nM cross-linked microtubules were prepared in GAB-GDP buffer, pH 6.5.  
The assay was performed in a 384-well plate and the total volume was 40 µL.  The competitors 
were added in increasing concentrations into each well (concentration range: 1 nM-1 µM), final 
DMSO concentration was 2% v/v.  The samples were rotary shaken for 5 min and incubated for 
20 min at the desired temperatures (room temperature and 37 oC).  Measurements were taken in a 
microplate reader twice within 30-90 min after equilibration.  The λexc is 480 nm and λemi is 520 
nm.  A sample consisting of 50 nM paclitaxel binding sites was the blank and another sample of 
50 nM Flutax-2 solution in GAB-0.1 mM GTP was the anisotropy standard.  Measurements of 
anisotropy of Flutax-2 in the presence of docetaxel (excess, 1 µM or 10 µM) and also in the 
absence of competitors were required for data analysis.  Inhibition constants were to be 
calculated for competition experiments.  This set of experiments is in progress. 
Data analyses: Data were analyzed using either WINNONLIN version 3.0 or PRISM 
software version 4.0 (GraphPad Software, Inc., San Diego, CA USA).  Equilibrium binding 
constants and thermodynamic parameters were calculated from fluorescence anisotropy data. 
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3. DISCODERMOLIDES - BIOLOGICAL AND SAR EVALUATIONS 
3.1. Introduction and literature cited 
The yield of discodermolide from its natural source is very low (0.002%); hence intensive efforts 
were put in place to devise efficient strategies to synthesize this complex molecule in high yields.  
Several total and partial syntheses of discodermolide have been developed based on convergent 
retrosynthetic approaches, but all these require not less than thirty steps from commercially 
available starting materials to the final product (Curran et al. 2002; Day et al. 2002; Francavilla 
et al. 2003; Harried et al. 2003; Hung et al. 1996a; Marshall et al. 1998; Mickel et al. 2004a, 
Mickel et al. 2004b, Mickel et al. 2004c; Mickel et al. 2004d; Mickel et al. 2004e; Paterson et al. 
2000; Paterson et al. 2001; Smith et al. 1999).  Consequently, few analogues have been reported 
and SAR data on discodermolide is not complete.  Hence, one goal over the past decade has been 
to make simpler analogues of discodermolide in fewer synthetic steps than necessary for the 
natural product.  Moreover, clinical trials of discodermolide were put on hold, presumably 
because of previously unseen toxicity (Novartis 2005).  Hence, efforts made towards the 
synthesis of potent analogues of discodermolide could give rise to new lead molecules for drug 
development.    
 The initial structural variants of discodermolide were prepared by Schreiber’s group and 
tested for biological activity (Hung et al. 1996a and Hung et al. 1996b).  These are stereoisomers 
prepared from the epimeric side products obtained in the synthesis of discodermolide.  The 
biological activities of these isomers show that the 16-normethyldiscodermolide is as active as 
discodermolide in cytotoxicity assays.  The configuration at C16 and C17 positions is very 
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important for the activity of the parent molecule.  The analogue with R-configuration at C16 had 
an IC50 of about 300 nM and the one with S-configuration at C17 was totally inactive.   
 Truncated versions of discodermolide, fragments including the C1-C15 or C8-C24 
regions of the parent molecule, were also made and tested.  These two compounds lacked 
biological activity, implying that the full length of discodermolide is necessary.  The authors also 
studied the importance for activity of the four hydroxyl functionalities of discodermolide by 
examining acylated analogues.  17-Acetyldiscodermolide had a reasonably good antiproliferative 
IC50 value (70 nM), though it is less potent than discodermolide (6 nM).  The descarbamoyl 
analogue, C19-acetyldiscodermolide, was inactive.  Modification of the terminal diene through 
replacement with a pivaloyl group led to an analogue with activity less than that observed for 
discodermolide.  The α- and β-thiophenyl anomers at C1 of the lactol form of the lactone ring of 
discodermolide retained activity equivalent to that of the parent molecule.  Finally, removal of 
the C16 methyl group and extending the C16 carbon yielded an analogue with no activity, 
indicating that modifications at the C16 position of the C16-normethyldiscodermolide would not 
lead to analogues possessing good biological activity.   
 Longley and co-workers reported that effects of semisynthetic acetyl analogues of 
discodermolide on microtubule function (Gunasekera et al. 2001; Isbrucker et al. 2001) by 
selective acetylation of the hydroxyl groups at C3, C7, C11, and/or C17 of discodermolide.  The 
resultant mono-, di-, tri-, and tetra-acetates of discodermolide were studied for biological 
potency in in vitro cytotoxicity assays.  The IC50 values of these analogues towards A459 cells 
were quite interesting; while C3- and/or C7-acetylated versions showed biological activities 
greater than/or equivalent to discodermolide, acetylation of the C11 (discodermolide 3, 11-
diacetate and discodermolide-3,7,11-triacetate) and C17 (3,7,11,17-tetraacetate, discodermolide-
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3,7,17-triacetate, discodermolide-3,17-diacetate) hydroxyl groups caused a decrease in the 
biological potency.  The effect was more drastic with C17 substitution than that observed with 
C11 substitution.  These studies are in agreement with that reported by Schreiber’s group where 
reduced activity of the C17-substituted compounds was observed.  Moreover, the C3- and/or C7-
acetylated versions, like the parent molecule, blocked the cell cycle at the G2/M phase and the 
proliferation of A459 cell line (at 100 nM).  The remaining analogues had no effect on cell cycle 
distribution at this concentration.  Further studies of these analogues on microtubule morphology 
revealed that at 100 nM the C3- and/C7-acetylated compounds induce microtubule bundling 
comparable to discodermolide.  Discodermolide-7-acetate and discodermolide-3,7-diacetate 
caused more pronounced microtubule bundling than did discodermolide itself when all were 
studied at 10 or 100 nM.  The other analogues were less active.  Temperature-controlled tubulin 
polymerization experiments also show similar trends in that the C3- and/or C7- acetylated 
analogues of discodermolide, at 10 μM with 1 mg/mL purified bovine brain tubulin, induced 
assembly of tubulin at low temperatures (at and above 6oC, for discodermolide it is >4oC) and 
that the assembled tubulin was quite resistant to cold-induced disassembly (discodemolide-
stabilized polymer is not affected by changes in temperature).  The remaining analogues were all 
inactive.  These SAR studies on the acetylated derivatives of discodermolide provide conclusive 
evidence that the C11 and C17 hydroxyl groups are important for the cytotoxic action of the 
parent molecule and that the hydroxyl groups at C3 and C7 are amenable to modifications.   
 Smith’s group reported that syntheses of C14-normethyl (i.e., the C8-C9 cis-disubstituted 
olefin) and C7-deoxygenated analogues were feasible during the course of total synthesis of the 
parent molecule (Smith et al. 1999; Martello et al. 2001.  Of all the analogues, the C3-dehydro 
and C3-dehydro/C7-deoxy analogues are approximately 2-fold more and 3-fold less cytotoxic 
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than discodermolide.  This suggests extreme sensitivity to structural changes at C1-C14 portion 
of the parent molecule.  The α,β-unsaturated lactone containing ring analogue analogue was 
found to be more or less as active as discodermolide.  This indicates that the lactone ring is a 
flexible moiety in terms of modifications it can withstand and still provide analogues with potent 
biological activity.  The C14-normethyl and C7-deoxy analogues were less active than 
discodermolide and its α,β-unsaturated lactone containing ring analogue.  The nucleating ability 
of all the analogues differed significantly from that of the parent molecule.  The cytotoxic action 
of these compounds was studied in A549 and SKOV3 cells.  Discodermolide and its α,β-
unsaturated lactone analogue had similar growth inhibitory IC50 values in A549 cells, and 
discodermolide was shown to be less cytotoxic.  This indicates that the methyl group at C14 and 
the hydroxyl group at C7 are important for the activity of the parent molecule.  These analogues 
were approximately 2- and 3-fold less cytotoxic than discodermolide.  Flow cytometry and 
immunofluorescence analyses using A549 cells also showed these analogues caused G2/M block 
and microtubule bundling, though each compound showed these effects at different 
concentrations.  The geometry at C14-C15 is important for activity.  This group reported that 
C14-cis-C14-normethyl discodermolide is only 2-fold less cytotoxic than discodermolide, while 
its C14 trans-C14-normethyl geometric isomer is far less biologically active.  The SAR studies 
by this group also suggest that at least one of the hydroxyl groups at C3 or C7 is required for 
discodermolide-like activity. 
3.2. Simplified discodermolide analogues - design and synthesis 
Based on the structure-activity studies reported in the literature for discodermolide, it was 
hypothesized that the left and the right portions of the molecule (lactone, carbamate and the 
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diene) are amenable for structural manipulation to make synthetically easier and simpler 
discodermolide analogues that would retain biological activity.  Hence, the goal of this study was 
to establish structure-activity relationship (SAR) for discodermolide by evaluating simpler 
analogues of discodermolide for microtubule-targeting activities. 
Hypothesis I: Simplified analogues of discodermolide would retain the biological activity of and 
have microtubule-targeting (binding, stabilizing, and antiproliferative) activities similar to the 
parent molecule.  
Rationale: Literature reports suggest that discodermolide binds to paclitaxel site on tubulin 
polymer (ter Haar et al. 1996b; Kowalski et al. 1997).  Discodermolide was known to bind with 
high affinity at the taxoid site and is known to competitively inhibit Paclitaxel from binding to 
microtubules.  Studies performed to understand mechanisms of synergism also suggest minimum 
overlapping binding sites for discodermolide and paclitaxel (Martello et al. 2000).  
Discodermolide analogues were evaluated for their ability to inhibit paclitaxel from binding to 
tubulin polymer in comparison to the parent molecule discodermolide.  Understanding the SAR 
of discodermolide on a structural basis provides important clues for establishing protein-ligand 
models and for discerning the optimum binding conformation for the molecule.  Hence, 
paclitaxel binding experiments were set up to look at the binding properties of the analogues.  
The potent antiproliferative activity of discodermolide is primarily attributed to its ability to 
hypernucleate tubulin assembly and to stabilize assembled microtubule thereby causing cell 
cycle arrest (ter Haar et al. 1996b).  Therefore, along with the binding experiments, analogues 
were examined for microtubule stabilization and antiproliferative activities. 
The first library of discodermolide analogues was synthesized by Drs. Jose Minguez and 
Sun-Young Kim in the laboratories of Prof. Dennis Curran at the University of Pittsburgh 
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Department of Chemistry.  The modifications introduced in the design of the analogues are 
represented in Figure 5 (Minguez et al. 2003). 
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Figure 5. Configuration of discodermolide and domains of variation for SAR studies 
Domain A. Replacement of the lactone with simple esters.  Domain B. Replacements of the 
carbamate on C19 with an acetoxy group.  Domain C. Inversion of the configuration at C17 and 
derivatizing the hydroxyl group at this carbon keeping the hydroxyl group at C19 free.   
Domain D.  Inversion of the configuration at C11. Note: The analogues also differed from the 
natural product, apart from removal of the lactone, in that the methyl groups at C14 and C16 as 
well as C7 hydroxyl group were omitted. 
 
 
 
The strategy of convergent retrosynthetic plan of fragment coupling by Wittig-olefinations was 
utilized to build the library of diverse set of analogues for extensive SAR analysis.  Details of the 
experimental procedures and schemes for the synthesis of the first library of discodermolide 
analogues can be found in Minguez et al. 2003.  A simpler scheme adopted for the synthesis of 
the first set of discodermolide analogues is shown in Scheme 1.  Retrosynthetically, the 
polypropionate backbone was divided into three fragments disconnecting at the C8-C9 and C13-
C14 double bonds: a THP-protected phosphonium salt as the ‘left display’, a diene phosphonium 
salt as the ‘right display’, and an aldehyde as the central scaffold.  The latter two fragments 
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Scheme 1. Retrosynthetic strategy adopted for the synthesis of the first library analogues 
 
 
 
have a common stereochemical triad that can be retrosynthetically reduced to a common 
intermediate, the homoallylic alcohol 2, the starting material for which was the commercially 
available hydroxy ester, methyl (S)-(+)-3-hydroxy-2-methylpropionate 1.   The first library 
consisted of the following discodermolide analogues: 
1) 11S, 17R, 19S-carbamoyloxy analogues 
2) 11S,17R,19S-acetoxy analogues 
3) 11S,17R-carbamoyloxy and 11S,17R-acetoxy analogues 
4) 11R,17R-carbamoyloxy and 11R,17R-acetoxy analogues 
5) 11S,17S,19S-carbamoyloxy analogues 
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3.2.1. Biological evaluation of discodermolide analogues 
The first library of discodermolide analogues were evaluated for their ability to inhibit 
tritiated paclitaxel ([3H]paclitaxel) from binding to tubulin polymer.   
Experimental procedures:  
Paclitaxel site inhibition assay: The abilities of test agents to displace radiolabeled paclitaxel 
from binding to tubulin polymer were determined following the procedure described in the 
Chapter 2.  Monosodium glutamate at pH 6.6 was used in this experiment since tubulin and 
microtubule polymer were known to be stable in this vehicle.  The critical concentration to 
polymerize tubulin to form microtubules was previously reported to be lower in the presence of 
ddGTP, a dideoxy analogue of GTP, than GTP itself.  Hence, ddGTP was used to assemble 
tubulin to microtubule polymer at 37 oC.  Radioactive counts from the supernatant (50 μL) were 
determined by scintillation spectrometry. Bound tracer was calculated from the amount of total 
tracer added to each reaction mixture minus the amount of tracer found in the supernatant.  
Percent inhibition values were determined with respect to controls. 
Microtubule stabilization assay: Tubulin polymerization assays were done in Beckman-Coulter 
DU7400 spectrophotometers as described in the Chapter 2.  The percent microtubule 
stabilization was calculated for each analogue with respect to the turbidity readings obtained for 
positive (in the presence of 10 µM paclitaxel) and negative controls (in the presence of DMSO). 
Antiproliferative assay: Three different human carcinoma cell lines were used to determine the 
antiproliferative potency of these compounds.  MDA-MB-231 is an estrogen receptor alpha 
negative breast cancer cell line, PC3 is an androgen-independent prostate cancer cell line, and 
2008 is an ovarian cancer cell line.  The protocol as described in Chapter 2 used the 
mitochondria-catalyzed formation of a water-soluble MTS formazan that was 
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spectrophotometrically detected at 490, minus non-specific absorbance at 650 nm, to estimate 
cell number. 
3.2.2. 11S, 17R, 19S-carbamoyloxy discodermolide analogues 
This set of analogues was modified on the left portion of the molecule.  The lactone 
moiety was replaced with simple to bulkier esters.  The biological activity data for these 
analogues is summarized in Table 1.  Analogue JMM452, having a bulkier tertiary butanoyl ester 
replacing the lactone ring, was the most active of all these analogues in all the biological assays.  
Antiproliferative assays showed that all the analogues (except for one) had GI50 values in the low 
micromolar range (1-8 μM).  JMM452 showed antiproliferative activity in low micromolar range 
(1-15 µM) in all the three cell lines.  Analogues having either a phenyl (JMM450), a methyl 
(JMM451), a hydroxyl methyl (JMM496) or a heteroaryl (JMM490 and JMM499) functionality 
substituted for the lactone ring of discodermolide were less active than JMM452.  JMM496 was 
the least active of all the analogues in cell-based assay.  The GI50s were in the range of 25-50 μM 
in the three cell lines studied.  The esterified analogues, although less effective than 
discodermolide, inhibited [3H]paclitaxel from binding to tubulin polymer when present in 2-fold 
molar excess over that of paclitaxel.  JMM452 at 4 μM inhibited [3H]paclitaxel binding to 
microtubule polymer to an extent of about 32%.  However, the analogues showed lower GI50 and 
% [3H]paclitaxel inhibition values when compared with either discodermolide or paclitaxel 
All these analogues showed some ability, although weak, to cause polymer assembly of 
isolated bovine brain tubulin (Minguez et al. 2003).  These two studies suggest that these 
analogues bound at a site coincident with or overlapping that of paclitaxel.   
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Table 1. Biological activity data for 11S, 17R, 19S-carbamoyloxy analogues 
 
 
 
R
O
O OOH
OH O
NH2
 
Antiproliferative activity 
GI50(µM); N=4 
Analogue %MT 
Assembly 
MDA-MB-231   PC-3              2008 
%Paclitaxel
Inhibition 
N=6 
JMM450 
R=Ph 
13 7.2±0.4 11±1 7.7±0.5 19±3 
JMM451 
R=Me 
5 12±1 6.6±0.3 5.8±0.7 19±4 
JMM452 
R=tBu 
14 2.6±0.9 3.0±0.8 1.5±1.0 32±6 
JMM490 
R=2-
Methylthiophene 
10 8.0±0.3 15±2 7.1±0.6 23±9 
JMM496 
R=CH2OH 
<5 41±2 >50 24±2 23±1 
JMM499 
R=2-Methylfuran 
21 7.5±0.1 14±1 6.4±0.6 18±1 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.0016 
 
0.015±0.002
 
0.0092±0.0016 
 
37±1 
 
 
 
 
3.2.3. 11S, 17R, 19S-acetoxy discodermolide analogues 
This set of analogues had an acetoxy group at C19 in place of the carbamate moiety of 
discodermolide, and as in the previous set of analogues, the lactone moiety was substituted with 
simple esters.  The ability of the acetoxy analogues to inhibit [3H]paclitaxel from binding to 
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tubulin polymer, to induce microtubule stabilization and to inhibit carcinoma cell lines from 
proliferating are represented in Table 2.  At 4 μM, these analogues showed some inhibition of 
radioligand binding to polymer to an extent almost similar to the previous set of analogues.  
However, the assembly-inducing properties and antiproliferative activities of the acetoxy 
analogues were decreased to a considerable extent, indicating that the carbamate moiety at C19 
is important for the activity of the parent molecule.  The GI50 values were in mid-μM range for 
all the analogues except the tertiary butanoyl derivative that had GI50 values in low-mid μM 
range.  The analogues had lower biological activity compared to either discodermolide or 
paclitaxel.   
 
Table 2. Biological activity data for 11S, 17R, 19S-acetoxy analogues 
 
 
 
R
O
O OOH
OH O
 
 
Antiproliferative activity - GI50(µM); N=4 Analogue %MT 
Assembly MDA-MB-
231           
PC-3              2008 
%Paclitaxel 
Inhibition 
N=6 
JMM460 
R=Me 
18 22±2 25±4 15±1 19±2 
JMM461 
R=Ph 
9 20±2 21±2 20±2 17±1 
JMM462 
R=tBu 
8 6.8±1.9 14±1.0 14±2 24±2 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.0016
 
0.015±0.002
 
0.0092±0.0016 
 
37±1 
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3.2.4. 11S, 17S, 19S-carbamoyloxy analogues 
The stereochemistry at C17 in this set of analogues was inverted from R to S and the 
lactone ring substituted with simple esters.  The biological evaluation data is represented in 
Table 3.  The data suggests that inversion of the configuration at C17 decreased biological 
activity to a considerable extent (Minguez et al. 2003).  The percent inhibition values from the 
binding assay and percent microtubule assembly from the polymerization assay were lower than 
the previously described analogues.  The GI50 values against the three carcinoma cell lines were 
in mid-μM range for all the analogues except for the hydroxymethyl derivative that yielded GI50s 
> 50 μM.   
 
Table 3.  Biological activity data for 11S, 17S, 19S-carbamoyloxy analogues 
 
 
R
O
O OOH
OH O
NH2
 
Antiproliferative activity - GI50(µM); N=4 Analogue %MT 
Assembly MDA-MB-
231   
   PC-3             2008 
%Paclitaxel 
Inhibition 
N=6 
JMM503 
R=tBu 
7 24±1 23±2 27±1 17±1 
JMM504 
R=Ph 
179 20±2 23±2 21±3 11±2 
JMM506 
R=CH2OH 
15 >50 >50 >50 18±0 
JMM508 
R=2-
Methylfuran 
20 19±0 23±1 20±7 20±4 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004 
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.0016
 
0.015±0.002 
 
0.0092±0.0016 
 
37±1 
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3.2.5. 11S, 17R-carbamoyloxy or 11S,17R-acetoxy analogues 
These analogues had the carbamoyl or the acetoxy groups positioned at C17 instead of at 
C19 and the lactone ring of the parent molecule replaced with simple esters.  The biological 
activity data is presented in Table 4.  Data from the paclitaxel binding assay showed this set of 
analogues to have moderate inhibition properties.  The analogues, except for JMM416 and 
JMM417, showed considerable microtubule-stabilizing activities as well (Minguez et al. 2003).  
Also, there was decreased antiproliferative activity with these analogues, but the structural 
manipulations done were not as detrimental as was the inversion of configuration at C17.  The 
GI50 values for most of these analogues were in low to mid μM range.  The analogues had lower 
antiproliferative and [3H]paclitaxel inhibition activities than either paclitaxel or discodermolide. 
The methylester analogue had GI50s greater than 50 μM in all the cell lines studied.  
3.2.6. 11R,17R-carbamoyloxy and 11R,17R-acetoxy analogues 
The next set of analogues had both the configuration of the C11 changed from S to R and 
also the carbamate or the acetoxy groups switched to the C17 position, along with the lactone 
ring replaced with simple esters.  The paclitaxel site binding activity data for this set of 
analogues yielded moderate results (Table 5).  Inversion of configuration at C11 proved highly 
detrimental for the biological activity of these analogues, with none showing microtubule-
stabilizing properties (microtubule assembly < 5%) and very few of them having even very weak 
antiproliferative activities (Minguez et al. 2003).  The GI50s were higher (ranging from 20->50 
μM) for this set of analogues than in the remainder of this library when compared with either 
discodermolide or paclitaxel.   
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Table 4. Biological activity data for 11S,17R-carbamoyloxy or 11S,17R-acetoxy analogues  
 
 
R1
O
O OHO
OH
COR
 
Antiproliferative activity - GI50(µM); N=4 Analogue %MT 
Assembly MDA-MB-
231 
PC-3 2008 
%Paclitaxel 
Inhibition 
N=6 
JMM365 
R=NH2, R1=tBu 
12 11±2 20±3 2.7±3.5 15±3 
JMM416 
R=NH2, R1=Ph 
13 15±0 15±1 21±2 12±5 
JMM417 
R=NH2, R1=Me 
18 >50 >50 >50 10±4 
JMM369 
R=Me, R1=tBu 
10 20±4 20±3 5.8±2.2 21±3 
JMM370 
R=Me, R1=Ph 
<5 25±6 >50 3±0.9 16±2 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.0016
 
0.015±0.002
 
0.0092±0.0016 
 
37±1 
 
 
 
 
3.2.7. Discussion of the first library of discodermolide analogues 
 From the SAR studies of the first set of discodermolide analogues, it can be concluded 
that left display (lactone) of discodermolide can be simplified or modified without much loss of 
activity.  The tertiary butanoyl ester analogue retained biological activity to a considerable extent 
suggesting that the lactone ring of discodermolide can be substituted with bulkier groups with 
retention of microtubule-targeting activities.  However, the lactone seems to play a significant  
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Table 5. Biological activity data for 11R,17R-carbamoyloxy or 11R,17R-acetoxy analogues 
  
R1
O
O OHO
OH
COR
 
 
Antiproliferative activity - GI50(µM); N=4 Analogue %MT 
Assembly MDA-MB-
231 
PC-3 2008 
%Paclitaxel 
Inhibition 
N=6 
SKY1 
R=NH2, R1=Me 
<5 >50 >50 >50 21±2 
SKY2 
R=NH2, R1=iPr 
<5 >50 >50 31±4 19±2 
SKY3 
R=NH2, R1=tBu 
<5 22±2 33±1 33±1 17±1 
SKY4 
R=NH2, R1=Ph 
<5 25±6 20±1 26±4 18±1 
SKY5 
R=NH2, 
R1=CH2OMe 
<5 >50 >50 >50 18±1 
SKY-A1 
R=Me, R1=Me 
<5 >50 >50 >50 15±1 
SKY-A2 
R=Me, R1=iPr 
<5 12±5 >50 >50 17±2 
SKY-A3 
R=Me, R1=tBu 
<5 23±1 43±11 41±5 17±2 
SKY-A4 
R=Me, R1=Ph 
<5 7±3 26±6 29±2 20±5 
SKY-A5 
R=Me,  
R1=CH2OMe 
<5 >50 >50 >50 16±2 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004 
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.002 
 
0.015±0.002 
 
0.0092±0.002 
 
37±1 
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role in the biological potency of the parent molecule. Stereochemistry at C11(S), C17(R), and 
C19(S) and the carbamate moiety at position C19 are important for activity.  Switching the 
carbamate group to C17 or introducing an acetoxy group at C19 led to loss of microtubule 
binding activity but proved not to be as detrimental as was modifying the configuration at any of 
these two positions.  These data correlate with the antiproliferative assay data wherein GI50 
values greater than 20 µM were obtained for these analogues.   
3.3. 4-epi-7-Dehydroxy-14,16-didemethyl-(+)-discodermolide 
NMR analysis of discodermolide in acetonitrile showed that the molecule assumed a helical 
conformation and this observation was in congruence with the designated X-ray crystal structure 
(Smith et al. 2001; Ballone et al. 1999).  Conformational analysis suggested that the major 
conformer seemed to assume a curved tilde (~) shape in which an elongated hydrophobic core 
was surrounded by polar groups projecting outward.  The center part of the molecule adopted the 
U-turn shape to minimize syn-pentane interactions by the methyl groups in the main chain and to 
avoid A-1,2 strain by the vinyl groups projecting outward from the methyl-bearing stereocenters.  
It was assumed that the 3’-OH group of the lactone ring might be interacting with the nitrogen of 
the carbamate group via hydrogen-bonding interactions.  The resulting hypothesis then explored 
by the Day and Curran laboratories was that analogues having an extended spacer that reduced 
the distance between the functional groups involved in hydrogen bonding interactions, thus 
stabilizing the overall conformation of the molecule, would be more potent or retain activity 
similar to the parent molecule.  The solution conformational properties obtained for 
discodermolide was the basis for designing novel conformational analogues along the lines of 
rational drug design.  Structural variants of left and right displays of discodermolide were 
synthesized and evaluated for further SAR analysis (Choy et al. 2003).  Modifications that were 
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done included the introduction of a C4-epi-lactone on the left display, alterations on the right 
display, truncation of the C19 analogues, wholesale replacement of the diene on the right display 
and substitution of the C3-OH group with a methoxymethyl (MOM) protecting group for 
incorporating an extended H-bond acceptor.  The analogues were synthesized by Drs. Nakyen 
Choy, Phu Qui Nguyen and Youseung Shin in the Curran laboratory, following a retrosynthetic 
methodology represented in Scheme 2 (Choy et al. 2003). 
3.3.1. Biological evaluation of 4-epi-discodermolide analogues 
This class includes 7-dehydroxy-14,16-didemethyl-(+)-discodermolides, C19-truncated 
analogues, diene-containing analogues with the C4-epi-lactone, C1 and C3 substituted 
analogues, and analogues with wholesale replacement of the diene.  
 The first set of analogues in this library consisted of compounds that had the C19-diene 
truncated and the configuration at C4 of the lactone modified with or without installment of a C3 
MOM-protecting group.  The biological activity data obtained with these analogues is presented 
in Table 6.  Evaluation of the C19-truncated analogues (NC164, NC165, NC142 and NC112) 
showed that these compounds were all much less active than discodermolide in their ability to 
inhibit paclitaxel from binding to tubulin polymer (< 10%), to induce microtubule stabilization 
(<10%) and to exhibit antiproliferative action against human carcinoma cell lines (> 50 μM).   
Similar results were observed for the two C4 epimers.  All the C4-epi analogues with C19 
truncated dienes had similar, weak biological activities.  The antiproliferative and % 
[3H]paclitaxel inhibition values were lower than those observed for discodermolide and/or 
paclitaxel.  This data underlines the significance of the diene group of discodermolides for 
microtubule-stabilizing activities.  Hence, the next set of analogues was prepared with the diene 
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 (R1 = alkyl, aryl; R2 = CH=CH2)
 (R1 = tBu; R2 = H, Et, CH=CH2, Ph)
 (R1 = H, MOM; R2 = H, alkyl)
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Scheme 2. Retrosynthetic strategy plan for the second library of analogues  
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Table 6. Biological activity data for 4-epi-discodermolides  
This includes 4-epi-7-dehydroxy-14,16-didemethyl-(+)-discodermolides and C19-truncated  
analogues. 
 
 
 
 
 
 
Antiproliferative activity - GI50(µM); N=4 Analogue %MT 
Assembly MDA-MB-231 PC-3 2008 
%Paclitaxel 
Inhibition 
N=6 
NC164 
4R,R1=MOM, 
R2=iPr 
7 >50 >50 >50 10±1 
NC165 
4R,R1=H, 
R2=iPr 
13 >50 >50 >50 10±3 
NC142 
4S,R1=MOM, 
R2=iPr 
<5 46±1 >50 >50 3±10 
NC112 
4S,R1=MOM, 
R2=H 
<5 30±8 >50 >50 13±1 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004 
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.002 
 
0.015±0.002 
 
0.0092±0.002 
 
37±1 
 
 
 
intact but with a modified left display, namely, altered or natural configuration at C4 and 
introduction of a MOM group or a free hydroxyl group at C3 of the lactone.   
The retrosynthetic strategy followed by the synthetic chemists yielded five analogues that had 
either a free hydroxyl group or a MOM substitution at the C3 position, and/or a methoxy group 
at C1 and a diene or an alkyl substituent at C19.  The compound NC84 had the lactone, a free 
4
O
OR1
OOH
OH
O R2
O
NH2
7
14
3
1916
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hydroxyl group at C3 and an intact diene.  NC86 had the lactone, a MOM group at C3 and an 
intact diene.  NC85 is the lactol derivative of NC86.  Derivatives of NC85 were made wherein 
the diene was totally replaced by an alkyl functionality (compounds PN1 and PN2).  Biological 
evaluation of these analogues included paclitaxel site inhibition, microtubule stabilization and 
antiproliferative activities.  The data are presented in Table 7. 
The biological studies with these compounds showed that the lactone MOM ether NC86 
was more potent than its closely related lactol NC85 or the free hydroxyl NC84 derivatives.  
NC86 inhibited the binding of tritiated paclitaxel to an extent of about 57%.  In antiproliferative 
assays, NC86 showed activity in high nanomolar to low micromolar range against three different 
human carcinoma cell lines GI50~0.6-1.8 μM) and this compound induced microtubule 
stabilization (27%) to a considerable degree.  Interestingly, at 40 μM, NC86 caused 
hypernucleation of tubulin assembly.  Although the biological activity of NC86 was less potent 
than that of discodermolide and paclitaxel in all the three assays, the results were quite 
encouraging.  NC84 and NC85 were not as biologically active as was NC86.  The 
antiproliferative activity values were lower for NC84 and NC85 compared to that obtained for 
either discodermolide or paclitaxel.  However, in 2008 cell line, the GI50 value was not different 
from the values observed for either discodermolide or paclitaxel.  Their ability to inhibit 
paclitaxel from binding to tubulin polymer was about 20% and percent microtubule stabilization 
was about 11%, while their GI50 values were in the low micromolar range (GI50 ~ 2-15 μM).  
PN1 and PN2 had the diene replaced with a saturated alkyl group and the stereochemistry at C19 
erased by either deleting or adding methyl groups, respectively.  The biological activity data 
from these two compounds showed them to be less active than NC86, with antiproliferative  
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Table 7. Biological activity data for 4-epi-discodermolides   
This includes C1- and C3-substituted and C19 diene intact or truncated analogues. 
 
  
  
O
R1
OH O
R2
OH
NH2
O
C1
 
 
Antiproliferative activity - GI50(µM); N=4 Analogue %MT 
Assembly MDA-MB-231 PC-3 2008 
%Paclitaxel 
Inhibition 
N=6 
NC84 
C1:C=O, 
R1=OH, 
R2=diene 
11 2.1±1.8 7.5±2 5.2±1 21±1 
NC86 
C1:C=O, 
R1=OMOM, 
R2=diene 
27 0.87±0.21 1.8±0.9 0.65±0.25 57±2 
NC85 
C1:C=OMe, 
R1=OMOM, 
R2=diene 
11 3.4±0.8 15±3 4.7±0.6 19±2 
PN1 
C1:C=OMe, 
R1=OMOM,  
R2= alkyl  
6 24±1 >50 29±4 9±0 
PN2 
C1:C=OMe, 
R1=OMOM,  
R2= alkyl  
9 23±0 38±1 42±5 15±5 
 
Discodermolide 
 
>100 
 
0.016±0.003 
 
0.067±0.004 
 
0.072±0.005 
 
64±2 
 
Paclitaxel 
 
100 
 
0.0024±0.002 
 
0.015±0.002 
 
0.0092±0.002 
 
37±1 
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values in 20-50 μM range and only modest abilities to stabilize microtubules or compete for 
paclitaxel site on microtubules.  The GI50 and % [3H]paclitaxel inhibition values were lower than 
those observed for either discodermolide or paclitaxel. 
3.3.2.  Discussion of the second library of discodermolide analogues 
 Biological activity data from the 4-epi-7-dehydroxy-14,16-didemethyl-(+)-
discodermolides strongly supported the hypothesis that conformational analogues of 
discodermolide could yield compounds with potency comparable to the parent molecule.  The 
data further supports the conformational analysis and pharmacophore studies on discodermolide 
that hypothesize a hydrogen bonding interaction between the C3 or C7 hydroxyl and the C19 
carbamate moieties, and for this close proximity in space of the lactone and carbamate to playing 
a major role in the stabilization of the most biologically active conformer of discodermolide.  
Introduction of a hydrogen bond acceptor and a spacer like the MOM group at C3 seemed 
promising and one of these analogues (NC86) retained microtubule-targeting activity to a 
considerable extent.  The right display (diene portion) was more sensitive to changes and 
changes there proved detrimental, yielding agents with very weak biological activity. 
3.4. Design and biological evaluation of discodermolide/dictyostatin hybrids 
Dictyostatin, like discodermolide, is a natural product derived from marine sources (Pettit et al. 
1994).  It was first isolated by Pettit and was assigned structure 7 or 1b (Figures 3 and 6, 
respectively).  Cytotoxicity assays done in P388 leukemia cells have shown dictyostatin to be 
more potent than discodermolide with an ED50 of 0.38 nM.  The Curran and Day groups 
proposed that, structurally, discodermolide and dictyostatin appear to be similar, assuming the 
theoretical cyclization of discodermolide's carbamate amino group with the lactone carbonyl  
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Figure 6. Representation of structural resemblances of discodermolide and dictyostatin  
Pettit’s original structure (1b) and Paterson’s modified structure (3) of dictyostatin are shown.  
Also represented are structures for discodermolide, in its linear form (4), and paclitaxel (5). 
Adapted from: Pettit et al. 1984 and Paterson et al. 2004a. 
 
 
(Shin et al. 2002).  Dictyostatin has two additional carbon atoms and differs, at least in the 
structure originally proposed by Pettit, in stereochemistry with that of discodermolide (Figure 6).  
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Hence, it was hypothesized that macrocyclic analogues of discodermolide might have interesting 
biological activities.  On the basis of these assumptions, discodermolide/dictyostatin hybrids 
were constructed and evaluated. for microtubule-targeting actions.  Macrolactones of 
discodermolide were synthesized by Drs. Youseung Shin, Nakyen Choy, and Ms. Tiffany Turner 
in the Curran group.  Following the convergent retrosynthetic strategy outlined for the synthesis 
of discodermolide analogues, the macrocyclic hybrids YSS072 and YSS133 were constructed 
using sequential Wittig coupling reactions (Shin et al. 2002).  Acyclic analogues YSS083, 
YSS085 and YSS086 were also synthesized from the appropriate synthetic intermediates as 
reference molecules.  This small library was evaluated for microtubule-targeting and 
antiproliferative activities, which revealed that the macrocyclic analogue YSS133 indeed had 
promising biological activity (Table 8).  This compound had GI50 values in low micromolar 
range (1-1.4 μM) and competed with paclitaxel for binding to tubulin polymer (27% inhibition) 
to a reasonable extent.  The GI50 values obtained for the other analogues tested against three 
different cancer cell lines showed that the macrolactone YSS072 and the acyclic analogues 
(YSS083, YSS085 and YSS086) had weak activity.  The GI50 as well as % [3H]paclitaxel 
inhibition values were similar for all the four analogues.  The fact that one of the 
discodermolide/dictyostain hybrids showed considerable microtubule-stabilizing activity raised 
hope for the design of potent discodermolide and dictyostatin hybrids and, more importantly, the 
synthesis of dictyostatin itself and its synthetic analogues. 
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Table 8. Biological activity data for discodermolide/dictyostatin hybrids  
 
HO
O
OHO
OH
OH
O
O
NH2
HO
O
OHOH
O
OH
(+)-Discodermolide
GI50: 0.016+0.003 μM
% Paclitaxel inhibition: 64+2
YSS086
GI50: > 50 μM
% Paclitaxel inhibition: 16+3
YSS083
GI50: 18+1 μM
% Paclitaxel inhibition: 21+2
YSS072
GI50: 27+1 μM
% Paclitaxel inhibition: 16+3
YSS085
GI50: 26+3 μM
% Paclitaxel inhibition: 17+1
YSS133
GI50: 1.4+0.1 μM
% Paclitaxel inhibition: 27+8
(-)-Dictyostatin
Pettit's proposed structure
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3.5. Discussion 
Preliminary evaluation of discodermolide and discodermmolide/dictyostatin analogues for 
antiproliferative and tubulin polymerization activities helped establish a reasonable SAR.  
Earlier, it was shown that removal of the methyl groups at C14, C16 and the hydroxyl group at 
C7 led to analogues with some retention of activity.  Schreiber’s group observed that C16-
normethyldiscodermolide was as active as the parent molecule in cytotoxicity assays (Hung et al.  
1996b).  Studies from Longley’s group suggest that one of the hydroxyl groups at C3 or C7 is 
important for the activity of the parent molecule (Gunasekera et al. 2001; Isbrucker et al. 2001).   
It was found that the C3-dehydro and C3-dehydro/C7-deoxy analogues were approximately 2-
fold more and 3-fold less cytotoxic than discodermolide.  Smith’s group reported that the 
geometry at C14 was important for biological activity of discodermolide (Martello et al. 2001).  
The C14-cis-normethyldiscodermolide was found to be only 2-fold less cytotoxic than 
discodermolide and C14-trans-normethyldiscodermolide had less cytotoxic activity.  The first 
and second library set of analogues in the current studies lacked methyl groups at C14 and C16 
and the hydroxyl at C7.   
Biological evaluation data for the first and second libraries of discodermolide analogues 
suggested that the lactone moiety of discodermolide is amenable to modifications.  Bulkier 
functional groups were well tolerated and this was shown to be the case with JMM452 wherein 
the lactone group was replaced with tert-butanoate ester.  Nevertheless, the lactone is critical for 
biological activity of discodermolide.  One of the 4-epi-7-dehydroxy-14,16-didemethyl-(+)-
discodermolides, NC86, was the most promising (in drug discovery vernacular, "A Hit!") of all 
the discodermolide analogues studied for microtubule-targeting activities.  NC86 was designed 
via a rational drug design standpoint based on the solution conformational properties of 
discodermolide.  Conformational analysis of discodermolide suggests that a hydrogen bond 
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interaction between an acceptor like a hydroxyl group or a MOM group positioned at C3 of the 
lactone ring or the hydroxyl at C7 with the C19 carbamate would stabilize the tilde conformation 
of discodermolide.  Intensive cellular profiling immunofluorescence experiments done with these 
analogues strongly suggest that JMM452 and NC86 caused:  (i) microtubule perturbation with 
morphologies varying from normal bipolar to abnormal multipolar mitotic spindles; (ii) 
condensation of nuclear chromatin; and (iii) elevated levels of certain mitotic markers like 
phosphohistone H3 and stress pathway kinase downstream targets (phosphoRSK90).  
Noteworthy in these studies is the finding that JMM452 was more selective for mutated β-
tubulin ovarian carcinoma cell lines than for the non-mutated parental cells (Minguez et al. 
2003).   
 Following the intensive SAR analyses done by replacing the lactone moiety of 
discodermolide with a variety of esters which led to retention of biological activity to a 
considerable extent, Smith’s group has recently made a series of 7-deoxy aryl discodermolide 
analogues wherein the lactone functionality is replaced with aryl substituents (Burlingame et al. 
2004).  The 2,3-anhydro analogue of discodermolide showed considerable cytotoxicity against 
all cell lines tested.  Also, incorporation of a phenolic (meta to the ethylene linker) moiety in 
place of the lactone in discodermolide gives an analogue with increased cytotoxic action relative 
to the unsubstituted derivative.  Introduction of another hydroxyl group, meta to the hydroxyl in 
the previous analogue, provided no change in the cytotoxicity.  These results led to preparation 
by the Smith group of a library of 7-deoxy aryl discodermolide analogues having a range of 
functionalized phenyl rings and thiophene moieties.  This set of analogues was evaluated for 
biological activity and most were active against various cancer cell lines in low micromolar 
range.  The methylthiophene and meta-substituted aryl analogues exhibited greater cytotoxic 
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effects than the remaining analogues.  Aryl analogues with para-substitution or difluoro 
derivatives and unsubstituted thiophenes had drastically decreased cytotoxic actions  These 
results indicate that removal of five stereogenic centers and replacement of the entire ‘C’ region 
(as shown with phenylethylene substituent and derivatives of it) with various aryl and thiophene 
substituents gives analogues with promising biological activities. 
 Novartis chemists have synthesized discodermolide analogues wherein isosteric 
replacements of the C1-C5 lactone ring with aromatic groups, of the trisubstituted olefin with an 
N-methyl amide group, and of the C21-24 diene were done (Palermo et al. 2002; Weichun et al. 
2002; Peng et al. 2002).  A structurally diverse set discodermolide analogues was also 
synthesized.  The biological activity studies for these analogues were performed against five 
different human carcinoma cell lines, three paclitaxel-sensitive -- A549, HCT 116, 1A9, and two 
paclitaxel-resistant -- MIP101, 1A9PTX22.  7-Acetyldiscodermolide was found to be the most 
potent of all the analogues tested for microtubule bundling and growth inhibition, and the 
truncated analogue was as potent as discodermolide in microtubule bundle formation but was 
less potent in inhibiting the growth of the cell lines studied.  In the paclitaxel-resistant MIP101 
cell line, the C14-demethylated analogue showed a drastic reduction in antiproliferative activity. 
Also, most of the C21-C24 modified analogues turned out to be less potent.   
 Smith’s group has further explored the critical functional groups on the lactone ring that 
are important for activity (Shaw et al. 2005).  In these studies, analogues with modifications 
done on the lactone ring showed greater antiproliferative activity (IC50s in the range of 2-9 nM) 
than the parent molecule (IC50s of 16-28 nM).  The 2-normethyl-2,3-anhydro and 2,4-normethyl-
2,3-anhydro analogues were quite active, suggesting that the 2- and 4- methyl groups and the 3-
hydroxyl group of the discodermolide lactone have no significant role in the biological potency 
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of the parent molecule.  The α,β-unsaturated carbonyl was found not to be important.  The 
unsubstituted lactone showed greater activity in all the cell lines except the NCI/ADR cell line, 
known to overexpress P-gp.  4,5-Bis-epi-2,3-anhydrodiscodermolide turned out to be active as 
well.  A five-membered unsubstituted butyrolactone showed marked improvement in biological 
activity as compared to the parent molecule.  These studies are on par with the data discussed in 
this dissertation that suggest that the lactone moiety of discodermolide is flexible for 
modification and analogues with the correct conformation, as reported in the NMR solution 
structure of discodermolide analysis, yielded promising results.  Later studies from Smith also 
evaluated analogues with alterations of the carbamate group (Smith et al. 2005).  Derivatives of 
2,3-anhydrodiscodermolide and 14-normethyldiscodermolide that were made and of interest are 
the analogues having the N,N-dimethylaniline substituent on the nitrogen of the carbamate.  
These two analogues had greater antiproliferative potencies than discodermolide.   
 Structure-activity relationship evaluations of discodermolide analogues suggest that the 
structural framework of the parent molecule is amenable for modifications. Based on our 
observations and findings in the literature the SAR for discodermolide can be represented as 
shown in Figure 7.  The future holds promise for developing conformationally active and less 
toxic variants of discodermolide as novel microtubule-stabilizing agents.  Interesting amongst all 
the libraries of compounds is the one consisting of macrocyclic analogues of discodermolide.  
One of the macrolactones, YSS133, which was designed based on the stereochemistry of 
discodermolide, showed promising activity in paclitaxel site inhibition, microtubule stabilization, 
and antiproliferative experiments.  This result paved way for the total synthesis of dictyostatin, a 
macrocycle and a structural congener of discodermolide, and laid the foundation for future scope 
of the project. 
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Figure 7.  Representation of SAR for (+)-discodermolide 
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4. TUBULIN ASSEMBLY, PACLITAXEL SITE BINDING, AND CELLULAR 
EFFECTS OF DICTYOSTATIN AND DICTYOSTATIN ANALOGUES 
4.1. Introduction and literature cited 
 (–)-Dictyostatin is a 22-membered macrolactone with 11 stereocenters, an endocyclic Z,E-
dienoate and a pendant Z-diene (3 in Figure 6, Chapter 3). It was first isolated from a marine 
sponge of the genus Spongia collected in the Republic of Maldives and found to be a potent 
antiproliferative agent of nanomolar potency (Pettit et al. 1994).  Cytotoxicity assays done in 
P388 leukemia cells showed dictyostatin to be a potent molecule with an ED50 0.38 nM.  NMR 
experiments revealed dictyostatin to be a polyketide that was assigned structure 1b (Chapter 3, 
Figure 6).  Several questions remained as to the proposed structure of this compound.  Even with 
the first structural assignment, it was clear that the compound had great similarities to that of (+)-
discodermolide (Shin et al. 2002).  A hypothetical cyclization of the sp3-hybridized oxygen in 
the carbamate group with the lactone carbonyl group of discodermolide gives a structure 
resembling that of dictyostatin, although the latter has two additional carbon atoms.  If one does 
this hypothetical cyclization with the carbamate nitrogen and the lactone carbonyl, the 
macrocycles would be the same size.  Before knowing the true relative and absolute 
stereochemistry of dictyostatin, the macrocyclic hybrids of discodermolide/dictyostatin 
structures discussed earlier were designed and evaluated for microtubule-targeting actions.  One 
of the analogues, YSS133, shown also in Table 8 of Chapter 3, indeed caused assembly of 
tubulin, exhibited a GI50 potency in the low micromolar range (~1 µM) and competed, albeit 
weakly, with paclitaxel for binding to tubulin polymer. 
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During this time, dictyostatin was again isolated from a Lithistida sponge of the family 
Corallistidae harvested near Jamaica (Isbrucker et al. 2003). In that study, the natural product 
was further evaluated in biological assays and found to promote tubulin assembly in the presence 
of GTP but in the absence of MAPs at temperatures (4 oC) where paclitaxel is inactive, to 
enhance tubulin assembly much more potently than paclitaxel at 37 oC, and to form  microtubule 
polymer that is, unlike that formed by paclitaxel, cold-stable.  Antiproliferative potencies against 
various human tumor cell lines (A549, MCF7, MES-SA) were found to be in the 1-5 nM range, 
comparable to, or even lower than those observed for paclitaxel.  Even the NCI/ADR-RES cell 
lines that overexpress the ABC1 drug efflux transporter (a.k.a. the P-glycoprotein pump) were 
susceptible to the antiproliferative effects of natural dictyostatin (GI50 ~20 nM).  Flow cytometric 
analyses of A549 cells treated with 10 nM natural dictyostatin showed induction of G2/M block 
and the effect was more extensive than that seen with cells treated with 10 nM paclitaxel.  
Immunofluorescence studies of treated cells revealed that natural dictyostatin caused microtubule 
rearrangement and bundling at very low concentrations (10-100 nM).  Natural dictyostatin also 
promoted nuclear degradation characteristic of apoptosis and induced aneuploidy.  
The relative stereochemistry of dictyostatin was proposed after high field NMR 
experiments and molecular modeling (Paterson et al. 2004a). Shortly thereafter, simultaneous 
publications describing full syntheses of the compound gave unequivocal evidence for the 
structure and its absolute stereochemistry as shown in Figure 6 of Chapter 3 (Paterson et al. 
2004b, Shin et al. 2004). These full syntheses and our previous approaches to 
dictyostatin/discodermolide hybrids opened the door for detailed biological evaluations of this 
rare natural product and for building analogues of the parent structure.  The total syntheses of 
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dictyostatin and its analogues were done by Drs. Youseung Shin, Jean-Hugues Fournier, 
Yoshikazu Fukui and Arndt Brückner in Prof. Curran’s laboratory. 
Hypothesis II: Synthetic dictyostatin, like its structural congener discodermolide, 
hypernucleates tubulin assembly more potently than paclitaxel in the presence and absence of 
MAPs and/or GTP, binds to taxoid site on tubulin polymer with greater affinity and is active 
against paclitaxel-resistant cells.   
Rationale: Discodermolide binds to taxoid site on tubulin polymer with high affinity, competes 
with paclitaxel for binding on tubulin polymer, and hypernucleates tubulin assembly more 
potently than paclitaxel in the presence and absence of MAPs and/or GTP (ter Haar et al. 1996b; 
Kowalski et al. 1997).  It would be of interest then to investigate if dictyostatin binds to tubulin 
polymer and nucleates microtubule assembly much more potently than paclitaxel by direct 
evaluation of its polymerization ability as well as polymer morphology.  Also important would 
be to evaluate the role of MAPs and GTP in modulating the interaction of dictyostatin with 
tubulin.  Previous reports on breast carcinoma cell lines have shown that discodermolide potently 
induced microtubule bundle formation than paclitaxel, in spite of these two compounds having 
almost equivalent IC50 values (Kowalski et al. 1997; Balachandran et al. 1998).  Microtubule 
bundle formation was seen in cells treated with 10 nM discodermolide as opposed to paclitaxel, 
which required 1 μM to show this same effect.  It would be important to study if dictyostatin, 
like discodermolide, promotes microtubule bundle formation and mitotic aberrations more 
potently than paclitaxel in human carcinoma cell lines.  Therefore, in-depth pharmacological 
investigations were undertaken to study tubulin assembly, paclitaxel site binding, and cellular 
effects of synthetic dictyostatin and to obtain comparison profiles against paclitaxel, 
discodermolide and epothilone B.  Dictyostatin analogues were synthesized for structure-activity 
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relationship evaluation.  Synthesis of the analogues was done by Drs. Youseung Shin and Jean-
Hugues Fournier in Prof. Curran's laboratory.  The structures of the analogues are presented in 
Figure 8.  Modifications done on the parent molecule for SAR evaluation are listed below.   
1. YSS631 is dictyostatin. 
2. YSS629 is an open-chain methyl ester of dictyostatin.   
3. YSS479 has the configuration of the methyl groups at C6 and C16 epimerized.  The functional 
groups at C6 and C7 are syn to each other.   
4. YSS133 is a previously reported macrocyclic hybrid of discodermolide/dictyostatin.  
5. YSS652 is an epimer of dictyostatin wherein the configuration of the hydroxyl group at C19 
was changed from R to S.   
6. YSS665 has the configuration at C6 and C14 modified and also the geometry of C4:C5 was 
changed from (E:Z) to (E:E). 
7. YSS675-1 has the configuration of the methyl groups at C6, C14, and the hydroxyl group at 
C19 modified.   
8. YSS675-2 has the configuration of the methyl groups at C6, C14, the hydroxyl group at C19, 
and also the geometry of C4:C5 was changed from (E:Z) to (E:E). 
9. YSS698-2 is C16-normethyldictyostatin. 
Structural analogues of dictyostatin were also evaluated for microtubule-targeting activities.  The 
goal was to establish a reasonable SAR for dictyostatin and analogues.  The biological activity 
data for this library is discussed below. 
4.2. Experimental approach and results 
Cell-based in vivo and isolated protein-based in vitro experiments were performed to evaluate 
dictyostatin and its analogues for their effects on microtubule binding and microtubule  
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Figure 8.  Structural analogues of dictyostatin for SAR and pharmacological evaluation  
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perturbing activities.  In vivo experiments included antiproliferative and immunofluorescence 
assays. In vitro studies included the radiolabeled, microtubule stabilization, critical concentration 
and pelleting assays. A brief description of those experiments is given below.  Details are given 
in Chapter 2 for all the assays employed for this study.  In addition, experimental details 
considered important for the studies aimed for this set of analogues are described in the results 
section for each assay.   
Antiproliferative assay:  The ability of dictyostatin and its synthetic analogues to inhibit cell 
growth was studied in three different ovarian cancer cell lines and two breast cancer cell lines.  
1A9 is a parental ovarian cancer cell line.  1A9PTX10 and 1A9PTX22 are the mutated ovarian 
carcinoma cells derived from the parental cell line.  The generation of mutated paclitaxel-
resistant cell lines is as described in Chapter 2.  The former has phenylalanine at position 270 on 
β-tubulin mutated to valine, the latter has alanine at 364 on β-tubulin mutated to threonine.  Two 
breast cancer cell lines included in the experiment were the MDA-MB-231, an estrogen receptor 
alpha negative breast cancer cell line and T47D, a cell line expressing substantial levels of 
estrogen receptor beta.  The experimental protocol is the same as described in Chapter 2 except 
that T47D cell line was grown in DMEM medium.  The assay was done in RPMI medium 
supplemented with 10% FBS for all the cell lines.  The GI50 values were calculated in the 
presence of all the test agents. 
Multiparameter immunofluorescence experiments:  Immunofluorescence technique was 
employed to investigate the microtubule bundling and mitotic effects of dictyostatin and its 
analogues.  An advanced robot technology in tandem with array scan equipment was used for the 
study.  The description of the experimental protocol is as described in Chapter 2.  
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Paclitaxel site inhibition assay: The abilities of test agents to displace radioligands from 
binding to tubulin polymer were determined following the procedure described in Chapter 2.  
Monosodium glutamate at pH 6.6 and ddGTP were used for reasons as described previously 
(Chapter 3).  The radioligands used for the inhibition study included [3H]paclitaxel, 
[3H]discodermolide, and [14C]epothilone B.  Radioactive counts from the supernatant (50 μL) 
were determined by scintillation spectrometry.  Bound tracer was calculated from the amount of 
total tracer added to each reaction mixture minus the amount of tracer found in the supernatant.  
Percent inhibition values were determined with respect to control experiments. 
Microtubule stabilization assay: Tubulin polymerization assays were done in Gilford 250 and 
Beckman-Coulter DU7400 spectrophotometers as described in Chapter 2 for different reaction 
conditions.  The percent microtubule stabilization was calculated for each analogue with respect 
to the turbidity readings obtained for positive (in the presence of 10 µM paclitaxel) and negative 
controls (in the presence of DMSO).  Electron microscopic analysis of the microtubule polymer 
formed in the presence of test agents was done following 1% v/v uranylacetate staining 
procedure as described in Chapter 2. 
Critical concentration was performed to determine the hypernucleating ability of 
dictyostatin in comparison with discodermolide.  The ability of dictyostatin and its analogues to 
induce polymerization was given a quantitative estimation by calculating the EC50 values from 
the pelleting assay.  The experimental details for these two experiments are as described in 
Chapter 2.   
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4.3. In vivo cell-based experiments 
4.3.1. Antiproliferative activity studies 
 
Parental (1A9 cell line) and β-tubulin mutated (1A9/PTX10 and 1A9/PTX22) ovarian cancer cell 
lines were used for studying antiproliferative activity of dictyostatin and its synthetic analogues.  
In addition, two breast cancer cell lines, T47D and MDA-MB-231, were also investigated for 
microtubule perturbing effects in the presence of test agents.  The paclitaxel-resistant cells were 
maintained in RPMI/10% FBS medium containing 17 nM paclitaxel and 10 µM of MDR1 
reversal agent verapamil.  Experiments with test agents were done in paclitaxel- and verapamil-
free RPMI/10% FBS medium.  Antiproliferation experiments were done following the protocol 
described in Chapter 2.  The experimental results are presented in Table 9.  The GI50 values 
determined show that dictyostatin was active in the very low nanomolar range and was the most 
potent growth inhibitory agent of all the compounds studied.  Dictyostatin and paclitaxel 
exhibited comparable GI50 values against the parental 1A9 cells (0.69 nM vs. 0.71 nM).  The 
mutant β-tubulin-expressing cells showed about 90- and 70-fold resistance to paclitaxel, while 
their cross-resistance to dictyostatin was only 2- to 4-fold.  Against the mutated cell lines, the 
GI50 values observed for dictyostatin were 3.2 and 1.3 nM, respectively.  Dictyostatin had over a 
two-fold lower GI50 value than that of discodermolide against 1A9 cell line (0.69 versus 1.7 nM, 
respectively).  The mutated β-tubulin cell line 1A9/PTX10 retained its sensitivity to both 
dictyostatin and discodermolide, but the GI50 value for dictyostatin was lower than for 
discodermolide (3.2 vs. 6.2 nM, respectively).  Against 1A9/PTX22 cells, dictyostatin was over 
5-fold more active than discodermolide (1.3 vs. 7 nM, respectively).  Comparison of the relative 
resistance values for 1A9/PTX22 cell line revealed that the fold-resistance observed in the 
presence of dictyostatin was about 2-fold lower than that with discodermolide.  The relative 
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resistance values for 1A9/PTX10 cell line in the presence of these two compounds were 
comparable.   
The analogues were also examined for their antiproliferative activities against 1A9, 
PTX10 and PTX22 cell lines.  Although less active than the parent compound, the GI50 values 
were in mid-nM range for all the analogues, except for the C6-epi/C16-epi analogue YSS479 
(for which the GI50 was >500 nM), against the three cell lines (Table 9).  It should also be noted 
that the fold-resistance values for these compounds against PTX10 and PTX22 cell lines were 
much lower than that observed for paclitaxel.  Of interest is the antiproliferative activity of 16-
normethyldictyostatin, YSS698-2.  The GI50 values for this compound ranged from 0.5-2 nM.  
While this compound showed potency equivalent to that of the parent molecule against parental 
1A9 cells as well as against one of the mutated β-tubulin cell lines (PTX22), its  GI50 was close 
to 500 nM in the other mutated cell line, PTX10.  The open-chain methyl ester analogue, 
YSS629, and the C19 epimer, YSS652 had activities in mid-nM range.  Likewise, YSS652, with 
the C19 configuration inverted, showed preferential antiproliferative activity against one mutated 
β-tubulin cell line over the other.  The PTX22 cell line exhibited a 2-fold resistance vs. that seen 
with the PTX10 cell line, which was about 6-fold resistant to YSS652 in comparison to the 
activity observed in the parental cell line.  This demonstrates the importance of C16 and C19 
position for binding of the parent molecule to the biological target.  The C2-E/C6-epi/C14-epi 
alterations in analogue YSS665-2 led to a loss of antiproliferative activity, with GI50 values in 
the range of 300-800 nM.  However, analogues with C19 epimerized and with retention of C6-
epi and C14-epi (YSS675-1) or C2-E, C6-epi and C14-epi (YSS675-2) configurations were quite 
active and had better antiproliferative activity profiles in all the cell lines studied than did 
YSS665-2 (GI50s ~ 25 nM).  Nevertheless, the activity was far less than seen for the parent 
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molecule, thus indicating the significance of E:Z geometry of the diene and the configuration of 
C14 and of C19 for biological activity.  Noteworthy is the observation that dictyostatin-like 
compounds, with an exception noted for the C16-normethyl analogue, retained their sensitivity 
against mutated paclitaxel-resistant cell lines.   
 
 
Table 9. Antiproliferative activities of dictyostatin and its analogues 
Fifty percent growth inhibitory concentrations (GI50) of dictyostatin, discodermolide and 
paclitaxel against human ovarian cancer cell lines after 72 h in continuous presence of the agents. 
1A9 cells express wild-type β-tubulin, whereas the 1A9PTX10 and 1A9PTX22 cells express, 
respectively, the Phe270→Val and Ala364→Thr mutant forms of the protein. 
 
GI50 + S.D., nM (fold-resistance) 
(N=4 ) 
Cell line 
Compound 1A9 1A9/PTX10 
(Phe270→Val) 
1A9/PTX22 
(Ala364→Thr) 
Discodermolide 1.7±1.2 6.2±3.6 (3.6) 7.0±8.4 (4.1)  
Paclitaxel 0.71±0.11 64±8 51±9 
Dictyostatin 0.69±0.80 3.2±2.4 (4.6)  1.3±1.0 (1.9)  
YSS479 > 500 > 500 > 500 
YSS629 56±16 79±13 (1.4)  85±2 (1.5)  
YSS652 21±14 120±60 (5.7)  43±12 (2.0)  
YSS665-2 310±40 780±200 (2.5)  790±560 (2.5)  
YSS675-1 28±1 26±0 30±1 
YSS675-2 25±2 25±1 30±1 
YSS698-2 0.41±0.52 470±70 5.6±4.7 
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Antiproliferative activities of dictyostatin and its 16-normethyl analogue were determined 
in breast cancer cell lines.  The data is presented in Table 10.  These results suggest that in T47D 
cell lines, epothilone B and dictyostatin were the most potent of all agents studied.  The GI50 
value observed for dictyostatin (0.5 nM) was over 3-fold and 7-fold lower than that observed for 
paclitaxel and discodermolide, respectively.  In MDA-MB-231 cell line, dictyostatin showed 
activity comparable to that of paclitaxel.  Epothilone B turned out to be the most potent of all, 
although the fold-difference in GI50 values for all the test agents.  16-Normethyldictyostatin 
(YSS698-2) showed lower GI50 values compared to dictyostatin in the two cell lines. 
The SAR determined include: the macrolactone is important, but not a full requisite, for 
MT stabilization; the configuration of the hydroxyl at C19 has an important role; the 
configuration of the C6 and C14 methyls are important; anti positioning of the C6 and C7 
functional groups seems mandatory for MT stabilization; the natural E:Z geometry of the diene 
seems crucial; and the C16 methyl is not a factor in antiproliferative activity. 
 
Table 10. Antiproliferative activities of dictyostatin and its analogues 
Fifty percent growth inhibitory concentrations (GI50) of dictyostatin, discodermolide and 
paclitaxel against human breast cancer cell lines after 72 h in continuous presence of the agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
GI50 + S.D., nM 
(N=4) 
Cell line 
Compound T47D MDA-MB-231 
Discodermolide 3.6±5 9.8±8 
Paclitaxel 1.5±1 5.5±6 
Dictyostatin 0.5±0 5.3±6 
Epothilone B < 0.2 1.2±1 
YSS698-2 76±14 57±5 
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4.3.2. Multiparameter fluorescence analysis of cellular effects.  
A high-throughout and high-content screening (HTS and HCS) methodology was 
employed to study the cellular effects of dictyostatin and its analogues.  HCS defines the effects 
that test agents have on the temporal and spatial regulation of multiple cell functions and has 
been adopted by the pharmaceutical industry as a standard platform for compound screening 
(Giuliano et al. 2003a; Abraham et al. 2004).  The multiplexed HCS assay described here 
provides measurements of nuclear morphology, microtubule stability, and histone H3 
phosphorylation, which is a marker of cells at the G2/M cell cycle boundary, was previously 
validated and used to generate results for several reports (Wipf et al. 2000; Minguez et al. 2002; 
Giuliano et al. 2003b; Giuliano et al. 2004).  The procedure is described in Chapter 2.   
Briefly, HeLa cells were plated on collagen-coated 384-well microtiter plates, allowed to 
attach, and then treated for 24 h with DMSO or test agents.  Test agent concentrations began at 1 
µM and two-fold dilutions were made down the plate to levels below 1 nM. After the treatment 
period, the cells were fixed with formalin and their chromatin stained with Hoechst 33342.  Cells 
were permeabilized and treated with primary antibodies for α-tubulin and phosphohistone H3, 
and then with fluorophore-labeled secondary antibodies (tubulin - FITC; phosphohistone H3 - 
Cy3). The three fluorescent channels were then examined on an ArrayScanII® after scanning the 
plate using either target activation or compartmental analysis bioapplications which gives 
quantitative pixel distribution and density information in each channel on a per cell basis.  An 
Omega XF93 filter set at excitation/emission wavelengths of 350/461 nm (Hoechst), 494/519 nm 
(FITC), and 556/573 nm (Cy3) was used for scanning and 1000 cells/well were imaged at these 
wavelengths.  The BioApplications portion of the software was used to perform automated image 
acquisition, characterization and classification of the cell population according to response 
 77
relative to controls.  The concentration-response curves were plotted for four parameters that 
were normalized to control values using PRISM 4.0 software version 4.0 (GraphPad Software, 
Inc., San Diego, CA USA).  The parameters include objects per field (refers to cell density), 
average tubulin polymer mass (a measure of microtubule stabilization), percent condensed nuclei 
(a measure of DNA content), and percent histone H3 phosphorylation (a measure of mitosis).  
The data were quantified and compared based on minimum detectable effective concentrations 
(MDECs) of each test agent required for initiating a cellular response (Wipf et al. 2000; Minguez 
et al. 2002).  Concentration-response data, MDECs for each parameter, representative composite 
immunofluorescent images and cell cycle data are presented and described below.   
The fluorescence intensity values detected on a per cell basis for a given subpopulation of 
cells are presented as concentration of test agent versus response normalized to control in Figure 
9A-E.  Test agents included in the graphs are dictyostatin (squares), paclitaxel (triangles), 
discodermolide (inverted triangles), and 16-normethyldictyostatin (diamonds).  Objects per field 
data (Figure 9A) suggested that dictyostatin more potently inhibits the growth of HeLa cells than 
all the other test agents.  The intensity of microtubules stabilized in the presence of paclitaxel 
seemed to be greater than that observed with dictyostatin or discodermolide (Figure 9B).  The 
phosphohistone H3 (mitotic marker) and condensation of nuclear chromatin responses were 
comparable in the presence of all the test agents (Figure 9C-E).  However, dictyostatin yielded 
greater cellular response than other test agents.  The data were quantified and compared based on 
minimum detectable effective concentrations (MDECs) of each test agent required for initiating a 
cellular response (Wipf et al. 2000; Minguez et al. 2002).  MDECs were determined for each test 
agent for a given parameter by interpolating the linear portion of concentration-response curve, 
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shown in Figure 9A-D, to the upper limit of the error in the measurements made in control cells.  
The data is presented in Table 11.   
The results showed that HeLa cells were most sensitive to the microtubule stabilization 
and mitosis-blocking effects of dictyostatin, closely followed by paclitaxel.  Discodermolide was 
ca. 10-fold less potent.  MDECs for increases in tubulin polymer mass with dictyostatin, 
paclitaxel and discodermolide were 3.6 nM, 5 nM and 40 nM, respectively; for the 
phosphohistone H3 response, 5.6, 6.0 and 89 nM; and for nuclear condensation, 6.1, 7.9 and 56 
nM (Table 11).  Of interest was the data for YSS698-2, the C16-normethyl analogue of 
dictyostatin.  The MDECs for tubulin polymer, phosphohistone H3, and Hoechst intensities were 
22.4, 27 and 22.4 nM, respectively.  This data correlates with the relative antiproliferative 
activities observed in the 1A9 parental ovarian cancer cell lines in the presence of the above test 
agents.   
The concentrations of YSS698-2 required for initiating a response were lower than that  
observed for discodermolide.  This C16-normethyl analogue was over 2-fold and about 3- 
fold more potent than discodermolide in causing condensation of nuclear chromatin and in 
causing elevation of phosphohistone H3 levels, respectively, but was over 4-fold less potent than 
dictyostatin or paclitaxel.  Nevertheless, the fact that YSS698-2 is synthetically simpler than 
dictyostatin, plus showed potent and promising cellular effects, make this analogue a very 
interesting lead compound.  These results suggest that MDECs for tubulin polymer, 
phosphohistone, and Hoechst intensities were comparable for dictyostatin, discodermolide, 
paclitaxel, and 16-normethyl dictyostatin.  The open-chain methyl ether YSS629 and the C19-
epimer YSS652 were less active than YSS698-2 or the parent molecule in initiating the cellular 
responses.  YSS665-2, YSS675-1, and YSS675-2 were about 40- and 80-fold less active than the 
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Figure 9. Sigmoidal profiles of multiparameter immunofluorescence analyses.   
The effects are from 24 h treatment over a range of test agent concentrations.  Each point 
represents the mean + S.D. of fluorescence intensity values obtained from at least 1000 cells in 
three independent experiments.  Experiments were conducted on HeLa cells. 
Figure  9A. Objects per field data in the presence of microtubule stabilizers 
Test agents: dictyostatin (squares), paclitaxel (triangles), discodermolide (inverted triangles), and 
normethyldiscodermolide, YSS698-2 (diamonds). 
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Figure 9B. Tubulin polymer intensities in the presence of microtubule stabilizers 
Test agents: dictyostatin (squares), paclitaxel (triangles), discodermolide (inverted triangles), and 
normethyldiscodermolide, YSS698-2 (diamonds). 
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Figure 9C. Nuclear phosphohistone H3 levels in the presence of microtubule stabilizers 
Test agents: dictyostatin (squares), paclitaxel (triangles), discodermolide (inverted triangles), and 
normethyldiscodermolide, YSS698-2 (diamonds). 
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Figure 9D. Condensed nuclear chromatin values in the presence of microtubule stabilizers 
Figure 9E. Condensed nuclear chromatin values in the presence of microtubule stabilizers 
 
D, E. Condensed nuclear chromatin value normalized to control. Test agents: dictyostatin 
(squares), paclitaxel (triangles), discodermolide (inverted triangles, D), and 
normethyldiscodermolide, YSS698-2 (inverted triangles, E) on HeLa cells.  
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Table 11. Minimum detectable effective concentrations  
 
  
 
 
parent molecule.  The C2-E, C6-epi/C14-epi analogue (YSS665-2) and analogues with C19 
epimerized and with C6- and C14-epi configurations (YSS675-1) or C2-E, C6-and C14-epi 
configurations (YSS675-2) were all inactive, yielding flat concentration-response curves.  All the 
dictyostatin analogues, except for the 16-normethyldictyostatin, had higher MDECs when 
compared with either paclitaxel or dictyostatin. 
Representative immunofluorescent images depicting tubulin polymer (FITC: green), 
condensed nuclear chromatin (Hoechst 33342: blue), and phosphohistone H3 (Cy3: red) 
intensities are shown in Figure 10A-F.  The images depict the quantitative data described above.  
Dictyostatin induced microtubule bundling and formation of either round or elongated cells 
having needle-like microtubule morphology (FITC, green).  Most of the cells exhibited elevated 
phosphohistone H3 levels (Cy3, red) and had a rounded shape, indicating that most of the 
dictyostatin-treated cells were arrested in the G2/M phase of the cell cycle (Figure 10A).  The  
 
                             Minimum detectable effective concentration (nM) 
                              (mean±SD., N=4) 
Compound Average tubulin polymer intensity 
Phosphohistone H3 
response 
Hoechst 33342 
intensity 
Dictyostatin 3.6±0.6 5.6±0 6.1±1.5 
Paclitaxel 5±1.9 6.0±0.9 7.9±0 
Discodermolide 39.8 89.1 56.2 
YSS698-2 22.4±0 27±6.5 22.4±0 
YSS629 178.7±64 175.6±107 277.2±110 
YSS652 531.8±43 398±0 474±39 
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Figure 10. Representative composite immunofluorescent images 
A. Dictyostatin (8.5 nM). B. Paclitaxel (12.8 nM). C. Normethyldictyostatin (53 nM). D. 
YSS629 (250 nM). E. YSS652 (250 nM). F. 4% v/v DMSO.  Each image represents FITC: 
green), condensed nuclear chromatin (Hoechst 33342: blue), and phosphohistone H3 (Cy3: red) 
fluorescence intensities in the presence of test agents at concentrations corresponding to the EC50 
values obtained from the objects (i.e., cell nuclei) per field data for each compound.  The values 
in parenthesis next to each test agent represent the EC50 values observed for the test agent.  
Paclitaxel and vehicle (DMSO) are the positive and negative controls, respectively.   
A B C 
D E F 
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cells lost their original architecture, plus attained abnormal subcellular morphology as evidenced 
by nuclear condensation (Hoechst, blue staining) and membrane blebbing, characteristic of  
apoptosis.  Similar observations were made from discodermolide-treated cells (images not 
shown, see Balachandran et al. 1998).  The cells were quite distinct from control (DMSO-
treated) cells (Figure 10F).  All the above features were also seen upon treatment with paclitaxel 
(Figure 10B), with the major differences being that the cells had more rounded than elongated 
features and binucleated or multinucleated cells were more prominent.  The analogues YSS698-
2, YSS629 and YSS652 elicited similar features with cells showing more elongated microtubule 
morphology and cells were seen arrested at mitotic and cytokinesis phases (Figure 10C-E).  These 
effects were similar to dictyostatin treated cells, but the intensity to which the analogues exerted 
cellular response in each case was less than the parent molecule.   
Cell cycle distribution data was obtained in order to determine the qualitative and quantitative 
information about the effects of each compound on cell cycle distribution.  Cell cycle profiles for 
quantification of DNA content were obtained from total Hoechst staining intensity with respect 
to the cell density (valid cell count/field parameter was used) using S-Plus statistical software.  A 
normal bimodal (first node G1, second node G2/M) distribution pattern of cell cycle is shown in 
Figure 11.  Representations of various distribution patterns of cell cycle upon treatment with an 
agent that caused cell cycle arrest in a time-dependent manner are given in Figure 11.  One of 
these patterns was observed in the presence of microtubule perturbing agents.  Cell cycle 
analysis and comparison of the cell cycle distribution upon various treatments, shown in Figure 
12, were done primarily by examining the shifts in the bimodal distribution pattern with respect 
to control (DMSO-treated cell).  The cell cycle profiles were quantified by taking the ratio of 
distributions of a given sub population of cells in G2/M and G1 phases.   
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Figure 11. Representation of cell cycle profile during different phases of cell cycle 
 
This image also represents cell cycle distribution in the event of mitotic arrest at G2/M phase.   
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Figure 12. Cell cycle analysis of dictyostatin and synthetic dictyostatin analogues 
The starting concentrations for each test agent are represented in parenthesis and concentration 
of each test agent increased from left to right.  Boxes represent the range of concentrations 
within which the EC50s, calculated from objects per field data, are for each test agent.  Each test 
agent is studied either in triplicate or in quadruplicate (N=3 or N=4).  Paclitaxel and vehicle (4% 
v/v DMSO) are the positive and negative controls, respectively.   
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Numerical values for distribution of a given sub-population of cells were obtained by estimating 
the area under each distribution phase of the cell cycle, namely G1 and G2/M phases (data not 
shown).  Vehicle (DMSO)-treated cells had normal cell cycle distribution, meaning that the 
population histogram of cells was biased to the left due to distribution of the majority of cells in 
the G1 phase of the cell cycle (Figure 12).   Cells that received microtubule stabilizer treatment 
exhibited a shift in the distribution of cells to the right, indicating an increased number of cells in  
the G2/M phase of cell cycle.  This pattern was observed to be concentration- as well as test 
agent-dependent, with higher concentrations and more potent compounds showing a strong bias 
towards G2/M.  However, in the presence of inactive compounds, the cell cycle profiles were 
similar to the negative (DMSO only) controls.  Dictyostatin, like paclitaxel, caused extensive 
changes in the distribution profiles starting from 3-7 nM upward.  This data correlates with the 
EC50 values obtained from the objects (i.e., cell nuclei) per field data for each compound. 
These values were in the range of 7.8-15.6 nM for dictyostatin and paclitaxel.  Concentrations at 
and higher than 3 nM caused extensive shift towards the right of the cell cycle profiles, 
suggesting test agent-induced G2/M phase arrest of the cells.  C16-Normethyldictyostatin, 
YSS698-2, was the most potent of the dictyostatin analogues, giving G2/M arrest at around 30-
60 nM.  The open-chain analogue and the C19-epimer caused G2/M phase arrest in the range of 
250-500 nM.  All other analogues showed profiles similar to DMSO-treated cells.  Analysis of 
dictyostatin and dictyostatin analogues by this approach suggest that the configurations of the C6 
and C14 methyls are important, anti positioning of the C6 and C7 functional groups seems 
mandatory for cellular response, and the natural E:Z geometry of the diene seems crucial.  The 
configuration of the C19 and intact macrolactone are also important. 
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4.4. In vitro isolated protein-based experiments 
Previous studies have shown that dictyostatin, like discodermolide, promotes tubulin assembly 
(without MAPs but in the presence of GTP) at lower temperatures (4 oC), enhanced tubulin 
assembly much more potently than paclitaxel at 37 oC, and the microtubule polymer that is 
formed in the presence of discodermolide was known to be stable under cold conditions as well 
(Isbrucker et al. 2003).  It was therefore of interest to determine if dictyostatin and dictyostatin 
analogues nucleate microtubule assembly much more potently than paclitaxel by direct 
evaluation of tubulin polymerizing ability.  Also important was the evaluation of the effect of 
MAPs and GTP in modulating the interaction of these agents with tubulin.   
4.4.1. Tubulin polymerization activities of dictyostatin 
Sequential incubation studies.   
Tubulin assembly reactions under various conditions were performed to compare 10 µM 
dictyostatin, paclitaxel and discodermolide.  Polymer development was determined in 
temperature-controlled spectrophotometers by measuring turbidity at 350 nm.   The experimental 
procedure is described in Chapter 2.  Briefly, reaction mixtures consisting of tubulin  
(1 mg/ml), heat-treated MAPs (0.75 mg/ml, if present), GTP (100 µM, if present), and 0.1M 
Mes, pH 6.9, were prepared. Baselines were established after addition of all reaction 
components, except the compounds, to the cuvettes held at 0 oC.  Compounds predissolved in 
DMSO were added and each reaction mixture (0.25 mL final volume) was subjected to the 
sequential temperature change studies at the indicated temperatures.  The positive controls were 
either paclitaxel or GTP.  The negative control was 4% v/v DMSO.  The hypernucleating 
potencies of the test agents were evaluated by turbidimetry and the morphologies of resulting 
polymer were evaluated by electron microscopy by simultaneously preparing grids prepared 
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from aliquots withdrawn from each sample in the cuvette.  Polymerization reactions were carried 
out under four different conditions: tubulin with heat-treated MAPs and with GTP (complete 
system); tubulin with MAPs (no GTP); tubulin with GTP (no MAPs); and tubulin with no MAPs 
and with no GTP (tubulin-only system).  Tubulin polymerization activity of dictyostatin under 
various reaction conditions are described in the following paragraphs. 
Tubulin with MAPs and with GTP (complete system) 
Test agent-induced turbidity profiles in the complete system are shown in Figure 13A.  
Dictyostatin rapidly initiated polymer formation at 0 oC.  An increase in temperature to 10 oC 
resulted in a more extensive assembly reaction as shown by the rapid rise in turbidity readings. A 
further increase in temperature to 20 oC showed a slight increase in turbidity, and when 
temperature was increased from 20 oC to 30 oC the assembly reaction reached a plateau.  When 
the temperature was rapidly dropped from 30 oC back to 0 oC, the turbidity reading remained 
unchanged (i.e., the dictyostatin-induced tubulin polymer was completely cold-stable).  A similar 
turbidimetry profile was observed with discodermolide except that at the initial 0 oC incubation 
temperature assembly reaction was slightly more vigorous.  This pattern has been previously 
reported (ter Haar et al. 1996b).  The polymer was also completely cold-stable in the presence of 
discodermolide.  With paclitaxel, as also reported previously, polymer was not observed at 0 oC 
but was at 10 oC. The assembly was not as brisk as that induced by dictyostatin or 
discodermolide, however.  At 20 oC, the paclitaxel-induced assembly reaction was very vigorous 
and this continued at 30 oC, where polymer formation rapidly reached a plateau.  When the 
temperature was dropped to 0 oC, the paclitaxel-induced polymer was not completely cold-stable.  
At 30 oC, all three of the compounds caused similar turbidity readings and that at the initial 0 oC, 
dictysostatin, like discodermolide, showed hypernucleation of tubulin assembly.  Paclitaxel 
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lacked this hypernucleating ability at lower temperatures.  Although the vehicle (4% DMSO) 
allowed for GTP-induced polymer formation at 30 oC, the reaction was far less extensive than 
that seen with the test agents.  The percent microtubule stabilization values relative to that of 
paclitaxel at 30 oC were calculated for dictyostatin and discodermolide, after subtraction of the 
control, GTP-induced values (Table 12).  
Tubulin with MAPs (no GTP) 
Polymerization reactions carried out with tubulin in the presence of MAPs showed that 
dictyostatin induced polymer formation at 0 oC, although the extent of assembly was slightly 
lower than that seen in the complete system (Figure 13B).  Rapid assembly occurred when the 
temperature was increased stepwise from 0 oC to 10 oC to 20 oC to 30 oC.  The assembly induced 
at 10 oC by dictyostatin and discodermolide was nearly identical.  At 20 o and 30 oC, the reaction 
was more vigorous with dictyostatin than with discodermolide, and a decrease in the temperature 
from 30 o to 0 oC did not destabilize the polymer induced by dictyostatin nor that induced by 
discodermolide.  In reactions containing paclitaxel, assembly was induced only when the mixture 
reached 20 oC, after which polymer formation increased rapidly but the reaction was 
considerably less vigorous than that observed in the complete system and also as compared with 
dictyostatin in this system.  The polymer formed by paclitaxel was also less cold-stable.  DMSO 
caused some assembly, but only at 30 oC.  The percent microtubule stabilization values for this 
reaction condition are also presented in Table 12. 
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Figure 13. Turbidity profiles of tubulin polymerization assays  
Reaction mixtures contained 1.0 mg/mL (10 μM) tubulin, 0.1 M Mes (pH 6.9), 4% (v/v) DMSO, 
10 μM test agent, and further additions as indicated. A, Complete system: 0.75 mg/mL MAPs, 
100 μM GTP. B, MAPs-only system: 0.75 mg/mL MAPs. C, GTP-only system: 100 μM GTP. 
D, Tubulin-only system: no further additions. In each panel: 1, dictyostatin; 2, discodermolide; 
P, paclitaxel; 0, No test agent.  Reaction temperatures were as indicated, with the temperature set 
on the temperature controller at the time indicated by the vertical dashed line to the left of the 
temperature.  Test agents were added to the reaction mixtures at zero time at 0 °C.  Temperature 
in the cuvettes rose at about 0.5 °C/s and fell at about 0.1-0.15 °C/s. 
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Tubulin with GTP (no MAPs) 
Polymer formation occurred more vigorously when the reaction was performed in the 
presence of tubulin plus GTP than what was seen in the previous two systems (Figure 13C).  
Dictyostatin, like discodermolide, caused hypernucleation of tubulin assembly at 0 oC.  Stepwise 
increases in temperature from 0 oC to 10 oC to 20 oC, led to greater turbidity changes with time 
because of the more extensive assembly reactions.  The turbidity changes reached a plateau at 30 
oC.  Polymer formed in the presence of dictyostatin and discodermolide was again cold-stable. At 
all incubation temperatures, the assembly reactions were more vigorous in the presence of 
dictyostatin than in the presence of discodermolide.  Paclitaxel did not induce assembly until the 
reaction mixture reached 10 oC. Sequential increases in temperature thereafter caused a gradual 
increase in turbidity.  The paclitaxel-induced assembly was less vigorous than that observed with 
dictyostatin, and the polymer formed in the presence of paclitaxel was not cold-stable.  DMSO 
(4% v/v) did not cause detectable assembly.  Percent microtubule stabilization values for this 
condition are given in Table 12. 
No MAPs, no GTP (tubulin-only system) 
In the tubulin-only system, none of the test agents initiated polymerization at 0 oC (Figure 
13D). Turbidity increases were observed for dictyostatin and discodermolide beginning at 10 oC.  
Polymer formation induced by these agents was rapid and vigorous when the temperature was 
raised from 10 oC to 20 oC and to 30 oC.  As in the other systems, the polymer induced by 
dictyostatin and by discodermolide was cold-stable. During the time period analyzed, the 
turbidity developed in the presence of dictyostatin was greater than that in the presence of 
discodermolide.  With paclitaxel, assembly reactions were slower and polymer formation was 
observed only from 20 oC onward, and an increase in the reaction temperature to 30 oC caused 
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only a slight increase in turbidity.  The paclitaxel-induced polymer formed under these 
conditions was less cold-labile than the polymer formed by paclitaxel under the three previously 
discussed reaction conditions.  Little or no polymer formed in the presence of DMSO only.  
Percent microtubule stabilization values are given in Table 12. 
Temperature jump studies 
The sequential incubation studies performed in the complete and tubulin-only reaction 
conditions described above revealed turbidity profiles that were quite different. Temperature-
jump studies (incubation at 0 oC followed by a rapid jump in temperature to 30 oC) were 
therefore performed to detect any differences in the test agent activities. Polymer morphologies 
were also examined.  Aliquots, withdrawn from each sample at the initial 0 oC, after the 
temperature reached 30 oC and when the temperature was returned to 0 oC, were placed on grids, 
stained with uranyl acetate and polymer morphology was examined by electron microscopy.   
Complete system.  
Dictyostatin, like discodermolide, caused extensive tubulin assembly at 0 oC (Figure 
14A) in the presence of MAPs and GTP.  However, discodermolide caused slightly greater  
increases in turbidity readings than did dictyostatin.  At 30 oC, assembly reactions continued and 
then reached a plateau.  The polymers induced by both dictyostatin and discodermolide were 
cold-stable.  Paclitaxel initiated tubulin assembly at 0 oC to a slight extent. When the temperature  
was increased to 30 oC a very vigorous assembly reaction ensued that rapidly reached a plateau.  
The ultimate turbidity values caused by paclitaxel at 30 oC were comparable to those observed 
with dictyostatin and discodermolide. The paclitaxel-induced polymer was less cold-stable, 
however.  The DMSO control caused some polymer formation at 30 oC, but the solvent-induced 
polymer was cold-labile.  
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Table 12. Percent microtubule stabilization values in the presence of test agents 
Percent microtubule stabilization values in all the four reaction conditions studied are presented 
below. Each reaction mixture consisted of 1 mg/mL tubulin, 0.1M MeS (pH 6.9), 4% DMSO, 10 
μM compound, and/or MAPs, and/or GTP.  Percent microtubule stabilization is a measure of the 
polymer-inducing property of a compound. 
             
Reaction Condition/  % MT Stabilization  % MT Stabilization 
Compound   with respect to   with respect to 
(Test agent)    Paclitaxel   Discodermolide   
A. MAPs+GTP system (complete system) 
Dictyostatin    83    91 
Discodermolide   92    100 
Paclitaxel    100    >100 (109) 
B. MAPs only system 
Dictyostatin    >100 (160)   >100 (120) 
Discodermolide   >100 (133)   100 
Paclitaxel    100    75 
C. GTP only system  
Dictyostatin    >100 (226)   97 
Discodermolide   >100 (232)   100 
Paclitaxel    100    43 
D. No MAPs + No GTP (tubulin only system) 
Dictyostatin    > 100 (800)   >100 (155) 
Discodermolide   >100 (569)   100 
Paclitaxel    100    18    
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Figure 14. Turbidity profiles of tubulin polymerization assays  
Each reaction mixture contained 1.0 mg/mL (10 μM) tubulin, 0.1 M Mes (pH 6.9), 4% DMSO, 
10 μM test agent and further additions as indicated. A, Complete system: 0.75 mg/mL MAPs, 
100 μM GTP. B, Tubulin-only system: no further additions. In each panel: 1, dictyostatin; 2, 
discodermolide; P, paclitaxel; 0, No test agent.  Reaction temperatures were as indicated by the 
vertical dashed line to the left of the temperature.  See legend of Figure 7 for further details.  For 
panel A, test agents were added to reactions at zero time at 0 oC.  For panel B, test agents were 
added to reaction mixtures at 0 oC, and the temperature controller was set at 30 oC at zero time. 
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Tubulin-only system.   
With tubulin only, none of the compounds induced assembly at 0 oC.  When the 
temperature was increased to 30 oC, dictyostatin and discodermolide induced rapid and brisk 
assembly (Figure 14B).  Turbidity values observed with dictyostatin were greater than those 
observed with discodermolide.  Paclitaxel caused a slight but considerably lower induction of 
polymer formation at 30 oC. Polymer induced by dictyostatin and by discodermolide was stable 
at 0 oC.  Paclitaxel-induced polymer was less cold-stable, but more so than paclitaxel-induced 
polymer formed in the complete system.  DMSO caused very little, if any, polymer formation. 
4.4.2. Tubulin polymerization activities of dictyostatin analogues 
Tubulin polymerization activity was determined under complete reaction conditions 
consisting of tubulin (1 mg/mL), MAPs (0.75 mg/ml), GTP (100 µM), and dictyostatin 
analogues at either 10 or 40 µM.  Turbidity profiles show that the open-chain and the C19-epi 
analogues, YSS629 and YSS652, although less active than the parent molecule, induced tubulin 
polymerization even at lower temperatures (<30 oC).  Under the reaction condition studied, at 10 
μM, YSS629 induced tubulin assembly from 10 oC onward and the reaction was vigorous at 20 
oC and 30 oC.  However, the microtubule polymer formed was not cold-stable (Figure 15B).  
YSS652 also induced polymer formation at 20 oC onward, but the polymer mass as read from 
turbidity readings was lower than that observed in the presence of YSS629 (Figure 15A).  The 
assembly reaction was less vigorous at 30 oC and the polymer was not cold-stable.   YSS133 
(previous chapter) induced tubulin assembly from 20 oC onward, the reaction was rapid at 30 oC 
and the polymer formed was also cold-stable (Figure 15C).  Tubulin polymerization assays done 
with the other analogues did not give promising results.  YSS479, YSS665, YSS675-1 and  
 YSS675-2 when studied at 10 µM, were very weak in inducing tubulin assembly even at 30 oC 
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Figure 15. Turbidity profiles in the presence of dictyostatin analogues  
Reaction mixtures contained 1.0 mg/mL (10 μM) tubulin, 0.1 M Mes (pH 6.9), 4% (v/v) DMSO, 
10 μM test agent, 0.75 mg/mL MAPs, and 100 μM GTP. Reaction temperatures were as 
indicated, with the temperature set on the temperature controller at the time indicated by the 
vertical dashed line to the left of the temperature.  Test agents were added to the reaction 
mixtures at zero time at 0 °C.   
Panel A:  1, dictyostatin; 2, paclitaxel; 3, YSS652; 4, No test agent.   
Panel B:  1, dictyostatin; 2, discodermolide; 3, paclitaxel; 4, YSS629; 5, No test agent.   
Panel C:  1, dictyostatin; 2, discodermolide; 3, YSS133; 4, No test agent.   
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Figure 16. Turbidity profiles for dictyostatin analogues 
Reaction mixtures contained 1.0 mg/mL (10 μM) tubulin, 0.1 M Mes (pH 6.9), 4% (v/v) DMSO, 
10 μM or 40 μM test agent, 0.75 mg/mL MAPs, and 100 μM GTP. Reaction temperatures were 
as indicated, with the temperature set on the temperature controller at the time indicated by the 
vertical dashed line to the left of the temperature.  Test agents were added to the reaction 
mixtures at zero time at 0 °C. A:  10 μM dictyostatin analogues. YSS675-2 (brown); YSS675-1 
(rust/brick red); YSS665 (blue); no test agent (gray).  B:  40 μM dictyostatin analogues.  
YSS675-2 (brown); YSS675-1 (rust/brick red); YSS665 (blue); no test agent (gray).  
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Figure 17. Turbidity profiles of tubulin polymerization assays for 16-normethyldictyostatin 
Each reaction mixture contained 1.0 mg/mL (10 μM) tubulin, 0.75 M MSG (pH 6.6), 4% 
DMSO, test agent as indicated. 6, No test agent; 1, 10 μM discodermolide; 5, 5 μM 16-
normethyldictyostatin; 4, 10 μM 16-normethyldictyostatin; 3, 20 μM 16-normethyldictyostatin; 
2, 40 μM 16-normethyldictyostatin.  Test agents were added to reaction mixtures at 0 oC (set for 
1 min), and the temperature controller was set at 30 oC starting from 1 min until 20 minutes after 
which the temperature was dropped back to 0 oC.   
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compounds at 10 µM concentration at 30 oC, the overall assembly reactions were weak and 
polymer formed was not cold-stable (Figure 16B).  Figure 17 represents the tubulin 
polymerization activity of the normethyl analogue, YSS698-2, showing it to be an interesting 
compound.  It potently induced tubulin polymerization at lower concentrations (5 µM) as well as 
lower temperature and showed a concentration-dependent increase in polymer formation.   
However, MAPs were replaced by 0.75 M MSG in the experiment with this analogue.  This data 
suggests that YSS698-2 might hypernucleate tubulin assembly like the parent molecule.   
4.4.3. Electron microscopy studies 
Electron microscopic evaluation of test agent-induced polymer morphology.  
The immunofluorescence studies that demonstrated mitotic arrest (vide supra), are 
consistent with the enhanced turbidity development observed with dictyostatin representing 
drug-induced MT assembly.  Nevertheless, it was important to demonstrate this by electron 
microscopic observation.  Tubulin polymer formed in the presence of small molecule test agents 
and detected by turbidimetry can appear in a variety of forms. "Normal" polymer is 
microtubules, but near-normal (e.g., sheets) and abnormal (e.g., spirals, crystals, amorphous 
solid) polymers have been observed. Previous experiences in the Day laboratory with 
discodermolide and paclitaxel showed that these agents induce polymer largely in the form of 
microtubules, so it was of interest to evaluate the differences, if any, of the polymer 
morphologies caused by dictyostatin in complete and tubulin-only systems. 
Complete system.  
Electron microscopic analysis of polymer induced by dictyostatin and discodermolide at 
0 oC showed it to be largely in the form of microtubules.  In the presence of dictyostatin, 
microtubules were shorter in length than those observed from the discodermolide sample (Figure 
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18C versus 18D, Table 13).  As expected, since the hypernucleating ability of paclitaxel at this 
temperature is low, very few microtubules were seen in any given electron microscopic field 
(Figure 18B).  At 30 oC, all three of the compounds caused extensive microtubule polymer 
formation as seen in the EM images (Figure 18F-H).  However, the lengths of the polymer 
measured, in each case, was an approximate estimation since full length polymer couldn’t be 
measured accurately.  This is because at 30 oC, abundant polymer formation occurred unlike that 
observed at 0 oC.  Polymer formed in the presence of either dictyostatin or discodermolide was 
mostly in the form of either short microtubules or ribbons (Figure 18G-H).  The majority of the 
microtubules formed by paclitaxel at this temperature had curved ends, and the polymer showed 
some morphology in the form of ribbons (Figure 18F). Many of the paclitaxel-induced 
microtubules also showed characteristic peeling of apparent protofilaments at their ends.  The 
polymer morphology observed at 30 oC in the presence of dictyostatin or discodermolide was 
retained when the temperature was decreased to 0 oC (data not shown).  In agreement with the 
turbidity profile, EM analysis of the polymer in the paclitaxel sample after it was returned to 0 oC 
showed a large decrease in the microtubule mass as compared to the sample taken at 30 oC (data 
not shown).  Under both temperature conditions, 0 o and 30 oC, no polymer formed in the 
absence of test agent (Figure 18A & E).   
Tubulin-only reaction condition.  
Dictyostatin and discodermolide at 30 oC both caused formation of tubulin polymer, 
although not as extensive as that observed with the complete system.  Interestingly, mostly 
ribbon-like structures along with microtubules were noted (Figure 18K-L).  Discodermolide- and 
dictyostatin-induced polymer showed ring-like morphology (abnormal polymer) that was not  
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Figure 18. Electron microscopy images from complete and tubulin-only systems  
Images A-D: Electron microscopic observation of the polymer formed in the presence of 
microtubule stabilizers under complete reaction conditions at 0 oC.  A: 4% DMSO ; B: 10 µM 
Paclitaxel; C: 10 µuM Dictyostatin; D: 10 µM Discodermolide. 
Images E-H: Electron microscopic observation of the polymer formed in the presence of 
microtubule stabilizers under complete reaction conditions at 30 oC.   
E: 4% DMSO; F: 10 µM Paclitaxel; G: 10 µM Dictyostatin; H: 10 µM Discodermolide. 
Images I-L: Electron microscopic observation of the polymer formed in the presence of 
microtubule stabilizers under tubulin-only reaction conditions at 30 oC. I: 4% DMSO ; J: 10 µM 
Paclitaxel; K: 10 µM Dictyostatin; L: 10 µM Discodermolide. 
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Table 13. Microtubule polymer lengths in the presence of microtubule stabilizers  
Each reaction mixture consisted of 1 mg/mL tubulin, 0.1M MeS (pH 6.9), 4% DMSO, 10 μM 
compound, and/or 0.75 mg/mL MAPs, and/or 100 µM GTP. 
             
Reaction condition/   Microtubule length (µm) 
Compound     
 (Test agent)     0 oC    30 oC    
A. MAPs+GTP system (complete system) 
Dictyostatin    0.34 ± 0.02(70)*  1.1 ± 0.2(87) 
Discodermolide   0.42 ± 0.07(78)  0.9 ± 0.1(51)  
Paclitaxel    -    0.8 ± 0.02(3)  
B. No MAPs + No GTP (tubulin-only system) 
Dictyostatin    -    2.0 ± 0.8(4)    
Discodermolide   -    1.2 ± 0.7(3)  
Paclitaxel    -    3.4 ± 0.9(4)   
             
* number of microtubules measured is indicated in parenthesis. 
 
 
seen with paclitaxel-induced polymer.  These subtle differences could be accounted for MAPs 
and/or GTP in the reaction system, since in the complete system ring-like structures were not  
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observed.  Paclitaxel at 30 oC induced formation of ribbons mostly and also some microtubules, 
though not as extensive as that seen in the complete system (Figure 18J).  When the temperature 
was dropped to 0 oC, paclitaxel-induced polymer lost this morphology (since the paclitaxel-
induced polymer is more cold-labile).  The polymer induced by dictyostatin and discodermolide 
was, however, cold stable.  DMSO treated protein did not show polymer formation under these 
conditions (Figure 18I).  
To summarize the current studies, for any given reaction condition, there was little 
overall difference in morphology of the polymer formed with any of the test agents in that 
microtubules and ribbon polymers were seen under all conditions.  While relative proportions 
seemed to vary, this was difficult to quantitate.  Under both reaction conditions chosen, no 
polymer formed in the absence of test agent.  Figure 19A shows the short MTs and ribbons, 
observed in the complete system after 1 h at 0 ° and 30 oC in the presence of dictyostatin.  Figure 
19B shows the polymer, mostly in the form of short ribbons, observed in the tubulin-only system 
after 1 h at 30 °C in the presence of dictyostatin. 
4.4.4. Relative polymer-inducing potencies of dictyostatin and discodermolide 
The turbidimetry studies presented in Figures 13 and 14 indicated dictyostatin and 
discodermolide to have similar potencies as inducers of tubulin assembly.  A more quantitative 
measurement of their relative activities were desired; to achieve this, two types of experiments 
were performed. 1) critical concentration 2) centrifugation or pelleting assay. 
Critical concentration experiments.  
The hypernucleating ability of a microtubule-stabilizing agent can be quantitatively 
evaluated/assessed by determining the critical concentration (Cc) of tubulin required for 
initiation of polymer formation in the presence of the agent (Grover et al. 1995).  The Cc of a  
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Figure 19. Electron micrographs of dictyostatin-induced polymer  
Microtubules formed in the complete system (A) and in the tubulin-only system (B).   
The reaction mixtures were followed spectrophotometrically and prepared as described in Figure 
5, with aliquots removed from the cuvettes either at the end of the 0 oC incubation (A) or the end 
of the 30 oC incubation (B). 
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Figure 20. Tubulin critical concentration determinations  
 
A, Complete system. B, Tubulin-only system. In both panels: no test agent, diamonds; 
dictyostatin, circles; discodermolide, triangles. The critical concentration was the intersection of 
the interpolated control and test agent regression lines. The abscissa shows the concentrations of 
tubulin (mg/mL), while the ordinate values show the polymerized tubulin (mg/mL) present in the 
reaction mixture. Each data point was determined in triplicate. The concentration of dictyostatin 
or discodermolide was 10 µM.  Critical concentration values in the complete system were 0.06 
µM (0.006 mg/mL) for dictyostatin and 1.0 µM (0.1 mg/mL) for discodermolide. In the tubulin-
only system, the critical tubulin concentrations were 2.5 µM (0.25 mg/mL) for dictyostatin and 
2.1 µM (0.21 mg/mL) for discodermolide. 
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test agent is a function of both its nucleation properties and its binding affinity to the polymer.  
Experiments to determine Cc were performed under complete and tubulin-only reaction 
conditions to help explain if there is a difference in the nucleation reactions between dictyostatin 
and discodermolide.  The details of the experiment are described in Chapter 2.  Reaction 
mixtures contained tubulin (1 mg/mL), MAPs and GTP (0.75 mg/mL and 100 μM,  
respectively), if required, in 0.1M Mes, pH 6.9.  Reaction mixtures with test agent or 4% v/v 
DMSO were incubated at 37 oC for 30 min following which the samples were centrifuged at 
14,000 rpm for 15 min at RT.  The supernatants were collected and assayed by the Lowry 
method for protein quantitation.  The results showed that in the complete system the tubulin Cc 
was 0.6 µM for dictyostatin and 1.0 µM for discodermolide (Figure 20A).  In the tubulin-only 
system, the critical concentrations increased to 2.5 µM for dictyostatin and to 2.1 µM for 
discodermolide (Figure 20B).  These studies further demonstrated that the nucleation properties 
and polymer-inducing abilities of dictyostatin were slightly greater than those of discodermolide 
in the complete system, and in the tubulin-only reaction conditions these properties were nearly 
identical for the two compounds. In an earlier study (Kowalski et al. 1997) utilizing the tubulin-
only system, Cc values of 1.5 and 5.9 μM were obtained for discodermolide and paclitaxel, 
respectively.  This data suggests that MAPs and/or GTP play a very important role in the 
nucleation step during the polymerization reaction.  Probably, these regulatory elements stabilize 
the nucleation centers as well as the microtubules in the presence of paclitaxel.  The Gibb’s free 
energy calculations were done from critical concentration values for dictyostatin and 
discodermolide in order to determine the energetics of the nucleation process.  The data is 
presented in Table 14.  This data shows the difference in free energetics between the complete 
system and tubulin-only system.  MAPs and GTP lower the energetics required for nucleation 
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and promote microtubule stabilization.  The Gibb’s free energy values also underline the fact that 
MAPs and GTP play a crucial role in the energetics of binding in the presence of dictyostatin or 
discodermolide.  In the complete system, dictyostatin had lower Gibb’s free energy for 
hypernucleation (-14.5 Kcal/mol) than discodermolide (-14.2 Kcal/mol).  The free energies for 
hypernucleation were quite low for complete system than for tubulin-only system.  This is true 
for dictyostatin as well as discodermolide. 
Pelleting Assay.   
Centrifugation experiments were designed to quantitatively compare the tubulin 
polymerizing effectiveness of dictyostatin against those of discodermolide and paclitaxel. The  
 
Table 14. Summary of critical concentration and Gibb’s free energy calculations 
Critical concentrations for dictyostatin and discodermolide for complete and tubulin-only 
systems are tabulated below.  Gibb’s free energy calculations were done for 37 oC reaction 
condition.  
 
 
assay was performed under the reaction condition that employed 0.2 M MSG, 10 µM nucleotide-
free tubulin, 5% v/v DMSO and varying drug concentrations.  The protein concentrations in 
supernatants from each centrifugation run were determined by the Lowry method. Data is 
System/Compound Critical concentration (μM) 
(N=3) 
Gibb’s free energy 
(Kcal/mol) 
Complete system 
Dictyostatin 0.6 -14.5 
Discodermolide 1.0 -14.2 
Tubulin-only system 
Dictyostatin 2.5 -13.7 
Discodermolide 2.1 -13.6 
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presented in Table 15.  The quantitative measure chosen to compare the polymer-inducing 
properties of these compounds was the EC50 value, the concentration of test agent required to 
polymerize 50% of tubulin with respect to the control incubation. This assay exploits the 
interaction of MSG and tubulin in assembly reactions.  In the absence of GTP, tubulin assembly 
will not occur in MSG unless a taxoid-mimetic agent is present.  In the case of paclitaxel, 
detailed studies show that the lower the MSG concentration the higher the EC50 value.  Thus, the 
assay can be modulated to study taxoid site drugs both less active and more active than 
paclitaxel.  In the studies summarized in Table 15, a low concentration of MSG (0.2 M) was used 
because of the potent activity of dictyostatin and discodermolide.  Dictyostatin seemed slightly 
more active than discodermolide.  The EC50 for dictyostatin (3.1 µM) was slightly lower than 
that observed for discodermolide (3.6 µM).  Paclitaxel was less active and yielded a 7-fold 
higher EC50 (25 µM) than that observed for dictyostatin.  Along with dictyostatin, its synthetic 
analogues were also evaluated for their ability to promote tubulin polymerization.  The 
centrifugation assay for the analogues was performed under three different reaction conditions.  
Reaction condition 1 was similar to the one described for analyzing dictyostatin.  The activity of 
percent tubulin polymerized was assessed under other two reaction conditions, 2 and 3, to see if 
there would be any enhancement in the tubulin polymerization activity of the analogues.  The 
MSG and GTP percent in reaction conditions 2 and 3 are varied and are described in Table 15.  
Quantitative analysis of the data showed that all the analogues had EC50 values greater than 50 
µM under reaction condition 1 (Table 15).  These values were higher than that observed for 
dictyostatin.  The EC50 value observed for dictyostatin under these conditions was 3.1±0.2 µM.   
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Table 15. Tubulin polymerization abilities of dictyostatin analogues    
 
 aReaction condition 1 bReaction 
condition 2 
cReaction 
condition 3 
Compound EC50 (μM) ± 
S.D  (N) 
% of Control 
at 50 μM 
% of Control 
at 10 μM 
% of Control 
at 10 μM 
Dictyostatin 3.1 ± 0.2  (3) N/D 38 16 
Discodermolide 3.6 ± 0.4  (3) N/D 37 14 
Taxol  25 ±    3  (3)  N/D 42 20 
YSS-629 > 50 (2) 71 ± 7 51 34 
YSS-652 > 50 (2) 70 ± 2 71 67 
YSS-133 > 50 (2) 95 ± 4 66 53 
YSS-665 > 50 (2) 99 ± 1 96 100 
YSS-675-1 > 50 (2) 95 ± 1 100 97 
YSS-675-2 > 50 (2) 95 ± 4 94 100 
   
a:reaction condition 1 is 0.2M MSG, 10 µM tubulin, and 5% DMSO; b:reaction condition 2 is 
0.8M MSG, 400 µM GTP, 10 µM tubulin, and 5% DMSO; c:reaction condition 3 is 0.6M MSG, 
200 µM GTP, 10 µM tubulin, and 5% DMSO.  
 
  
 
 Under the other two reaction conditions there was very little improvement in the 
polymerization ability of the analogues.  The percent tubulin polymerized with 10 µM test agent 
with respect to control is reported for these two conditions as well.  From this data, it appears 
thatYSS629, YSS133 and YSS652 had moderate activity with percent unpolymerized values 
(with respect to control) of 51, 66 and 71 respectively, under reaction condition 2.  In the 
presence of dictyostatin, the percent tubulin unpolymerized with respect to control was about 40.  
The percent unpolymerized values were 34, 53, and 67, for compounds YSS629, YSS133 and 
YSS652, respectively, studied at 10 µM with reaction condition 3.  Dictyostatin had a percent 
unpolymerized value of 16 under these reaction conditions. This data also shows that YSS479, 
YSS665, YSS675-1 and YSS675-2 had weak tubulin polymerizing ability.  The EC50 value for 
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the normethyl analogue, YSS698-2, was estimated from the turbidity readings (Figure 17) and 
the value was around 14±7. 
4.4.5. Paclitaxel-site binding experiments  
Binding experiments with dictyostatin 
Previous work shows that discodermolide strongly inhibited the binding of radiolabeled 
paclitaxel to tubulin polymer (ter Haar et al. 1996b), while paclitaxel has little ability to inhibit 
the binding of radiolabeled discodermolide to polymer (Hung et al. 1996b).  Epothilone B also 
binds the taxoid site and potently inhibits paclitaxel from binding to tubulin polymer (Kowalski 
et al. 1997).  Moreover, studies with radiolabeled paclitaxel at 37 °C have indicated the 
following order of affinity of taxoidmimetic drugs for the taxoid site: paclitaxel/epothilone A < 
docetaxel/epothilone B < discodermolide (Hamel et al. 1999).  More precise measurements of Ka 
values for the taxoids and epothilones, obtained by measuring inhibition of binding of a 
fluorescent taxoid to MTs (Buey et al. 2004), show the affinity of epothilone B to be 
significantly greater than the affinities of paclitaxel, docetaxel, and epothilone A (the Ka values 
at 37 °C for the four compounds were reported to be, respectively, 61, 1.1, 3.1, and  
2.9 x 107 M-1).  Since the structure of dictyostatin so closely resembles that of discodermolide, 
we anticipated that it would inhibit [3H]paclitaxel, [3H]discodermolide and [14C]epothilone B 
from binding to tubulin polymer. 
Dictyostatin, paclitaxel, discodermolide, epothilone B and docetaxel were examined for 
their abilities at 4 µM to displace these radioligands at 2 µM from polymer induced by ddGTP 
from 2 µM tubulin.  The percent inhibition values for dictyostatin and the other compounds are 
shown in Table 16.  Dictyostatin potently displaced [3H]paclitaxel bound to tubulin polymer 
(75% inhibition). Discodermolide yielded a similar value (76% inhibition). When 
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[3H]discodermolide was used as the tracer, dictyostatin displaced less than 50% of the 
radioligand.  None of the test agents studied were as potent as dictyostatin at displacing bound 
[3H]discodermolide: epothilone B, paclitaxel and docetaxel only weakly displaced 
[3H]discodermolide, yielding inhibition values of ca. 10% (Table 16).  The data also suggests 
that discodermolide has a stronger affinity for tubulin polymer than does paclitaxel and 
epothilone B, and that dictyostatin has a similar affinity.  The value for dictyostatin found with 
polymer bound [14C]epothilone B (88% inhibition) was again essentially identical to that 
obtained for discodermolide (90%).   
Epothilone A and docetaxel had negligible inhibitory effects on the binding of 
[3H]discodermolide, intermediate effects on the binding of [14C]epothilone B, and their greatest 
inhibitory effects on the binding of [3H]paclitaxel to tubulin polymer.  However and for 
unknown reasons, the maximum inhibitory effect observed with the tritiated ligands (paclitaxel 
and discodermolide) is 70-80%, while total inhibition of [14C]epothilone B binding could be 
observed.  This provided further evidence that the activity of dictyostatin is comparable to that of 
discodermolide in this assay and that the two compounds have the same or very similar binding 
sites on tubulin polymer. Displacement of 2 µM [3H]discodermolide by 20 µM dictyostatin,  
paclitaxel and epothilone was also examined.  Dictyostatin was by far the most effective of the 
three in displacing discodermolide. The effects of lower concentrations of dictyostatin and 
discodermolide on paclitaxel and epothilone B binding were also examined, and again little 
difference was observed between the two compounds.  These competition experiments provided 
conclusive evidence that dictyostatin binds the taxoid site on tubulin polymer, and that it is the 
most effective of the test agents in displacing discodermolide from this site. 
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Table 16. Percent radioligand inhibition by test agents.   
Percent inhibition values are expressed as mean+S.D (N). 
 
Inhibitor 
%  Inhibition of 
[3H]discodermolide 
binding 
%  Inhibition of 
[14C]epothilone B 
binding 
%  Inhibition of 
[3H]paclitaxel binding
 
4 μM discodermolide nda 90 ± 1 (3) 76 ± 6 (4) 
4 μM dictyostatin 40 ± 3 (3) 88 ± 1 (3) 75 ± 5 (3) 
20 μM dictyostatin 70 ± 1 (2) nd nd 
4 μM epothilone B 14 ± 3 (3) nd 71 ± 5 (4) 
20 μM epothilone B 31 ± 6 (2) nd nd 
4 μM paclitaxel 6 ± 5 (3)  26 ± 1 (3)  nd 
20 μM paclitaxel 3 ± 4 (2) nd nd 
4 μM docetaxel 8 ± 6 (3) 36 ± 1 (3)  63 ± 8 (4) 
4 μM epothilone A 6 ± 6 (3) 25 ± 3 (3)  53 ± 4 (4) 
a: not determined 
 
 
 Binding experiments for dictyostatin analogues 
Since dictyostatin displaced paclitaxel from binding to tubulin polymer, it was anticipated 
that analogues of dictyostatin would also possess similar property.  Dictyostatin analogues were 
examined for their abilities to displace [3H]paclitaxel from binding to microtubule polymer 
induced by ddGTP and 2 µM tubulin.  The percent inhibition values for dictyostatin analogues 
are shown in Table 17.  All the analogues had lower [3H]paclitaxel inhibition values when 
compared to dictyostatin.  Two of the six analogues studied for this activity showed inhibition 
values >40%.  All other analogues turned out to be weak inhibitors.  The data for the open-chain 
analogue YSS629 correlates with tubulin polymerization data which also suggested this analogue 
to be moderately active.  The C19 epimer, YSS652, was less active.  The interesting analogue is 
the C16-normethyl analogue YSS698-2.  Although the normethyl analogue of dictyostatin 
showed potent tubulin polymerizing activity (Figure 17), its ability to inhibit [3H]paclitaxel from 
binding to tubulin polymer was less than 50%.  In antiproliferative assays this compound also 
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showed differential sensitivities towards two mutated β-tubulin cell lines, 1A9PTX22 
(Ala364→Thr) and 1A9PTX10 (Phe270→Val). While the former cell line was sensitive to 
YSS698-2 the latter showed over a 1000-fold resistance to the normethyl analogue.  This might 
be an indication that the C16 methyl group is in orientation towards Phe270 in the paclitaxel-
binding site on β-tubulin.  
 
 
Table 17. Percent inhibition by test agents of [3H]paclitaxel binding to tubulin polymer 
 
 
 
 
 
 
 
 
 
 
 
 
4.5. Discussion 
Cellular assays showed dictyostatin to be a potent antiproliferative agent, a property unaffected 
by mutations in the taxoid binding site that confer resistance to paclitaxel. Multiparameter cell-
based fluorescence analyses also provided good evidence that dictyostatin caused massive 
polymerization of cellular tubulin, which correlated well with its in vitro effects on isolated 
Inhibitor Added % Paclitaxel 
Inhibition  
(Mean+S.D) (N) 
 
Discodermolide 80 ± 2 (4) 
Dictyostatin 78 ±2 (6) 
YSS629 42+1 (6) 
YSS652 7±2 (6) 
YSS665-2 0±0.4 (6) 
YSS675-1 0±1 (6) 
YSS675-2 0±1 (6) 
YSS698-2 48±3 (6) 
Paclitaxel 20±1 (6) 
Podophyllotoxin 3±1 (6) 
Laulimalide 0±0.4 (6) 
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bovine tubulin. The effects of dictyostatin on cellular markers of mitotic block were also well 
correlated with its antiproliferative and cellular MT-stabilizing activity.   
Experiments using radiolabeled paclitaxel, discodermolide and epothilone demonstrated 
that dictyostatin binds the taxoid site on microtubules with avidity very close to that of 
discodermolide, which has one of the most potent known affinities for this site (ter Haar et al. 
1996b, Kowalski et al. 1997).  When 2 µM [3H]discodermolide was used as the radioligand in 
this assay, 4 µM dictyostatin inhibited the binding of the former by less than 50%.  It is 
impossible to determine accurately the ability of normoisotopic discodermolide to inhibit the 
binding of [3H]discodermolide to tubulin polymer, but as a point of reference the theoretical 
isotope dilution with 4 µM unlabeled compound competing with 2 µM of bound radiolabeled 
compound would give an apparent inhibition of 67%.  It should be noted, that 4 µM unlabeled 
paclitaxel inhibited only ca. 33% of 2 µM polymer-bound [3H]paclitaxel in such experiments 
(Hamel et al. 1999). 
Assuming that the four microtubule stabilizers examined here all bind to the taxoid site, 
the present data suggests that discodermolide and dictyostatin have the strongest and similar 
affinities for binding to this site on tubulin polymer.  When the inhibitory effects of dictyostatin 
on [3H]discodermolide binding were examined, the first impression was that dictyostatin bound 
somewhat less well than discodermolide, since only 40% inhibition was observed with both 
compounds at 4.0 μM.  However, a nearly identical effect was obtained when 4.0 μM 
nonradiolabeled discodermolide was mixed with 4.0 μM [3H]discodermolide, reflecting the 
apparent inability to completely inhibit binding of the tritiated ligands to tubulin noted above.  
This suggests that the affinities of dictyostatin and discodermolide for tubulin polymer are nearly 
identical.  The only other test agent that showed significant ability to inhibit discodermolide 
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binding at the concentrations examined was epothilone B.  However, the inhibitory effect of 20 
μM epothilone B was less than that of 4.0 μM dictyostatin or 4.0 μM nonradiolabeled 
discodermolide.  This indicates that the affinity of dictyostatin and discodermolide for the taxoid 
site is at least 5-fold greater than that of epothilone B.  Thus, it can be predicted, based on the 
earlier work of (Buey et al. 2004), that the Ka value for dictyostatin and discodermolide will be 
greater than 3 x 109 M-1. 
While the inhibitory effects of dictyostatin have not been evaluated simultaneously, all 
studies to date with inhibitors of [3H]paclitaxel binding to tubulin polymer have yielded 
competitive patterns – for epothilones A and B (Kowalski et al. 1997), for eleutherobin (Hamel 
et al. 1999) and for discodermolide (Kowalski et al. 1997).  Even though such a finding with 
discodermolide implies that it and paclitaxel bind at essentially the same site on tubulin polymer, 
cytotoxicity studies (Martello et al. 2000) have demonstrated synergism between the two agents 
that has not yet been demonstrated with other combinations of agents that bind at the taxoid site.  
Earlier reports have hypothesized overlapping, but not identical, binding sites for paclitaxel and 
discodermolide (Hung et al. 1996b).  The possibility of two mutually exclusive binding sites on 
tubulin polymer for discodermolide has been suggested to be a reason for the synergistic 
cytotoxicity of combined paclitaxel and discodermolide (Hung et al. 1996b; Martello et al. 
2000).  The synergism was attributed to the presence of a minimum overlapping binding site on 
tubulin polymer for these two compounds.  This distinct feature was recently hypothesized to be 
one of several possible mechanisms that could contribute to the synergistic suppression of 
microtubule dynamics observed with paclitaxel and discodermolide (Honore et al. 2004).  Such 
synergism appeared to occur between discodermolide and paclitaxel when intracellular 
microtubule dynamics are examined, but no such synergy occurs in tubulin assembly reactions 
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between paclitaxel, discodermolide and dictyostatin (unpublished data).  In contrast, assembly 
synergy can be readily demonstrated when laulimalide, which binds at a site on tubulin polymer 
distinct from the taxoid site (Gapud et al. 2004), is combined with paclitaxel (Dabydeen et al. 
2004), or with discodermolide or dictyostatin (unpublished data).  A potential explanation for 
this puzzling discrepancy between the cytological and biochemical findings with discodermolide 
may lie in the recent report that discodermolide, but not paclitaxel, induces accelerated 
senescence in cells in culture (Klein et al. 2005).  However, it was also recently reported that 
paclitaxel and epothilone A bind to taxoid site on tubulin polymer but have minimum 
overlapping binding sites that explains the sensitivity of paclitaxel-resistant ovarian cancer cell 
lines to epothilone A.  These subtle differences in binding sites might reflect in either synergistic 
cytotoxicities and/or differences in polymer morphology.  However, these differences do not 
quite reflect in tubulin polymerization experiments when combinations of test agents are studied.  
This could be because the change in polymer mass is insignificant to be revealed as a big 
difference in turbidity profile.  Nevertheless, the possibility of higher affinity for tubulin 
polymer, hypernucleating ability, and minimum overlapping binding sites for discodermolide as 
compared to paclitaxel on microtubule polymer might help explain the accelerated mitotic 
response induced by discodermolide over paclitaxel and hence the synergism observed in 
cytotoxicity studies.   
These results correlate to some degree with the results from antiproliferative assays. 
Dictyostatin, like discodermolide, was unaffected by the mutations expressed in the β-tubulin of 
the paclitaxel-resistant cells.  The antiproliferative activity of dictyostatin was comparable to that 
of paclitaxel in parental 1A9 cell lines.  On the other hand, dictyostatin was more slightly potent 
than discodermolide as an antiproliferative agent in all three ovarian cell lines, and definitely 
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much more potent in HeLa cells.  Noteworthy is the biological activity of the normethyl 
dictyostatin.  Considering that the normethyl analogues, YSS698-2, is as potent as parent 
molecule in antiproliferative assays and that it inhibited only 50% of the tracer from binding to 
tubulin polymer, it is very likely that there could an overlapping binding site at the taxoid site on 
tubulin polymer on which YSS698-2 binds.  This data substantiates the antiproliferative data 
obtained for YSS698-2 with paclitaxel-resistant cell lines 1A9PTX22 and 1A9PTX10.  While 
the former cell line almost completely retained sensitivity for the 16-normethyl analogue, the 
latter was quite resistant.  This data suggests that the C16-methyl group in dictyostatin is oriented 
towards Phe270.  In addition, Ala364 mutation had no effect on the antiproliferative activity 
suggesting YSS698-2 does not interact with this residue.  The data from [3H]paclitaxel inhibition 
(that showed ~ 50% inhibition) and antiproliferative assays for YSS698-2 lead to a possibility of 
a site partially different from the binding site of paclitaxel on β-tubulin subunit.  It could also be 
possible that β-tubulin subtype selectivity might have a role to play.  Efforts are underway to 
understand the binding orientation of YSS698-2.   Also of interest would be to use YSS698-2 as 
a probe to investigate the differences in protein-ligand interactions between the two paclitaxel 
resistant cell lines.  
Many regulatory elements in the cell are known to have a significant role in the 
assembly/disassembly processes of tubulin polymer.  The primary regulatory factors include 
MAPs and GTP (Soifer 1986; Grover et al. 1995; Weisenberg and Deery 1976; Weisenberg et 
al. 1976).  In vitro polymerization experiments done under various reaction conditions can in 
part explain the differences observed in the antiproliferative activity profile of these compounds 
against parental and mutated β-tubulin cell lines. Tubulin polymerization experiments done 
under conditions ranging from a system consisting of tubulin alone to its combination with 
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MAPs and/or GTP demonstrated that dictyostatin, like discodermolide, enhanced nucleation 
reactions at low temperatures, 0 o-10 oC.  The hypernucleating ability of paclitaxel was far less 
potent than that of dictyostatin and there was a considerable lag time in the paclitaxel-induced 
polymerization reaction.  Not only were the reactions more vigorous in the presence of 
dictyostatin, the dictyostatin-induced polymer was completely cold-stable.  In all these reaction 
conditions, greater polymer mass formation was observed with dictyostatin than with paclitaxel.  
In the complete system, polymer mass was greater in the presence of dictyostatin than with either 
paclitaxel or discodermolide.  This might help explain the slightly greater antiproliferative 
activity observed with dictyostatin in 1A9 cell lines, as cells contain MAPs and GTP.  This might 
also account for the lower Cc value observed with dictyostatin over that seen with 
discodermolide in the complete reaction conditions.  The energetics of binding and initiation of 
polymer formation were lower for dictyostatin than that observed for discodermolide. 
The qualitative differences observed between the turbidity profiles of paclitaxel and 
dictyostatin were consistent with the electron microscopic analyses.  Abundant microtubule 
bundling was observed with dictyostatin as well as with discodermolide under all reaction 
conditions. When individual microtubules in a given field were quantified for microtubule 
lengths, it was apparent that dictyostatin forms microtubules shorter in length than does 
discodermolide or paclitaxel.  Dictyostatin, similar to discodermolide, formed sheets of 
microtubule polymer.  Paclitaxel at 37 oC in the presence of MAPs and GTP formed abundant 
polymer that consisted of both sheets and ribbons.  These morphological differences were highly 
dependent on the presence or absence of MAPs and/or GTP in the reaction mixture.  Dynamic 
events during polymerization of tubulin are known to be regulated to a greater extent by the 
presence of GTP (Weisenberg and Deery 1976).  GTP is known to be localized in the 
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exchangeable (with GDP) site on β-tubulin and in a non-exchangeable site on α-tubulin.  
Tubulin heterodimer containing GTP bound to β-tubulin is therefore termed GTP-tubulin, and 
tubulin with GDP bound at the exchangeable site is termed GDP-tubulin. GTP-tubulin is 
competent for assembly and a cap of GTP-tubulin on MTs maintains their stability.  Although 
GTP is not necessary for tubulin polymerization, its presence enhances the assembly process.  
MAPs are known to shift the equilibrium of the tubulin polymerization process to the right of the 
polymer (Hamel et al. 1999).  Polymer induced by paclitaxel in the presence of GTP consisted of 
MTs with their ends curved or containing loops/ribbons, which appeared to be peeled 
protofilaments.  The number of such MTs with curved ends was low in polymer induced by 
paclitaxel in the tubulin-only system.  This data suggests that MAPs and/or GTP play a very 
crucial role in paclitaxel-induced assembly.  Although the presence of these two regulatory 
elements seems not to be crucial for dictyostatin- and discodermolide-induced polymerization 
reactions, the turbidity profiles do indicate their critical role in the abilities of these agents to 
hypernucleate tubulin assembly.  As mentioned earlier, the intracellular role of MAPs and GTP 
is important in explaining the near-identical GI50 values obtained for these three agents in the 
ovarian carcinoma cells, which correlated with the similar turbidity profiles observed in the 
reactions carried out with the complete system.   
Turbidimetric assays done under restricted reaction conditions showed dictyostatin to 
cause a greater extent of assembly than caused by discodermolide.  However, electron 
microscopic analyses of discodermolide-induced tubulin polymer in these experiments showed 
an apparently more abundant polymer mass than that observed for dictyostatin-induced polymer.   
Abnormal polymer in the form of rings was also observed under these conditions in the presence 
of discodermolide and dictyostatin.  This correlated with the lower Cc value obtained for 
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discodermolide compared to that for dictyostatin under these conditions.  EM images from the 
complete system showed more abundant polymer in the presence of dictyostatin than in the 
presence of discodermolide.  This might account for the lower Cc value observed for dictyostatin 
than for discodermolide in complete system.  Also, the lengths of MTs in dictyostatin-induced 
polymer were shorter than in the discodermolide-induced polymer under this reaction condition.  
The EC50 values for dictyostatin and discodermolide obtained from pelleting assay were similar, 
although dictyostatin appeared to be slightly more potent.  The free energies calculated from Cc 
values also suggest that in the presence of MAPs and GTP and dictyostatin, the Gibb’s free 
energy value for hypernucleation was lower than that observed in the presence of 
discodermolide. 
The results show dictyostatin to have in vitro properties essentially equivalent to those of 
the potent MT hypernucleating and taxoid binding site agent discodermolide. Both compounds 
cause tubulin to polymerize at low temperatures and at low concentrations, and the polymer 
formed by both is cold stable. These strikingly similar qualitative and quantitative results 
strongly suggest that the bioactive conformation of discodermolide is mapped by that of 
dictyostatin, which matches the compact, tilde-shaped conformation present in the 
discodermolide X-ray crystal structure as well as the NMR structure determined in deuterated 
acetonitrile (Gunasekera et al. 1990, Smith et al. 2001) versus the more open, extended 
structures suggested by the NMR analyses done with discodermolide dissolved in deuterated 
DMSO (Monteagudo et al. 2001). Interestingly, dictyostatin was the more potent 
antiproliferative agent of the two, especially in HeLa cells. This could be due to several reasons, 
including the fact that the carbamate moiety on discodermolide, lacking in dictyostatin, is known 
to be labile but also necessary for biological activity (Hung et al. 1996a), pointing to a potential 
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cellular (or culture medium) solvolytic or metabolic instability of discodermolide.  This might 
explain the toxicity shown with discodermolide upon dose escalation during trials clinical trials 
and led to this molecule being kept on hold for further clinical trials (Novartis 2005).  
Alternatively, dictyostatin could simply enter cells more readily than discodermolide and hence 
could be a promising clinical drug candidate.   
Evaluation of dictyostatin analogues for SAR based on biological assays show that of all 
the analogues, the 16-normethyldictyostatin, YSS698-2 was the most active analogue identified.  
It was shown previously that 14-normethyldiscodermolide was as active as the parent molecule.  
16-Normethyldictyostatin, in antiproliferative, tubulin polymerization, and immunofluorescence 
experiments had shown biological activity comparable to the parent molecule.  The C16 methyl 
group, although not crucial for antiproliferative activity, however was shown to be important for 
paclitaxel site binding.  This analogue also showed preferential antiproliferative activity in β-
tubulin mutated cell lines suggesting that C16-methyl group orients towards Phe270 of paclitaxel 
binding site on tubulin polymer.  The open-chain methyl ester of dictyostatin, YSS629 and the 
epimer of dictostatin, YSS652, seem to be moderately active.  YSS629 and YSS652 induced 
polymer formation at lower temperatures, assembly reactions at all temperatures were moderate 
compared to dictyostatin, and the polymer formed was not cold-stable.  In antiproliferative 
assays, the GI50 values were higher than that observed with the parent molecule but paclitaxel-
resistant cells retained their sensitivity for these analogues.  Based on these findings, a summary 
of SAR for dictyostatin was drawn out and can be represented as in Figure 21. 
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Figure 21. Representation of SAR for (-)-dictyostatin 
 
 
 
 
 
 
 
 
 
C16 Me disposable
C2:3 Z geometry required
Macrolactone better than 
open chain methyl ester, but
not a necessity
C19 R configuration required
Z alkene tolerated
yet, saturated analogue retains activity
C6 R configuration required
C14 R configuration required
C7:C9 S:S configuration
important, but C7 OH partially
disposable
O
OH
HO
OH
OH
O
 124
 
 
5. BINDING KINETICS 
5.1. Introduction and literature cited 
Previous studies have shown that discodermolide competed with [3H]paclitaxel from binding to 
MTs with an inhibition constant (Ki) of 0.4 μM (Kowalski et al. 1997).  When 
[3H]discodermolide was used as the tracer it was observed that the stoichiometry of binding to 
tubulin polymer was 1:1 (Hung et al. 1996b).  It was also reported that the binding of 
discodermolide and paclitaxel was mutually exclusive and that paclitaxel bound to 
discodermolide-induced polymer very weakly.  Other MT stabilizers like the epothilones, the 
eleutherobins and the sarcodictyins, when studied for binding kinetics were known to bind to 
paclitaxel site in a competitive manner (Kowalski et al. 1997; Hamel et al. 1999).  However, the 
affinities with which these ligands bound to the polymer were lower than discodermolide.  The 
reported Ki value for epothilone A and B were 0.6 μM and 0.4 μM, respectively as against the 
0.4 μM value obtained for discodermolide when [3H]paclitaxel was used as the tracer.   
Modeling studies suggest that discodermolide fits into the common pharmacophore 
model hypothesized for MT-stabilizing agents including paclitaxel, docetaxel, epothilones, 
eleutherobins and sarcodictyins (Ojima et al. 1999).  However, studies performed using the X-
ray crystal structure of discodermolide onto the taxol binding site on MTs suggest two binding 
modes (Martello et al. 2001).  From SAR studies, the model that was favored was the one that 
had the lactone of discodermolide overlapping with the C13-side chain of paclitaxel and the C19 
portion of discodermolide matching with the C2-benzoyl of paclitaxel rather than vice-versa.  
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Recently, X-ray crystallography, modeling, and NMR studies done on epothilone A bound to 
tubulin polymer suggested a binding model for epothilone A that differed from that proposed for 
paclitaxel (Nettles et al. 2004).  The results from this study help explain the sensitivity of 
paclitaxel-resistant cell lines towards epothilones A and B.   
Recent evidence of synergism observed in MT polymer dynamics in the presence of both 
discodermolide and paclitaxel draws our attention to the possibility of overlapping but not 
entirely superimposable binding sites for discodermolide and paclitaxel (Honore et al. 2004).  
Earlier, it also was shown that in A549-T12 paclitaxel-resistant human lung adenocarcinoma cell 
line no cross-resistance was observed with discodermolide (Martello et al. 2000).  Epothilone B-
resistant cells having mutations in β-tubulin were sensitive upon treatment with discodermolide.  
These observations strongly support the proposed minimum overlapping binding model for 
discodermolide and paclitaxel (and may be epothilone B) that would account for synergistic 
effect of these two molecules in the cells.  It was also hypothesized that the accelerated 
senescence that was recently reported for discodermolide might be one of the possible 
mechanisms contributing to the synergistic microtubule perturbation and cytotoxicity between 
discodermolide and paclitaxel (Madiraju et al. 2005).   
Preliminary findings in this work that dictyostatin inhibits [3H]paclitaxel from binding to 
tubulin polymer indicate that dictyostatin binds to the taxoid binding site on tubulin polymer 
(Chapter 4).   Since dictyostatin structurally resembles discodermolide one would anticipate an 
inhibition pattern against [3H]paclitaxel, similar to that of discodermolide, for binding to tubulin 
polymer.  Antiproliferative activity studies show that dictyostatin, like discodermolide, is active 
in paclitaxel-resistant ovarian cancer cell lines (Chapter 4).  This data suggests dictyostatin, 
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similar to discodermolide, might have a minimum overlapping binding site at the taxoid site on 
tubulin polymer.   
Hypothesis III: Dictyostatin, discodermolide, and the 4-epi analogue of discodermolide will 
have similar inhibitory effects on [3H]paclitaxel binding kinetics on tubulin polymer.   
Rationale: It is of interest to investigate the mode of binding and to determine the inhibition 
kinetics for discodermolide, dictyostatin and their analogues.  The rapid mitotic effects seen with 
discodermolide in comparison with paclitaxel could be attributed to the potent hypernucleating 
ability of discodermolide over paclitaxel.  There must be subtle differences in binding models 
between discodermolide and paclitaxel that could account for the high-affinity binding, 
hypernucleation, and stabilization effects of discodermolide on microtubule polymer 
characteristically different from that of paclitaxel.  These features could have an effect on the 
synergistic suppression of microtubule dynamics between discodermolide and paclitaxel.  Hence, 
it is of importance to obtain clues about the binding kinetics for discodermolide and paclitaxel 
that aid in understanding the differences in their microtubule perturbing effects.  Preliminary data 
with [3H]paclitaxel and [14C]epothilone B as tracers show a convincing evidence that dictyostatin 
is equivalent to discodermolide in binding to tubulin polymer with very high affinity (vide supra, 
Chapter 4).  The cellular effects of dictyostatin are similar to discodermolide.  Since, dictyostatin 
is a novel molecule, there are no studies done yet that report any sort of synergism between 
paclitaxel and dictyostatin on microtubule polymerization dynamics.  Nevertheless, dictyostatin 
is comparable to discodermolide in its ability to bind tubulin polymer with greater affinity, to 
hypernucleate tubulin assembly, and to retain potency in paclitaxel-resistant cell lines.  These 
features set dictyostatin on par with discodermolide.  Hence, it would be of interest to understand 
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the subtle differences in binding modes, if any, between dictyostatin and paclitaxel.  The 
quantitative estimation of binding data could help rationalize the in vivo findings.   
Therefore, a detailed kinetic study was undertaken to investigate the mode of binding and 
to obtain apparent inhibition constant values (Kis).  The Ki value could stand as a good parameter 
estimate for assessing the test agent’s potential as a taxoid site binding agent.  On par with these 
studies, the binding kinetics of the 4-epi analogue of discodermolide (NC86) was also 
determined.  This compound is one of the first library discodermolide analogues that showed 
interesting biological activity.  It inhibited [3H]paclitaxel from binding to tubulin polymer to an 
extent of 57% and had μM GI50 values in antiproliferative assays (Chapter 3).  Radioligand 
binding and fluorescent anisotropy techniques were employed for determining binding kinetics.  
[3H]paclitaxel was used as the tracer for radioligand binding experiments and Flutax-2, having a 
difluorocarboxyfluorescein as the fluorophore linked to C-7 of paclitaxel was used as the tracer 
in fluorescent anisotropy experiments.  Along with inhibition studies, saturation binding kinetics 
experiments were also done to derive the dissociation constant (KD) and binding affinity of 
[3H]paclitaxel itself, in an effort to re-establish the binding kinetic parameters for [3H]paclitaxel 
using the tubulin aliquot that we had.  The KD parameter is also necessary for determining the Ki 
values for the inhibitors.  Studies done earlier using radiolabeled as well as fluorescent-labeled 
paclitaxel show that paclitaxel binds to tubulin polymer with a 1:1 stoichiometry indicating only 
one binding site for paclitaxel.  The KD values reported were 0.01 μM and ~ 0.06-0.1 μM, 
respectively (Caplow et al. 1994; Ye et al., Diaz et al. 2000).  Following the approach of 
radioligand binding assay, fluorescence anisotropy methodology described earlier (Diaz et al. 
2000; Andreu and Barasoain 2001; Diaz et al. 2003) was also employed to obtain binding kinetic 
parameters and to provide conclusive evidence for stoichiometry of binding.  This study was 
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done based on the reason that fluorescence anisotropy is a more sensitive technique to decipher 
the optimum binding characteristics for a molecule since a wide range of protein and ligand 
concentrations could be studied in a single experiment.  Glutaraldehyde-fixed microtubules 
render stable polymer upon dilution and/or change in temperature (Andreu and Barasoain 2001).  
Additionally, work in the direction of determining the thermodynamics of ligand binding to MT 
polymer using Flutax-2 is in progress.  Anisotropy experiments were employed to understand the 
binding energetics of the ligands on tubulin polymer.  In this section, a portion of the work will 
only be presented since the studies are still on-going.    
5.2. Experimental procedures and results 
Paclitaxel saturation binding kinetics using tubulin aliquots and [3H]paclitaxel as the tracer were 
determined to establish the equilibrium dissociation constant and the concentration of binding 
sites.  A structural analogue of paclitaxel, docetaxel, was used to determine the effect non-
specific binding would have on the binding kinetics.  Docetaxel concentration required for doing 
non-specific binding experiments was first determined in the concentration range of 0.25-20 μM.  
The experimental procedure for determining saturation binding data is described in Chapter 2.  
The concentration of docetaxel was graphed against disintegrations per minute (dpm) for the 
tracer observed.  Saturation binding studies were performed with [3H]paclitaxel incubated at 
different concentrations (0.25-6 μM) with preformed MT polymer (2 µM) to determine the 
stoichiometry of binding following the protocol described in Chapter 2.  Stoichiometry 
experiments were performed in the presence and absence of docetaxel.  Nonspecific binding of 
[3H]paclitaxel in the presence of docetaxel (12 µM) was determined.  Specific binding of 
[3H]paclitaxel was determined from the difference of total and nonspecific bound values.   
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Inhibition studies were performed with radiolabeled paclitaxel and different inhibitors.  
Different concentrations of [3H]paclitaxel (ranging from 0.025-4.0 μM) were studied against 
different concentrations of discodermolide (in the concentration range of 0.25-4 μM).  The 
experimental protocol was similar to the preliminary studies done with [3H]paclitaxel and 
inhibitors studied at a single concentration.  The procedure for [3H]paclitaxel inhibition study is 
explained in Chapter 2.  The 4-epi analogue of discodermolide (NC86) was also studied for 
inhibition kinetics.  The experimental procedure was exactly similar to the one described for 
discodermolide except that the inhibitor concentrations ranged from 0.25-10 μM.   Inhibition 
studies with dictyostatin were also studied following similar procedure as described above. 
Saturation binding kinetic parameters were determined from the plots of free 
concentration of [3H]paclitaxel (μM) versus number of moles of [3H]paclitaxel bound per mole 
tubulin polymer.  The latter term was either total or specific bound value of the tracer.  
Saturation binding parameters (KD, Bmax, and Hill slopes) were determined based on Langmuir 
binding isotherm equation using the non-linear regression program in PRISM software version 
4.0 (GraphPad Software, Inc., San Diego, CA, USA) based on best-fit modeling strategy and are 
expressed in terms of mean+/-SEM.  The inhibition study with discodermolide was quantitated 
and data analysis done with PRISM software version 4.0 (GraphPad Software, Inc., San Diego, 
CA, USA).   
5.3. Docetaxel inhibition study 
The concentration of docetaxel that almost completely inhibited [3H]paclitaxel binding was 
determined from the graphical plot of docetaxel shown in Figure 22.  At 8-16 μM docetaxel 
seemed to have a plateau-effect on [3H]paclitaxel bound to tubulin polymer.  This concentration 
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of 12 μM docetaxel was used to determine non-specific binding for all the saturation binding and 
inhibition experiments.    
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Figure 22. Determination of docetaxel concentration for non-specific binding experiments  
Reaction mixtures consisted of 0.74M MSG (pH 6.6), ddGTP-induced microtubule polymer, and 
2 μM [3H]paclitaxel in the presence of docetaxel in the concentration range studied.  Data is 
expressed as mean±S.D (N=3).  Each data point represents total [3H]paclitaxel bound at any 
single concentration of docetaxel.  Abcissa (X-axis): docetaxel concentration (μM); Ordinate (Y-
axis): total [3H]paclitaxel bound (dpm).   
5.4. Saturation binding experiments with [3H]paclitaxel 
Saturation binding experiments done with tubulin polymer and [3H]paclitaxel revealed that 0.8 
mol of total [3H]paclitaxel bound per mol of tubulin polymer.  Figure 23A represents the 
stoichiometry data obtained for total [3H]paclitaxel bound per mol of tubulin polymer.  The Bmax 
and KD values expressed as mean ± SEM were 0.8±0.014 and 0.0587±0.0048 μM, respectively.  
 131
In this set of experiments, the total [3H]paclitaxel bound values were observed to be greater than 
10% of the total radioligand added at concentrations less than the observed KD value.  The 
percent bound values were greater than 25% for the concentration range studied.  The sigmoidal 
equations employed for calculating binding parameters assume that the free concentration of the 
radioligand measured is almost equal to the concentration of the radioligand added to the 
samples.  When >10% of the added radioligand binds to the receptor the free concentration is 
less than the added concentration of the radioligand and this phenomenon is referred to as ‘ligand 
depletion’.  A parameter estimate that indicates whether a simple bimolecular reaction would  
explain the data, or not, is the Hill slope (nH) (Morton et al. 2002).  A Hill slope of one indicates 
a one-site binding for the radioligand.  Hill slope less than unity meaning the tracer has a shallow 
affinity for the site.  A Hill slope greater than one suggests that the tracer or that the inhibitor 
have two active sites or equilibrium condition has not been reached or that the inhibitor has a 
positive co-operativity for radioligand binding to its active site.  In our studies, the Hill slope 
obtained for total binding was nH ~ 1.6, suggesting more than one binding site (nH ~ 1.56).  This 
indicates that paclitaxel binds to some nonspecific sites that might give an overestimation of the 
stoichiometric ratio if not corrected for.  Hence, the standard saturation binding equation based 
on Langmuir isotherm is modified to account for non-specific binding that largely contributes to 
ligand depletion and greater Hill coefficient.  Non-specific binding was accounted by using 
docetaxel as the non-specific inhibitor of [3H]paclitaxel binding to the polymer.  Specifically 
bound values were calculated form total bound minus non-specifically bound values from which 
the binding kinetic parameters were again determined.  When specifically bound values were 
taken into consideration, the stoichiometry value obtained was around 0.6 mol of the 
radiolabeled tracer bound to 1 mol of MT polymer (Figure 23B).     
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Figure 23. Stoichiometry data from [3H]paclitaxel binding experiments  
Figure 23A. Stoichiometry of total [3H]paclitaxel bound per mol microtubule polymer 
Stoichiometry experiments were conducted at concentrations that ranged from 0.01 μM-5.0 μM.  
Reaction mixtures consisted of 0.74M MSG (pH 6.6), ddGTP-induced microtubule polymer, and 
[3H]paclitaxel in the concentration range studied.  Data is expressed as mean±SEM (N=3).  Each 
data point represents total [3H]paclitaxel bound per mol tubulin polymer at a free [3H]paclitaxel 
measured in the reaction mixture.  Abcissa (X-axis): Free [3H]paclitaxel (μM); Ordinate (Y-axis): 
total [3H]paclitaxel bound per mol tubulin polymer.   
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Figure 23B. Stoichiometry of specific [3H]paclitaxel bound per mol microtubule polymer.  
Stoichiometry experiments were conducted at concentrations that ranged from 0.01 μM-5.0 μM.  
Non-specific binding was accounted from docetaxel containing sample set.  Reaction mixtures 
consisted of 0.74 M MSG (pH 6.6), ddGTP-induced microtubule polymer, and [3H]paclitaxel in 
the concentration range studied.  Data is expressed as mean±SEM (N=3).  Each data point 
represents [3H]paclitaxel bound per mol tubulin polymer at a free [3H]paclitaxel measured in the 
reaction mixture.  Abcissa (X-axis): Free [3H]paclitaxel (μM); Ordinate (Y-axis): specific 
[3H]paclitaxel bound per mol tubulin polymer.  
 
 
The Bmax and KD values obtained from specifically bound values expressed in terms of 
mean±SEM were 0.6±0.0143 and 0.0353±0.0041 μM, respectively.  The specific binding data 
yielded a Hill slope of ~ 1.0.  This correlates with the stoichiometry determined for total and 
specific binding of paclitaxel to tubulin polymer. 
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5.5. Radioligand inhibition studies  
Inhibition studies were performed to understand the inhibition pattern and to demonstrate the 
relative potency of the agents for binding to tubulin polymer.  The data were quantified to obtain 
the inhibition constant (Ki value) from the inhibition data profiles.  Both classical  
pharmacological inhibition approach and modified Michaelis-Menten kinetics were employed 
for data analysis and interpretation (Dixon 1978; Edler et al. 2005).  Figure 24 shows the 
inhibition profile obtained by plotting log concentration of discodermolide (μM) against percent 
inhibition.  The model chosen for this set of data was one-site competition since the data best fit 
to this model.  The equation for two-site model was tried, but the data did not converge.  Percent 
inhibition values were obtained after normalizing the [3H]paclitaxel bound values, in the 
presence of inhibitor, with respect to set of vehicle-only controls that had no inhibitor.  The 
inhibition plot in Figure 24 suggests that discodermolide competitively inhibited [3H]paclitaxel 
from binding to tubulin polymer at concentrations ranging from 0.5-2.0 μM.  Sigmoidal 
concentration-response curves generated from nonlinear regression analysis of the log inhibitor 
concentration versus percent inhibition data using PRISM 4.0 yielded series of sigmoidal curves.  
The model with different Hill slopes fit the data the best.  The Hill slopes for the set of 
[3H]paclitaxel concentrations included in this study were greater than 1.0, regardless of whether 
the data was corrected for specific binding or not.  Hill slopes greater than 1.0 could be because 
of several reasons which will be discussed in the next section.  In addition, when data was 
transformed to the one based on modified Hanes equation and redrawn (free concentration of 
[3H]paclitaxel versus free/bound concentration of [3H]paclitaxel, S vs. S/V, respectively), the 
slopes of the lines at different inhibitor concentrations were not truly 1.0.  The Hanes plot for  
 
 135
 
 
-1.5 -1.0 -0.5 0.0 0.5 1.0
0
20
40
60
80
100
120
140
160
Concentration of discodermolide (μM)
%
 In
hi
bi
tio
n
 
 
Figure 24. Graphical representation of discodermolide inhibition kinetics  
Inhibition experiments were performed at concentrations of [3H]paclitaxel that ranged from 0.01 
to 5.0 μM and discodermolide concentrations ranging from 0.25  to 4.0 μM.  Reaction mixtures 
consisted of 0.74 M MSG (pH 6.6), ddGTP-induced microtubule polymer, [3H]paclitaxel and 
discodermolide in the concentration range studied.  Percent inhibition was determined as 
described in Chapter 2.  Data is expressed as mean±SEM (N=3).  Each data point represents 
percent inhibition values plotted against concentration of discodermolide in log scale for each 
concentration of [3H]paclitaxel:  0.1 µM (gray); 0.25 µM (rust);  0.5 µM (brown); 1.0 µM (blue); 
1.5 µM (purple); 2.0 µM (green).  Abcissa (X-axis): μM discodermolide (log scale); Ordinate (Y-
axis): % inhibition. 
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Figure 25. Hanes plot of discodermolide inhibition kinetics 
Inhibition experiments were performed as described in Figure legend 24.  Data is expressed as 
mean±SEM (N=3).  Each data point represents free [3H]paclitaxel (μM) plotted against free 
[3H]paclitaxel over [3H]paclitaxel bound both in μM.  Abcissa (X-axis): Free [3H]paclitaxel 
(μM); Ordinate (Y-axis): free [3H]paclitaxel over [3H]paclitaxel bound to tubulin polymer, both 
in μM. Discodermolide was studied at 1.5 μM (circles); 1.75 μM (open triangles); 2 μM (open 
squares).  Note: slopes not equal, depicts mixed inhibition. 
 
 
discodermolide is shown in Figure 25.  It is known that for competitive inhibitors, Hanes 
analysis should yield lines with slopes more or less equal to 1.0 (Edler et al. 2005).  The profiles 
shown in Figures 24 and 25 suggest one of the following:   
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The inhibitor might have two affinity sites for binding and/or the inhibitor must be exerting a 
mixed inhibition for binding to tubulin polymer.  The equilibrium dissociation constant (KD) of 
the radioligand as well as the molar ratio of the bound radioligand and tubulin protein (Bmax) are 
known to be altered when a mixed inhibition occurs.  Hence, calculation of the two inhibition 
constants seemed necessary in the present situation.  The apparent inhibition constant values (Ki 
values) for high and low affinity sites were 34 nM and 178 nM, respectively.  These values 
seemed quite reasonable for a potent molecule like discodermolide.  The KD value for 
[3H]paclitaxel was 35 nM. 
Non-linear regression analysis of the log concentration versus percent inhibition data for 
the 4-epi analogue of discodermolide (NC86) yielded sigmoidal concentration-response curves 
with variable slopes.    Data accounted for non-specific binding resulted in nH values greater 
than 1.0 at lower concentrations (0.025, 0.05, 0.1 μM inhibitor concentrations) and about 1.0 at 
higher concentrations (0.25, 0.5, 1.0, and 2.0 μM).  The data however, did not show a complete 
plateau effect and needs higher concentrations.  Hanes analysis of the data was done by plotting 
free [3H]paclitaxel concentration versus free/bound values as described above.  Figure 26 
represents the Hanes plot for the 4-epi analogue.  
Sigmoidal concentration-response curves and Hanes plot suggest that the epi-analogue, 
similar to discodermolide, showed mixed inhibition pattern.  This could again be because of 
overlapping binding sites or presence of more than one isoform of tubulin in the protein aliquot 
used for inhibition studies. Hanes analysis showed shallow slopes compared to discodermolide 
owing to the fact that the 4-epi analogue had a lower affinity for binding to taxoid site on tubulin 
polymer.  The slopes were not the same for all the inhibitor concentrations.  The Ki values 
calculated from the high and low affinity sites were 0.2 and 2.55 μM, respectively.    
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Figure 26. Hanes plot of 4-epi analogue (NC86) inhibition kinetics  
Inhibition experiments were performed as described in Figure legend 24.  Concentrations of the 
inhibitor, 4-epi analogue, ranged from 0.25 to 10 μM.  Data is expressed as mean±S.D (N=3).  
Each data point represents free [3H]paclitaxel (μM) plotted against free [3H]paclitaxel over 
[3H]paclitaxel bound both in μM.  Abcissa (X-axis): Free [3H]paclitaxel (μM); Ordinate (Y-axis): 
free [3H]paclitaxel over [3H]paclitaxel bound to tubulin polymer, both in μM. 4-epi analogue 
concentrations were 10 μM (open triangles); 4 μM (circles); 1 μM (closed triangles); 0 μM (open 
squares).  Note: slopes not equal, depicts mixed inhibition. 
 
 
Graphical analysis of log concentration of dictyostatin versus percent inhibition data 
suggests a competitive inhibition pattern for this molecule (Figure 27).  The profile shown here 
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looked almost similar to that observed for discodermolide (Figure 24).  Sigmoidal concentration-
response curves from non-linear regression analysis of log concentration and % inhibition data  
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Figure 27. Graphical representation of dictyostatin inhibition kinetics  
Inhibition experiments were performed at concentrations of [3H]paclitaxel that ranged from 0.01 
μM-5.0 μM and dictyostatin concentrations ranging from 0.25  to 4 μM.  Reaction mixtures 
consisted of 0.74 M MSG (pH 6.6), ddGTP-induced microtubule polymer, [3H]paclitaxel and 
discodermolide in the concentration range studied.  Percent inhibition was determined as 
described in Chapter 2.  Data is expressed as mean±SEM (N=3).  Each data point represents 
percent inhibition values plotted against concentration of dictyostatin in log scale.  [3H[paclitaxel 
concentrations include: 0.05 μM (gray); 0.1 μM (rust); 0.5 μM (brown); 1 μM (purple); 2 μM 
(olive green); 3 μM (blue); 4 μM (dark green). Abcissa (X-axis): μM dictyostatin (log scale); 
Ordinate (Y-axis): % inhibition. 
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yielded concentartion-response curves with Hill slopes greater than 1.0.  The curves were 
comparable to that observed with discodermolide.  Hanes analysis of the dictyostatin inhibition 
data showed series of lines with slopes not equal to 1.0 suggesting a mixed inhibition pattern 
(Figure 28).  The Ki values determined for high and low affinity sites were, 23.4 and 332 nM, 
respectively.   
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Figure 28. Hanes plot of dictyostatin inhibition kinetics 
Inhibition experiments were performed as described in Figure legend 24.  Dictyostatin 
concentrations ranged from 0.25 to 4 μM.  Data is expressed as mean±SEM (N=3).  Each data 
point represents free [3H]paclitaxel (μM) plotted against free [3H]paclitaxel over [3H]paclitaxel 
bound both in μM.  Dictyostatin concentrations include: 4 μM (squares); 3 μM (triangles); 2 μM 
(inverted triangles); 1 μM (diamonds); 0.5 μM (circles); 0.25 μM (small squares); Abcissa (X-
axis): Free [3H]paclitaxel (μM); Ordinate (Y-axis): free [3H]paclitaxel over [3H]paclitaxel bound 
to tubulin polymer, both in μM. Note: slopes not equal, depicts mixed inhibition. 
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5.6. Fluorescence anisotropy experiments with Flutax-2 
Anisotropy experiments were performed using glutaraldehyde-fixed microtubules and 
fluorescence labeled paclitaxel in the presence and absence of inhibitors.  The primary objective 
of fluorescence anisotropy experiments was to elucidate the binding kinetics of paclitaxel and to 
relate the kinetics with the thermodynamics involved in ligand-induced assembly reactions.  
Glutaraldehyde-fixed microtubules were used since cross-linked microtubules withstand  
dilution- and temperature-induced microtubule disassembly (Andreu and Barasoain 2001).  
Microtubules were quite stable when checked under EM at 100-fold as well as 1000-fold 
dilutions (Figure 35 in the Appendix).  The concentration of free binding sites on microtubule 
polymer was determined from anisotropy experimental data.  Cross-linked polymer, in the 
concentration range 0.04-12.5 μM, was studied in the presence of 25 nM Flutax-2.  The 
equilibrium binding constant associated with it was determined using WINNONLIN version 3.0.  
Figure 29 represents the observed and predicted data from WINNONLIN obtained for this set of 
anisotropy data.  The best model was chosen based on the Akaike Information Criterion (AIC) 
(Motulsky and Ransnas 1987).  The lower the AIC value for a given model, the better fit is the 
model.  The best-fitted values for rmin and rmax were 0.079 and 0.163, respectively.  The 
equilibrium binding constant calculated based on the best-fit values for rmin and rmax was 
0.00347. 
 The number of binding sites for Flutax-2 and the equilibrium binding constants for 
Flutax-2 at room temperature and at 37 oC were determined.  The anisotropy data from 
experiments done with varying concentrations of Flutax-2 (0-100 nM) was fitted into the 
equation and iterations were performed using WINNONLIN as mentioned above.   
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Figure 29. Determination of microtubule binding parameters   
Glutaraldehyde-fixed microtubules were studied in the range of 0.4-12.5 μM.  The concentration 
of Flutax-2 used was 25 nM.  The concentration of binding sites and equilibrium binding 
constant.  Each data point represents N = 3.  Abcissa (X-axis): Concentration of cross-linked 
microtubules (nM); Ordinate (Y-axis): anisotropy values. 
 
 
The data obtained from best-fit modeling strategy for experiments done at 37 oC and at RT are 
represented in Figures 30 and 31, respectively.  Flutax-2 binding kinetics data at RT indicated 
the number of binding sites to be around 0.7.  The equilibrium binding constant was 0.078 nM.  
Upon increase in temperature from RT to 37 oC, the equilibrium binding constant observed was 
0.01 nM at 37 oC and the number of binding sites was around 1.0.  This data correlates with the 
previously reported studies on Flutax-2 kinetics.  The number of binding sites close to  
1.0 correlated with the data obtained when radiolabeled paclitaxel was used for determining  
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Figure 30. Determination of Flutax-2 binding parameters at 37 oC  
Flutax-2 studied in the concentration range of 1-100 nM.  The concentration of cross-linked 
microtubules was 100 nM.  The number of binding sites and equilibrium binding constants for 
Flutax-2 were determined.  Each data point represents N = 3.  Abcissa (X-axis): Concentration of 
Flutax-2 (nM); Ordinate (Y-axis): fraction bound. 
 
 
stoichiometry of paclitaxel binding to tubulin polymer (vide supra).  Thermodynamic parameters 
for Flutax-2 binding to tubulin polymer at two different temperatures were determined from 
Van’t Hoff plot (lnk versus 1/T).  The association constant ‘k’ is the inverse of the equilibrium 
binding constant.  Figure 32 represents the Van’t Hoff plot.  The data yielded negative enthalpy 
values suggesting that the thermodynamics of Flutax-2 binding to microtubules is an exothermic 
process.  This is an expected result since Flutax-2 stabilized the formation of microtubules, the 
reaction is driven to the left (more stable microtubule formation).   
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Figure 31. Determination of Flutax-2 binding parameters at RT 
Flutax-2 was studied in the concentration range of 1-100 nM.  The concentration of cross-linked 
microtubules was 100 nM.  The number of binding sites and equilibrium binding constants for 
Flutax-2 were determined.  Each data point represents N = 3.  Abcissa (X-axis): Concentration of 
Flutax-2 (nM); Ordinate (Y-axis): fraction bound. 
 
5.7. Discussion 
Saturation binding experiments with [3H]paclitaxel suggested a stoichiometry about 0.8 when 
total [3H]paclitaxel bound values were considered for determination of the molar ratio of 
[3H]paclitaxel bound to tubulin polymer.  However, the molar ratio for specific binding of 
[3H]paclitaxel bound to tubulin polymer was ~ 0.6 when docetaxel was used to account for non-
specific binding values.  The reported literature value was about 1:1 stoichiometry for 
[3H]paclitaxel bound to tubulin heterodimer in similar experiments (Diaz et al. 1993; Caplow et 
al. 1994; Hung et al. 1996b; Hamel et al. 1999), but it is not known whether non-specific 
binding was considered for the data presented in the literature.  Since, > 25% of the added tracer 
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bound to the protein at concentrations lower than the KD value, the free concentrations of tracer 
were not to be assumed the same as total tracer added.  This phenomenon is defined as ligand 
depletion and was understood to occur owing to non-specific binding of the labeled compound to 
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Figure 32. Van’t Hoff plot of ln k versus 1/ K  
The slope and intercept values were used to determine enthalpy and entropy terms, respectively 
for Flutax-2 binding to tubulin polymer.  Each data point represents N = 4. 
 
 
the protein (Morton et al. 2002).  Assumptions made in deriving Langmuir binding isotherms no 
longer hold true in this case, and correction for non-specific binding should be done to account 
for ligand depletion.  The Hill slope is a good estimate that provides clues for the existence of 
more than one affinity sites and/or heterogeneity in ligand binding to the protein.  Hence, the 
data obtained in stoichiometry experiments were corrected for non-specific binding and Hill 
coefficients evaluated.  The Hill slopes were different for total and specific binding of 
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[3H]paclitaxel bound to tubulin polymer (1.6 versus 1.0) indicating paclitaxel bound to non-
specific sites on tubulin polymer.  This data suggests a one-site model for [3H]paclitaxel binding 
to tubulin polymer.  It is also shown that depending on the nucleotides used for inducing tubulin 
assembly, reaction conditions like protein and radioligand concentrations, the stoichiometry of 
paclitaxel binding to microtubules ranged anywhere between 0.7-1.0 (Caplow et al. 1994; Hamel 
1999; Diaz et al. 2003).  These same studies have shown that radioligand binding assays with 
[3H]paclitaxel always yield maxima of about 80% of tracer bound to the polymer.  This value 
when represented on a molar basis with respect to the number of moles of protein used in the 
assay would yield a value of about 0.8.  Hence, 0.8:1 mol stoichiometry observed in the present 
studies is reasonable.  Similar calculations were done for the protein aliquot used for 
discodermolide and 4-epi analogue inhibition study.  The stoichiometry was about 0.5:1 or 0.3:1 
moles of [3H]paclitaxel bound per mole of tubulin polymer after accounting for non-specific 
binding.  The lower stoichiometry could be due to another isoform of tubulin in the protein 
aliquot.   
Inhibition analyses show that discodermolide, its 4-epi analogue (NC2-86) and 
dictyostatin had competitive effects at one site on the binding kinetics of paclitaxel.  The two-site 
binding model did not converge.  However, sigmoidal concentration-response curves afforded 
Hill slopes > 1.0 for discodermolide and dictyostatin, indicating there could be more than one 
high affinity site for discodermolide.  Steeper slopes were observed regardless of whether non-
specific or specific bound values were considered for inhibition plots.  Similar plots for the 4-epi 
analogue yielded Hill slopes of > 1.0 at lower concentrations but ~ 1.0 at higher concentrations.  
The steeper slopes observed in the presence of inhibitors could be because of several reasons, 
including ligand depletion.  Stoichiometry determination after accounting for ligand depletion 
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yielded Hill slope of 1.0.  However, specifically bound values considered for inhibition plots 
resulted in Hill slopes greater than unity.  One possible explanation for this could be that the 
correction for ligand depletion takes into account only the traceable ligand, i.e., [3H]paclitaxel.  
Ligand depletion could also occur for nonradioactive ligands or competitors, which were not 
accounted for in the equations described.  This heterogeneity in binding in a heterologous 
competition experiment, like this one, accounts only for the non-specific binding of the tracer 
and not the competitor as well.  Ligand depletion for inhibitors could be due to inhibitors 
themselves binding to some other site or have an overlapping binding site with respect to that of 
the tracer.  Another reason could be attributed to the mechanism of action of the competitors.  
The steep Hill coefficients observed could be due to the high affinity with which the competitors 
(discodermolide and dictyostatin, in particular) bind to tubulin polymer and/or exert a positive 
co-operativity for binding of the substrate ([3H]paclitaxel) to microtubule polymer.  Literature 
reports suggest that agonists for a protein or a receptor have this characteristic feature.  Since, the 
molecules have a stabilizing effect on microtubules, the action of one ligand may have an 
agonistic effect on the microtubule stabilization properties of the other.  The presence of more 
than one isoform of tubulin or MAPs could also explain this effect.  Yet another explanation 
could be due to existence of non-equilibrium conditions in the reaction mixture.  This could be a 
remote possibility since the incubation time was long enough for equilibrium condition to have 
reached.  In these experiments, since the two-site model did not quite fit well for any of the 
inhibitors, positive co-operativity seems to be the most plausible explanation for Hill slopes to be 
> 1.0.  These results are supported by Hanes analysis which suggested discodermolide, the 4-epi 
analogue of discodermolide and dictyostatin to have a mixed inhibition pattern.  Results from 
Hanes plots also highlight the possibility of minimum overlapping binding sites for 
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discodermolide, the 4-epi analogue of discodermolide, and dictyostatin with respect to paclitaxel 
on tubulin polymer.  The presence of two different isoforms of tubulin contributing to the mixed 
kinetics cannot be overruled.  Discodermolide showed high and low affinity Ki values of 34 and 
178 nM, respectively.  The Ki value reported in the literature for discodermolide was 0.4 μM, 
this is because total [3H]paclitaxel concentrations were considered for Hanes analysis versus the 
free tracer concentrations that were used in the present calculations.  Discodermolide seemed to 
have an allosteric effect on paclitaxel binding to tubulin polymer.  A similar effect was observed 
with the 4-epi analogue.  However, the possibility for the presence of another isoform of tubulin 
in the protein aliquot cannot be ruled out, especially considering the variable binding interactions 
and stoichiometries observed for the tubulin aliquot.  We previously reported that [3H]paclitaxel 
exhibited differential binding and inhibition kinetics on tubulin polymer in the presence of 
discodermolide and the 4-epi analogue (Madiraju et al. 2004).  Data from these experiments 
revealed the radioligand to tubulin stoichiometry to be ~ 0.4 and ~ 0.3 moles of total- and 
specifically-bound radiolabeled paclitaxel per mole of tubulin polymer, respectively, a value half 
that observed in the previous study.  The differences in stoichiometry between the two protein 
aliquots could be due to solution variables, nucleotide content, or another isoform being present 
in the tubulin aliquot.  Dictyostatin inhibition kinetics with the protein aliquot that showed a 
0.8:1 stoichiometry showed a competitive inhibition pattern with higher concentrations of the 
tracer.  Dictyostatin yielded Ki values of 23 and 300 nM at high and low affinity sites, 
respectively   This data suggests that dictyostatin might also have an allosteric effect on 
paclitaxel binding kinetics.   
The reasons behind the positive co-operativity and mixed inhibition pattern observed 
could be many.  Discodermolide and paclitaxel, as suggested in the literature and as discussed 
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above, might share an overlapping binding site for exerting an allosteric effect and/or positive 
co-operativity.  This latter term is reflected in Hill slopes > 1.0.  The presence of any of the 
inhibitors (known to be microtubule stabilizers) might stabilize the binding conformation of the 
protofilaments better, making the site amenable for facile binding of paclitaxel on tubulin 
polymer.  However, the presence of more than one isoform or subtype of tubulin might also 
contribute to the differential binding kinetics.  The latter could also be part of the explanation for 
mixed inhibition observed in these studies.  This is because, stoichiometry experiments done 
with tubulin aliquot used for these studies suggested a mol:mol [3H]paclitaxel to tubulin ratio of 
<0.5 (Figure 33 in the Appendix).  This data suggests there are two moles of protein to which 
[3H]paclitaxel bound.  The mixed inhibition pattern observed for discodermolide could be due to 
inhibition of [3H]paclitaxel bound to two moles of protein in the reaction mixture.  The Kapp 
values changed in the presence of discodermolide as compared to the KD value observed in the 
presence of no inhibitor, suggesting a competitive pattern of inhibition.  However, the slopes of 
the lines in the presence of inhibitor were not comparable to the one with no inhibitor, indicating 
that there is a change in Bmax values as well.  Hill slopes also provide similar result.  Ideally, one 
should observe a slope of ~ 1 for a one-site competitive inhibition profile (Edler et al. 2005).  
The Hill slopes of > 1.0 observed in our studies and the proposed mechanism of positive co-
operativity between microtubule provide a reasonable explanation for synergism observed in the 
suppression of microtubule dynamics in the presence of discodermolide and paclitaxel.  Studies 
done to evaluate the cellular effects in the presence of MT-targeting agents suggest a synergism 
between paclitaxel and discodermolide in their effects on in vivo suppression of MT dynamics 
(Honore et al. 2004).  This effect was attributed to the accelerated senescence observed for 
discodermolide- and not paclitaxel-treated cells.  The accelerated senescence and synergistic 
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effect in the presence of these molecules could be due to the presence of mutually exclusive 
binding sites for paclitaxel, overlapping binding sites, positive co-operativity, to the existence of 
more than one isoform of tubulin, or higher affinity of the ligands to the polymer all of which 
bring out sequelae of events starting from hypernucleation, potent stabilization, and suppression 
of microtubule dynamics to the initiation of mitotic cell death events.   
Studies done towards understanding the relationship between stoichiometry of paclitaxel 
binding to tubulin α,β-dimer and microtubule polymerization dynamics have shown that 
paclitaxel suppresses dynamic instability of microtubules differently depending on the 
stoichiometry of paclitaxel bound to tubulin polymer (Derry et al. 1995).  Results from these 
studies show that at high stoichiometries > 0.1 mol paclitaxel to mol microtubule polymer, the 
dynamic instability of microtubules was completely suppressed with a significant change in 
polymer mass.  At lower stoichiometries tubulin polymer dynamics were suppressed with out 
much change in the polymer mass.  Earlier, it was shown that heterogeneous binding sites exist 
for paclitaxel on microtubule polymer induced by GTP, one a low affinity site and the other a 
high affinity site (Li et al. 2001).  Paclitaxel was understood to bind to the high-affinity sites 
located at the GTP-cap on the polymerizing end or positive-end of the microtubules.  Upon GTP 
hydrolysis, this site becomes the low-affinity site and is either internalized or is located at the 
depolymerizing end or negative-end of the microtubules (Li et al. 2001; Caplow et al. 1994).  It 
was recently reported that paclitaxel exhibits two mutually exclusive binding sites one on the 
outer surface of microtubules (external site) and the other on the luminal side of microtubules 
(internal site) affording a stoichiometry of 1:1 (Diaz et al. 2005).  While understanding the 
mechanism binding kinetics of paclitaxel, it was proposed that paclitaxel or taxoid site binding 
agents bind to the outer microtubule surface, induce a conformational change, diffuse into the 
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luminal surface, and bind to the inner side of the microtubules.  Structural and biochemical 
evidence suggests that paclitaxel binds to the luminal surface of the microtubule (Nogales et al. 
1999).  In our studies, the ligands showed an overall mixed inhibition pattern, had Hill slopes 
greater than unity indicating an allosteric effect and/or positive co-operativity, and showed one-
site competitive inhibition.  However, at this point it cannot be stated with certainty that the 
ligands bound to the external or the internal site to show a competitive inhibition effect.  
Regardless, it would be of interest then to study for in vivo and in vitro synergism between 
paclitaxel and dictyostatin on tubulin polymerization dynamics.  Studies done to examine the 
possibility of two binding sites for paclitaxel also suggest that induction of microtubule assembly 
occurred regardless of whether paclitaxel bound to the external site or the internal site but 
induction of assembly was shown to be rapid when paclitaxel bound to the external surface (Diaz 
et al. 2005).  Hence, from a drug design perspective it would be important to investigate where 
exactly the ligands bind to the polymer, and ligands that bind to the external surface might have a 
better efficacy as microtubule stabilizers.    
Data obtained from fluorescence anisotropy experiments for Flutax-2 binding kinetics 
correlated with radioligand binding data.  Fluorescence anisotropy is a more sensitive and a 
robust technique.  Hence, lower concentrations of Flutax-2 were studied to understand binding 
kinetics in a wide concentration range.  Like in radioligand binding assay, Flutax-2 showed a 
unitary binding site on the microtubule polymer.  Inhibition studies with Flutax-2 are currently in 
progress.  Thermodynamic evaluation of Flutax-2 binding to tubulin polymer suggests that the 
binding mechanism is exothermic and an entropy-driven process.  Previous studies have 
suggested that paclitaxel binding to microtubules is an exothermic process.  Inhibition studies are 
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worth doing to understand the binding affinities and energetics of both the tracer and the 
inhibitor.   
The presence of overlapping binding sites for discodermolide-paclitaxel and/or 
dictyostatin-paclitaxel might be a possibility since in silico modeling studies done in the Day lab 
suggest that a paclitaxel binding model might not truly fit the ligands that were studied (Hu and 
Day 2005).  Modeling studies showed that discodermolide is away from the B9-B10 helix 
(Phe270 residue) and via hydrophilic interactions is positioned towards the M-loop.  This is 
supported by biological studies done on mutated ovarian carcinoma cell lines that have Phe270 
residue mutated (1A9PTX22), where in it was shown that 14-normethyldiscodermolide was as 
active as the parent molecule (Smith et al. 2001).  Recently, it was also shown that epothilone A 
had a pharmacophore model different from that proposed for paclitaxel.  These studies suggest 
that epothilone A to have many hydrophilic interactions with the residues on M-loop of the β-
tubulin subunit of the polymer.  In contrast to 14-normethyldiscodermolide, the analogous C16-
methyl group of dictyostatin was shown to orient towards Phe270, and mutation of this residue 
led to loss of activity of C16-normethyldictyostatin (Chapter 4).  However, the parent molecule, 
dictyostatin, seemed not be sensitive to these mutations indicating a binding conformation 
possibly similar to discodermolide, but different from C16-normethyl analogue.  Studies directed 
towards understanding the binding kinetics and conformations are ongoing. 
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6. CONCLUSIONS 
The investigations performed for this dissertation were aimed at pharmacological evaluation and 
structure-activity relationship studies of discodermolide, dictyostatin and their synthetic 
analogues for microtubule-targeting and perturbing activities.  A structurally diverse set of 
natural product-derived molecules and synthetic analogues have been identified to have potent 
microtubule-stabilizing actions (Chapter 1).  A few of them are going though clinical trials.  The 
marine sponge-derived discodermolide had shown potent microtubule-targeting activities in in 
silico and biochemical studies.  The SAR data on discodermolide was sparse at the time when 
this project began.  Hence, discodermolide analogues were evaluated for microtubule-targeting 
activities.   
The experiments for performing evaluations were established to understand the 
pharmacological activity and SAR for microtubule-stabilizing agents (Chapter 2).  The first 
library of discodermolide analogues gave valuable clues on the structural elements important for 
biological activity (Chapter 3).  Modifications done on the diene and carbamate moieties of 
discodermolide yielded analogues with poor activity.  These two positions were sensitive for 
modifications.  The 11S and 17R stereochemistry is important for activity, since modification of 
the configuration at these positions led to compounds with very weak microtubule-stabilizing 
activities.  The lactone functionality afforded little more flexibility for SAR studies.  Bulkier 
esters like the tbutanoyl replacing the lactone moiety yielded analogues with reasonably good 
microtubule-targeting activities.  The second library had interesting set of analogues (Chapter 3).  
One of the analogues, the 4-epi analogue NC86, was designed from a rational drug design 
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approach and the biological activity data is in agreement with the proposal that hydrogen 
bonding interaction between the C-3-OH and the nitrogen of the carbamate at C-19 stabilizes 
better the conformation of discodermolide.  NC86 has the C3-OH group replaced with an 
extended spacer, a methoxymethyl ether group, and had shown activity in low micromolar range 
and inhibited [3H]paclitaxel from binding to tubulin polymer to an extent of about 57% (Chapter 
3).  Hence, conformational analogues of discodermolide might yield analogues with better 
microtubule-targeting activity profiles.  The third set of analogues set the scope for the future of 
this project.  The hypothesis that because dictyostatin and discodermolide resemble each other 
structurally and macrocyclic analogues of discodermolide should therefore retain biological 
activity, proved to be supported by one of the macrocyclic hybrids, YSS133, which had 
antiproliferative activity in the low micromolar range (Chapter 3).   
Synthetic dictyostatin is the present molecule of interest.  Studies on MT binding 
properties, MT-stabilization effects and anti-proliferative activities revealed dictyostatin to be a 
very potent MT stabilizer (Chapter 4).  Preliminary results strongly suggest dictyostatin to be 
having a potent MT perturbing effect.  The inhibition of [3H]paclitaxel and [14C]epothilone B 
from binding to tubulin polymer by dictyostatin was comparable to discodermolide.  However, 
dictyostatin had a lower   ability to inhibit [3H]discodermolide from binding to MTs.  This could 
be because of higher affinity of discodermolide for MTs than dictyostatin.  Tubulin 
polymerization studies showed a comparative profile for dictyostatin, discodermolide and 
paclitaxel under various reaction conditions.  Dictyostatin, like similar to discodermolide, 
hypernucleated tubulin assembly starting at 0 oC onwards.  Paclitaxel lacked this ability at lower 
temperatures.  MAPs and GTP showed a differential effect on the regulation of polymerization 
dynamics in the presence of dictyostatin, discodermolide, and paclitaxel.  These studies show 
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that dictyostatin and discodermolide induce tubulin assembly regardless of the presence of MAPs 
and/or GTP.  In addition, the polymer inducing ability of paclitaxel was equal to that of 
dictyostatin and discodermolide at 30 oC in complete system consisting of MAPs and GTP.  This 
differential effect could be due to better stabilization of paclitaxel-bound tubulin conformation in 
the presence of MAPs and GTP.  There could be some positive cooperativity of MAPs on the 
stabilization of binding conformation of paclitaxel to MTs.  Since dictyostatin and 
discodermolide bind to tubulin polymer with higher affinity than paclitaxel, the stabilization of 
the M-loop conformation at the interprotofilament interface of the polymer might be better in the 
presence of these agents, thus precluding the requirement for MAPs and/or GTP.  Electron 
microscopic images showed MT polymer in the presence of dictyostatin when polymerization 
experiments were done in complete system containing MAPs and GTP.  Abnormal polymer 
forms were noticed in the system lacking MAPs and GTP and these were more commonly seen 
for discodermolide-induced polymer.  These subtle differences in polymer morphology could be 
due to small, but significant, binding site differences.  In vitro studies show the rank order of 
potency to be: dictyostatin ~ discodermolide > paclitaxel.  Dictyostatin, like discodermolide, is 
active in paclitaxel-resistant mutated β-tubulin cell lines.  Immunfluorescence experiments on 
HeLa cells showed dictyostatin to be the most potent of all the agents studied.  MT bundling, 
antimitotic effects and condensation of nuclear chromatin were more extensive in the presence of 
dictyostatin than that observed for either paclitaxel or discodermolide.  The minimum detectable 
effective concentrations of dictyostatin were lower than those of paclitaxel and discodermolide.  
The rank order of potency of these agents on in vivo cellular effects is that: dictyostatin > 
paclitaxel > discodermolide.  This discrepancy between in vitro and in vivo findings could be that 
the transport of discodermolide might not be sufficient and discodermolide may be metabolically 
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more labile.  These two features might contribute to the needed dose escalation of  and 
subsequent toxicity observed with discodermolide that led to termination of its clinical trials.  
Dictyostatin, like epothilone B, is a more rigid, cyclic molecule, and for these features could also 
be a good candidate for clinical evaluation. 
 SAR evaluation studies on dictyostatin analogues showed that the macrolactone and the 
bottom half of dictyostatin are essential for activity (Chapter 4).  The top half is crucial for 
binding of the molecule to the target.  The 16-normethyl analogue was less active in 
[3H]paclitaxel inhibition studies.  The 16-normethyl analogue is the interesting molecule with 
antiproliferative activity profile similar to that of the parent molecule.  Interesting is the 
observation that this molecule showed differential activity profile against two mutated ovarian 
cancer cell lines that was not seen with dictyostatin.  In one cell line (1A9PTX10), it showed 
activity similar to that observed in the parental cell line, while in the other mutated cell line it 
showed very weak activity (1A9PTX22).  This suggests the orientation of the C16-Me is towards 
Phe270 and modeling studies support this hypothesis.  
 Analyses of binding kinetics showed ~ 0.8:1 stoichiometry for [3H]paclitaxel bound to 
tubulin polymer (Chapter 5).  There could be mutually exclusive binding sites for paclitaxel.  
The inhibitors, discodermolide, dictyostatin and the 4-epi analogue NC86 showed mixed 
inhibition patterns with Hill slopes greater than 2.0.  These inhibitors might be exerting an 
allosteric effect or positive cooperativity on the binding kinetics of paclitaxel.  Studies done to 
understand the binding energetics suggest dictyostatin to be similar to discodermolide in having 
lower binding energetics.  Fluorescence anisotropy experiments with Flutax-2 suggest that the 
binding thermodynamics is an exothermic and an entropy-driven process (Chapter 5).  Inhibition 
studies are in progress.   
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The future holds much promise for dictyostatin and its synthetic analogues.  It would be 
of interest to determine  any synergism between dictyostatin and paclitaxel.  This is suggested 
because the present results suggest an allosteric effect and/or positive cooperativity of 
dictyostatin on paclitaxel binding kinetics.  It is known that discodermolide and paclitaxel exhibit 
synergism in suppressing cellular MT dynamics and in causing cytotoxicity.  The 
binding/pharmacophore model for dictyostatin, discodermolide and 16-normethyldiscodermolide 
needs to be established via in silico approaches to help give  a better understanding of the 
binding kinetics.  [3H]Discodermolide binding kinetic parameters would be of great help to 
understand differences in binding interactions between paclitaxel and discodermolide.  SAR 
studies can be pursued further.  Finally, synthetic analogues of dictyostatin with modifications on 
the diene and the bottom half, conversion of the macrolactone (cyclic ester) functionality of 
dictyostatin to a macrolactam (cyclic amide) would also be of great interest. The challenges now 
are in the hands of the synthetic chemists. 
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Figure 33. Saturation binding kinetics with previous tubulin aliquot 
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Figure 34. Structure of Flutax-2 and its spectrofluorimetric characteristics 
(Adapted from: http://probes.invitrogen.com/servlets/structure?item=22310  
and http://probes.invitrogen.com/servlets/spectra?fileid=6380ph8, respectively). 
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Figure 35. Electron microscopic images of glutaraldehyde-fixed microtubules 
 Upper image:  undiluted fixed microtubules 
 Image on the left: fixed microtubules after 1000-fold dilution 
 Image on the right: fixed microtubules after 100-fold dilution 
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